Characterization of spike glycoprotein fusion core and 3C-like protease substrate specificity of the severe acute respiratory syndrome (SARS) coronavirus: perspective for anti-SARS drug development. by Chu, Ling Hon Matthew. & Chinese University of Hong Kong Graduate School. Division of Molecular Biotechnology.
Characterization of Spike Glycoprotein Fusion Core 
and 3C-like Protease Substrate Specificity 
of the Severe Acute Respiratory Syndrome 
(SARS) Coronavirus: 
Perspective for Anti-SARS Drug Development 
CHU Ling Hon Matthew 
B.Sc. (Hons). CUHK 
A Thesis Submitted in Partial Fulfilment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Molecular Biotechnology 
• The Chinese University of Hong Kong 
September 2006 
The Chinese University of Hong Kong holds the copyright of this thesis. 
Any person(s) intending to use a part or whole of the materials in the thesis 
in a proposed publication must seek copyright release from the Dean of the 
Graduate School. 
/ y 統 系 紐 ^ 
liiliiL)書 




I declare that the assignment here submitted is original except for source material 
explicitly acknowledged. I also acknowledge that I am aware of University policy 
and regulations on honesty in academic work, and of the disciplinary guidelines and 
procedures applicable to breaches of such policy and regulations, as contained in the 
website h t tp : ( /www.cuhk.edu .hk/pol icy /academichones ty / 
Sifnatufe Date 
CHU LING HON MATTHEW s04080620 
Name Student ID 
MBT604T RESEARCH 
Course code Course title 
i i 
Thesis/Assessment Committee 
Professor WONG Kam Bo (Chair) 
Professor WAYE Miu Yee Mary and Professor NGAI Sai Ming 
(Thesis Supervisors) 
Professor AU Wing Ngor Shannon (Committee Member) 
Professor WATTS Anthony (External Examiner) 
i i i 
Abstract 
Abstract of thesis entitled: 
Characterization of Spike Glycoprotein Fusion Core and 3C-like Protease 
Substrate Specificity of the Severe Acute Respiratory Syndrome (SARS) 
Coronavirus: Perspective for Anti-SARS Drug Development 
Submitted by CHU Ling Hon Matthew 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in June 2006 
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a newly 
discovered virus responsible for the worldwide epidemic in 2003. Scientists and 
researchers are searching for viral protein target-based anti-SARS therapies in 
preparation of the possibility of future recurrences of SARS outbreak. Amongst 
different viral protein targets, the spike glycoprotein (S protein) and 3C-like protease 
(3CLPr�) are of major focuses in SARS research. In this project, we are particularly 
interested in investigating the S protein fusion core and characterizing the substrate 
specificity of3CLP''°. 
The S protein of SARS-CoV consists of two subunits, SI and S2. SI contains 
the receptor-binding domain, whereas S2 contains two heptad repeat (HR) regions, 
HRl and HR2, which form coiled-coil structures. These HR regions can associate 
i v 
into an antiparallel six-helix bundle to form the fusion core, which play an important 
role in mediating the membrane fusion process between viral and target cells. To 
investigate the structural basis of the fusion core, we characterized the sites of 
interaction between HRl and HR2 using both recombinant protein and synthetic 
peptide approaches via different biophysical techniques, such as multidimensional 
chromatography, native polyacrylamide gel eletrophoresis, pull-down assay, circular 
dichroism (CD) spectroscopy and laser light scattering analysis. Moreover, in order to 
identify SARS-CoV entry inhibitors that target the S protein fusion core, we 
V 
employed the HIV-luc/SARS pseudotyped virus entry inhibition assay to screen 
several peptide analogs derived from the SARS-CoV S protein HR regions and a 
series of small molecule compounds. Three peptides and five small molecules were 
identified as potential inhibitors. This study can broaden our knowledge on the fusion 
mechanism of SARS-CoV and provide insights for the development of virus fusion 
entry inhibitors. 
The 3CLPro of SARS-CoV mediates extensive proteolytic processing of replicase 
polyproteins. There are at least 11 conserved 3匸17阳 cleavage sites on the SARS-CoV 
polyprotein pplab, in which the substrate specificity involves preferentially the 
Leu-Gln4' sequence in the P2 and PI positions at the cleavage site, respectively. We 
developed a rapid and high-throughput screening method to study the substrate 
specificity of SARS-CoV 3CLP'°. Six target amino acid positions flanking the S C I / ' � 
cleavage site (Leu-GlnJ^) were investigated. Each batch of mixed peptide substrates 
XXV 
with defined amino acid substitutions at the target amino acid position was 
synthesized via the 'cartridge replacement' approach, and was subjected to enzymatic 
cleavage by recombinant SARS-CoV SCL"""". Susceptibility of each peptide substrate 
to the 3CLPr° cleavage was monitored simultaneously by matrix-assisted laser 
I 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). This 
study generated a comprehensive overview of SARS-CoV SCL'"^ " substrate specificity 
which serves as the basis of design of synthetic peptide-based SARS-CoV 
inhibitors. 
Our study in the S protein fusion core and 3CLP™ of SARS-CoV is definitely a 

































我們對S ARS-CoV病毒S蛋白融合核心和3CLPr°的硏究爲開發抗S ARS病毒的 
藥物提供了極其有用的資訊。 
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CHAPTER 1. INTRODUCTION 1 
Chapter 1 
Introduction 
1.1 Severe Acute Respiratory Syndrome (SARS) 
- T h r e e Years in Review 
1.1.1 Epidemiology 
The outbreak 
Several hundred cases of severe atypical pneumonia of unknown etiology were 
reported in Guangdong Province of the People's Republic of China beginning in 
late 2002. After similar cases were detected in patients of Hong Kong, Vietnam 
and Canada during February and March 2003, the World Health Organization 
(WHO) issued a global alert on 15 March 2003 for this novel but severe, 
untreatable, and rapidly spreading respiratory illness, designated "severe acute 
respiratory syndrome" (SARS). 
The first international dissemination of SARS could be traced through 
multiple chains of transmission to a "superspreader", a 65-year-old medical doctor 
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from Guangdong Province, who had treated patients with atypical pneumonia 
prior to departure and was symptomatic upon arrival in Hong Kong on 21 
February 2003. Within 24 hours of stay on the ninth floor of the Metropole Hotel 
in Hong Kong, he spread the infection to at least 16 other guests before being 
hospitalized with pneumonia and died. These infected guests thus became the 
seeds of SARS transmission around the world via international air travel routes. 
By 31 July 2003, a total of 8098 probable SARS cases with 774 deaths were 
reported to WHO from 29 countries around the world. In addition to the huge 
casualty, economic impact was also tremendous: the amount was estimated in the 
range of US$30 — 140 billion, which was largely attributed to reduced travel and 
investment in Asia (WHO, 2003). 
Routes of transmission 
The transmission of SARS was a combination of direct contact (touch), 
short-range (large droplet, within 1 m) and long-range (droplet nuclei; beyond Im 
and further) transmissions. Direct contact and short-range transmission through 
respiratory droplets in the context of close contact with SARS infected persons in 
the hospitals or household settings were the primary routes of transmission. 
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Moreover, SARS could be spread by long-range airborne transmission. For 
instances, the major community outbreak in a single housing estate (Amoy 
Gardens) in Hong Kong was attributed to passive carriage of viruses by pests, 
drying up of U-shaped bathroom floor drain which allowed the backflow of 
contaminated sewage or its aerosolized particles and creation of infectious aerosol 
current by the use of residential exhaust fans in the toilet (Lee, 2003; Ng, 2003; 
Yu et al, 2004). Also, the spread of SARS among healthcare workers and patients 
in a medical ward at the Prince of Wales Hospital in Hong Kong was also 
consistent with airborne transmission (Yu et al., 2005). Therefore, the broad range 
of routes was the main difficulty in controlling SARS transmission during the 
early stages of the worldwide epidemic. 
1.1.2 Clinical presentation 
SARS is an atypical form of acute pneumonia, which is characterized by fever, 
1 • 2 
chills and rigors, malaise , myalgias , headache, nonproductive cough and 
dyspnea^ along with radiologic evidence of pneumonia (Booth et al, 2003; 
' a general state of discomfort, tiredness, or illness 
^Muscle pain or tenderness 
^Difficulty breathing or pain on breathing 
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Nicolaou et al, 2003; Poutanen et al., 2003; Peiris et ai, 2003). The estimated 
incubation period of SARS infection in humans was 2 to 10 days (Booth et al, 
2003; Lee N et al., 2003) and most patients were admitted to hospitals between 3 
to 5 days following the onsets of illness (Donnelly et al, 2003). Patients with 
SARS are most infectious at around day 10 of illness (WHO, 2003). 
Chest radiographic and laboratory findings helped the doctors to make an 
early diagnosis of SARS. At the onset of fever, 70 to 80% of the patients had 
abnormal chest radiographs on presentation (Booth et al, 2003; Wong et al, 
2003). Subtle peripheral pulmonary infiltrates were often shown in early chest 
radiographs, which were readily detected as consolidation or ground-glass 
opacification using high-resolution computed tomographic lung scans (Wong et 
al, 2003). In addition, laboratory findings showed that SARS produced 
characteristic changes in peripheral blood counts including leucophenia'^ and 
lymphopenia^ (Ksiazek et al, 2003; Kuiken et al., 2003). Remarkable declines in 
both CD46 and CD8^ T cells were noted along with reduction in B cells and 
''An abnormal reduction of the white blood cell count 
^An abnormal reduction in the number of lymphocytes in the blood 
6八 glycoprotein that is expressed on the surface of helper T cells 
7八 glycoprotein that is expressed on the surface of cytotoxic T cells 
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natural killer cells (Cui et ai, 2003). Low-grade disseminated intravascular 
O Q 
coagulation (DIC-thrombocytopenia，prolonged activated partial thromboplastin 
time and elevated D-dimers'®), elevated lactate dehydrogenase (LDH), creatine 
kinase (CK) and aspirate or alanine aminotransferases were common 
abnormalities detected in SARS patients (Booth et ai, 2003; Lee et ai, 2003; 
Tsang et a/., 2003). 
1.1.3 Diagnostic tests 
Laboratory confirmation of SARS was based on virus isolation, detection of viral 
RNA or detection of antibody of the etiological SARS-associated coronavirus. 
SARS-associated coronavirus was first isolated using Vero-E6' ' cells 
(Drosten et ai, 2003; Ksiazek et al, 2003) and so the virus could replicate very 
successfully in these cells (Ng et al., 2003). In fact, isolation of SARS-associated 
coronavirus in Vero-E6 cell culture is not a diagnostic method, but it is an 
important tool for the diagnosis: the presence of SARS-associated coronavirus in 
®The presence of relatively few platelets in blood 
9八 substance present in endothelial tissue, platelets, and leukocytes necessary for the initiation 
of thrombin formation from the zymogen prothrombin 
'°A blood test to diagnose thrombosis 
"Epithelial cells of kidney from African green monkey 
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the specimens from SARS patients, such as plasma, stool, urine and secretions of 
upper respiratory tract, could be detected by inoculating the specimens with 
Vero-E6 cells to propagate the virus in vitro (Drosten et al.’ 2003). 
Reverse transcription-polymerase chain reaction (RT-PCR) and nucleic acid 
sequence-based amplification (NASBA) were employed to detect 
SARS-associated coronavirus-specific RNA in the specimens from SARS patients 
(Drosten et al., 2003; Keightley et al, 2005). Amongst the nucleic acid tests, 
conventional and real-time quantitative RT-PCR assays were the more common 
and preferable methods for laboratory confirmation of SARS (Emery et al., 2004; 
Poon et al, 2003; Poon et al.’ 2004; Yam et al., 2003) 
SARS-associated coronavirus-specific antibodies can be readily detected by 
immunologically-based assays: enzyme-linked immunosorbent assays (ELISA), 
western blot and immunofluorescence microscopy; and biologically-based assay: 
microneutralization test. Both ELISA and western blot based on the 
SARS-associated coronavirus-infected cell lysates, which detect immunoglobulin 
(Ig) specifically bound to native or denatured SARS-associated coronavirus 
proteins, respectively (Ksiazek et al., 2003; Wu et al., 2004b). Amongst the 
immunological assays, immunofluorescence microscopy assay is the simplest to 
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perform (Wu et al., 2004b). The SARS-associated coronavirus-infected cells was 
incubated with patients' serum and subsequently with an antihuman IgG or IgM 
conjugate and they are then examined with a fluorescence microscope. 
Microneutralization test is the most applicable biologic assay and is the most 
specific serologic tests for SARS-associated coronavirus (Wu et al, 2004b). It 
measures the presence of SARS-associated coronavirus-specific Ig indirectly by 
its ability to neutralize the virus. As it measures biologically relevant antibody, 
this makes it a definitive test for determining immunity to infection and response 
to potential vaccines. 
1.2 Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV) 
1.2.1 SARS - Identification of the etiological agent 
In response to the dangerous outbreak and to develop scientific knowledge of 
SARS, identification of the causal agent was the most urgent and important task. 
On 15 March 2003, WHO set up a multicentre collaborative network of scientists 
from 11 leading laboratories around the world to expedite identification of the 
unknown etiological agent of SARS (Stohr, 2003). In the beginning of the 
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investigations, the network laboratories ruled out the presence of some respiratory 
pathogens such as Chlamydia (Drostent et al., 2003), rhinovimses (Ksiazek et al.， 
2003) and paramyxoviruses (Poutanen et al, 2003; Stohr, 2003), which were 
some known causative agents of interstitial pneumonia that were found in some 
SARS patients from different sites of outbreaks. However, no laboratory could 
confirm the presence of these pathogens in all SARS cases. 
In late March 2003, the participating network laboratories used various 
strategies, including light and electron microscopy, immunohistochemistry, animal 
inoculation, bacterial and cell-culture isolation techniques, serology, and PGR 
analyses, to classify the causative agent of SARS (Stohr, 2003). Finally, on 22 
March 2003, the Centers for Disease Control and Prevention (CDC) Atlanta team 
in the USA was the first to isolate a SARS virus in Vero-E6 cells and observed the 
presence of coronavirus-like particles on electron microscopy (size 70-100 nm) 
(Ksiazek et al, 2003). On the next day, they further confirmed the classification as 
a coronavirus based on a coronavirus-like sequence of the PCR-amplified product. 
Later, different laboratories were able to isolate the new coronavirus from 
Vero-E6 cells and fetal rhesus kidney cells (FRhK-4). This novel coronavirus was 
finally found and fulfilled Koch's postulates for SARS causation by infecting 
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cynomolgus macaques {Macaca fascicularisf^ with an isolate of the coronavirus 
from Hong Kong in early April 2003 (Fouchier et al, 2003), to provide proof 
from experimental infection that the newly discovered coronavirus is the 
etiological agent of SARS. WHO then formally announced that the 
SARS-associated coronavirus was provisionally termed SARS-Coronavirus 
(SARS-CoV) (Stohr, 2003). 
1.2.2 The coronaviruses 
Coronaviruses (order Nidovirales, family Coronaviridae, genus Coronavirus) are 
a diverse group of large, enveloped, single positive-stranded RNA viruses that 
cause respiratory and enteric diseases in humans and other animals. At 
approximately 30,000 nucleotides in length, the genome size of coronaviruses is 
the largest found in any of the RNA viruses. The size of each coronavirus particle 
is about 100 to 140 nm in diameter. Most of the coronaviruses show distinct 
crown ('corona ‘ in Latin) surface appearance which is attributed to the 20 nm 
projections of spike glycoprotein (S protein) from the vims surface. 
'^Scientific name of Crab-eating Macaque, is an arboreal macaque native to South-East Asia. It 
is also called the Cynomolgus Monkey or Long-tailed Macaque. 
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Coronaviruses have been divided into three different serologically distinct 
groups. Groups 1 and 2 contain mammalian viruses, whereas group 3 contains 
only avian viruses. Within each group, coronaviruses are classified into distinct 
species by host range, antigenic relationships, and genomic organization (Marra et 
al, 2003; Rota et al.’ 2003). Group 1 contains human coronavirus 229E 
(HCoV-229E), transmissible gastroenteritis virus (TGEV), porcine epidemic 
diarrhea virus (PEDV)，feline infectious peritonitis virus (FIPV) and canine 
coronaviruses (CCoV); Group 2 contains human coronavirus OC43 
(HCoV-OC43), mouse hepatitis virus (MHV) and bovine coronavirus (BCoV); 
and Group 3 contains avian coronaviruses, including infectious bronchitis virus 
(IBV) of chickens and turkey coronavirus (TCoV) (Gonzalez et al., 2003). 
Before the SARS epidemic, only two human coronaviruses, which were 
found in group 1 (HCoV-229E) and group 2 (HCoV-OC43), had been 
characterized (Sizun et al, 2000). Both of them caused only a mild upper 
respiratory tract illness (Makela et al, 1998). However, the newly discovered 
SARS-CoV appeared to be the first human coronavirus associated with severe 
respiratory infection in human. Phylogenetic analysis suggests that SARS-CoV 
does not belong to any of the three defined coronavirus groups (Figure 1.1). The 
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novel SARS-CoV was defined in a group of its own: the distinct forth group of 
coronaviruses (Marra et al, 2003; Rota et al, 2003). 
Group 1 
略 铁 I f … 滚 > 谈 . 
‘MHV BCoVX Group 4 ？ 
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Figure 1.1: Phylogenetic analysis of coronaviruses. 
Phylogenetic analysis of coronaviruses shows that SARS coronavirus is different from each of 
the three groups of the previously known coronaviruses. It is still debatable whether the novel 
SARS-CoV should be assigned to a new fourth group. (Modified from Groneberg et al., 2005) 
1.2.3 The genome organization of SARS-CoV 
The genome of SARS-CoV is an approximately 30,000 nucleotides 
polyadenylated RNA, which is organized into 13 to 15 open reading frames 
(ORFs) (Kuiken et al, 2003; Marra et ai, 2003; Rota et al., 2003). The genomic 
organization is typical of coronaviruses, having the characteristic gene order: 5 ‘— 
replicase (rep) — spike (S) - envelope (E) — membrane (M) — nucleocapsid (N)-
3 \ and short untranslated regions at both termini (Figure 1.2). The 
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hemagglutinin-esterase (HE) gene, which is present in the majority of group 2 and 
some group 3 coronaviruses, was not found. The SARS-CoV rep gene ORFla and 
ORFlb comprises two-thirds of the genome. ORFla and ORFlb encode two 
polyproteins, ppla and pplab, which are processed by virus-encoded proteases to 
yield 16 individual proteins. More details on replicase polyproteins are discussed 
in chapter 1.5. 
3b 7b 8b 9b 
Leading 3a 6 
sequence • IIP^ 
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Figure 1.2: Genome organization and mRNA mapping of SARS-CoV. 
Overall organization of the -30,000 nucleotides SARS-CoV genomic RNA. The 72 
nucleotides leading sequence is represented by a small grey square at the 5' terminus of the 
genome. Predicted ORFs la and lb, encoding the nonstructural polyproteins, and those 
encoding the S, E, M, and N structural proteins are indicated. (Modified from Hofmann and 
Pohlmann, 2004) 
There are four ORFs downstream of rep that are predicted to encode the 
structural proteins spike glycoprotein (S protein), envelope (E) protein, membrane 
(M) protein, and nucleocapid (N) protein, which are common to all known 
coronaviruses. The N protein and M protein interact to form a spherical core. 
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whereas the S protein and E protein constitute the viral envelope (Marra et al, 
2003; Rota et al., 2003) (Figure 1.3). These structural proteins function during 
host cell entry, virus morphogenesis and release. 
靠： 
Figure 1.3: Structural proteins of SARS-CoV. 
Structural proteins of SARS-CoV include spike glycoprotein (S), envelope protein (E), 
membrane protein (M) and nucleocapsid protein (N). (Modified from Holmes, 2003b) 
1.2.4 The life cycle of SARS-CoV 
The primary target cells of SARS-CoV infection are respiratory epithelial cells. In 
order to infect the target cells, SARS-CoV binds to receptor(s) localized on the 
surface of cell and its viral membrane fuses with the cell membrane. SARS-CoV 
S protein is responsible for these two initial steps; more details on S protein are 
described in chapter 1.3. After entering the target cell via plasma membrane 
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fusion and acidic pH-dependent endocytosis (Yang et al, 2004), SARS-CoV 
genetic materials, the viral RNA, are injected into the cell and viral replication 
occurs in the cytoplasm. Within the cell, SARS-CoV genome expression starts 
with the translation of the two large replicase polyproteins, ppla and pplab. The 
ppla and pplab polyproteins are processed by viral proteases to yield the 
functional components of the membrane-bound replicase complex (Thiel et al.’ 
2003). The replicase complex, including RNA-dependent RNA polymerase 
(RdRp) (Xu et al.’ 2003), helicase (Ivanov et al, 2004) and proteases, mediates 
both genome replication and transcription of a ‘nested’ set of subgenomic mRNAs. 
These mRNAs encode the structural proteins, S, E, M and N, and a set of 
accessory proteins. After the post-translational processing and maturation of the 
viral proteins, virus assembly occurs by budding into the golgi apparatus. During 
virus assembly, the N protein binds to a defined packaging signal on viral RNA, 
leading to the formation of the helical nucleocapsid. The M protein is localized at 
specialized intracellular membrane structures, and interactions between the M and 
E proteins and nucleocapsids result in budding through the membrane (Rota et al, 
2003). The S protein is incorporated into the viral envelope, again by interaction 
with the M protein. Finally, mature SARS-CoV particles are transported to the 
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surface of the target cell by the secretory nature of the organelle and released by 
exocytosis (Figure 1.4). 
: ’ Membrane fuswr 
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Figure 1.4: The life cycle of SARS-CoV. 
The SARS life cycle involves: (1) Virus binding to cellular receptors. (2) Membrane fusion 
and acidic pH-dependent endocytosis of the virus with the target cell. (3) Replicase 
polyprotein, ppla and pplab, are cleaved into functional units by virus encoded proteases. (4) 
Viral RNA replication, transcription, translation and protein processing. (5) Virus assembly 
and budding. (6) Virus particles exit by exocytosis. (Modified from Holmes, 2003a) 
1.3 Spike glycoprotein (S protein) of SARS-CoV 
1.3.1 SARS-CoV S protein 
Among the structural proteins of SARS-CoV, the spike glycoprotein (S protein) is 
a major focus in SARS research. Indeed, interaction between S protein and 
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receptors on the target cell surface is the initial step of infection and an essential 
step for SARS-CoV replication. 
The type I membrane glycoprotein, S protein, is the main component of the 
characteristic spikes on the surface of SARS-CoV. It contains 1255 amino acid 
residues, which is the largest structural protein in SARS-CoV. There are 23 
potential N，-linked glycosylation sites and 69 potential phosphorylation sites, 
including 37 serine, 15 threonine, and 17 tyrosine residues (Choy et al, 2004).丁he 
SARS-CoV S protein demonstrates a low sequence similarity of 20 to 27% 
pairwise amino acid identity with the S proteins of other coronaviruses (Rota et al, 
2004). However, the topology of the SARS-CoV S protein is similar to the S 
proteins of other coronaviruses, which usually have large ectodomains and short 
transmembrane spans. The SARS-CoV S protein can be divided into four regions: 
the signal peptide (residues 1 - 12), the N-terminal ectodomain (residues 13 -
1190)，a transmembrane domain (TM) (residues 1190 - 1227) and the C-terminal 
cytoplasmic tail (CT) rich in cysteine residues (residues 1227 - 1255) (Rota et al., 
2003) (Figure 1.5). 
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Figure 1.5: Structural features of the SARS-CoV S protein. 
The SARS-CoV S protein can be divided into four regions: the signal peptide (SP) (residues 
1 - 12), the N-terminal ectodomain (residues 13 - 1190), a transmembrane domain (TM) 
(residues 1 1 9 0 - 1227) and the C-terminal cytoplasmic tail (CT) (residues 1 1 2 7 - 1255). It can 
be further subdivided into receptor-binding SI subunit (residues 12 - 680) containing the 
receptor binding domain (RED) (resides 318 - 510) with the receptor binding motif (REM) 
(residues 424 - 494), followed by the S2 subunit (residues 681 - 1255) containing structural 
elements required for membrane fusion: a fusion peptide (FP) (residues 770 - 788)，the two 
heptad repeat regions, HRl (residues 900 - 1005) and HR2 (residues 1151 - 1185)，and the 
interdomain loop (IL) (residues 1 0 0 5 - 1151). (Modified from Li et al., 2005) 
1.3.2 S protein-driven infection 
S proteins of many coronaviruses, such as avian infectious bronchitis virus 
(AIBV), bovine coronavirus (BCoV), human coronavirus OC43 (HCoV-OC43) 
and mouse hepatitis virus (MHV), are cleaved into two functional subunits, SI 
and S2 (Abraham et al., 1990; Frana et al., 1985; Jackwood et al., 2001; Moimir 
and Talbot, 1993). However, the SARS-CoV S protein lacks the basic amino acid 
CHAPTER 1. INTRODUCTION 18 
cleavage site'^ found in other coronaviruses, suggesting that it is probably not 
cleaved into SI and S2 subunits (Rota et al., 2003). Nevertheless, SARS-CoV S 
protein is presumed to have the S1 and S2 subunits, in which they are predicted to 
be localized at the regions of residues 12 - 680 and 681 - 1255, respectively (Lio 
and Goldman, 2004; Spiga et al, 2003). 
Infection of target cells by SARS-CoV is driven by the S protein, which 
facilitates binding to target cell receptor(s) and promotes fusion of the viral and 
the cellular membranes, thereby allowing the insertion of the viral genome into 
the cellular cytoplasm. In SARS-CoV S protein, SI subunit is responsible for the 
receptor binding and S2 unit is responsible for the membrane fusion process. 
SI subunit 一 Receptor binding 
SI subunit, the peripheral region of the S protein, is located outside of the 
SARS-CoV and it harbors the receptor-binding domain (RED). The first cellular 
r e c e p t o r f o r S A R S - C o V w a s f o u n d as t h e m e t a l l o p e p t i d a s e 
ang io tens in -conver t ing enzyme 2 (ACE2) , which was iden t i f ied by 
13 Cleavage sites in the S proteins of coronaviruses are RRFRR, RRSRR, RRSRR and RARS in 
AIBV, BCoV, HCoV-OC43 and mouse hepatitis virus, respectively. 
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immunoprecipitation and proteomic analysis using soluble Sl-immunogloblin (Ig) 
fusion protein (residues 12 — 672) with the lysates from Vero-E6 cells (Li et al., 
2003). Several studies proved that ACE2 is a functional receptor for SARS-CoV 
infection and plays an important role in SARS-CoV replication in the infected 
target cells (Hamming et al., 2004; Li et al, 2003; Nie et al, 2004). The details of 
molecular interactions between the RBD of SARS-CoV S protein and ACE2 were 
elucidated two years after the discovery of ACE2. A minimal RBD had been 
narrowed down to a fragment of 193 amino acids (residues 318 - 510), which 
actually binds ACE2 with greater affinity than the entire S1 subunit does (Wong et 
al., 2004). The structure of RBD complexed with ACE2 had also been solved (Li 
et al., 2005). The receptor-binding motif (RBM) was identified (residues 424 -
494), which makes all the contacts with ACE2. 
In addition to ACE2, a different human cellular glycoprotein, CD209L, a 
C-type lectin also called DC-SIGNR^^ and DC-SIGN2, was reported to 
serve as an alternative receptor for the SARS-CoV S protein (Jeffers et al, 2004). 
It was demonstrated that human CD209L could interact with a SI subunit 
"liver/lymph node-specific intercellular adhesion molecule-3-grabbing nonintegrin 
'^ A protein related to DC-SIGN (dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin) 
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fragment from residues 1 to 590 (Jeffers et al, 2004). However, this finding is 
contradictory to results from other studies, which suggested that DC-SIGNR, as 
well as DC-SIGN, enhance SARS-CoV infections mediated by ACE2 but do not 
function as receptors by themselves (Marzi et al.’ 2004; Yang et al., 2004). 
Since infection of target cells by SARS-CoV is initiated by the interaction of 
SI subunit with receptors, the SI subunit can define the host range of virus and 
the RBD is suggested to be the major antigenic determinants for eliciting immune 
response in the hosts (He et al, 2005a; He et al, 2005b; Jiang et al, 2005). 
Analysis of the mutation distribution between the S protein sequences of other 
coronavirus with the SARS-CoV S protein suggested that seven of the ten 
mutation sites are in the SI subunit (Spiga et al, 2003). This high mutation rate of 
51 subunit may allow SARS-CoV to escape from recognizing by the immune 
system and also provide extraordinary variations in host range and tissue tropism. 
52 subunit - Membrane fusion 
S2 subunit, the stem and membrane-spanning region of the S protein, contains 
functional elements involved in SARS-CoV membrane fusion: a putative FP and 
two highly conserved 4,3-hydrophobic repeat domains, the heptad repeat 1 (HRl) 
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and heptad repeat 2 (HR2) regions. The HRl and HR2 regions are located 
between FP and TM. The function of these elements had been elucidated in the 
context of prototype type I fusion proteins, such as human immunodeficiency 
virus (HIV-1) gpl60 (Eckert and Kim, 2001b), suggesting a similar membrane 
fusion mechanism for the SARS-CoV S protein. After the binding of the SI 
subunit to target cell surface receptor, this action will induce global changes in the 
conformation of S protein that convert S2 subunit from a native pre-fusion state to 
a pre-hairpin intermediate state (Figure 1.6). This receptor-induced 
conformational change facilitates the release of FP and positions it to interact with 
the target cell membrane. The pre-hairpin intermediate state of S protein resolves 
itself to a final fusogenic or post-fusion hairpin state (Eckert and Kim, 2001a). 
These conformational changes are arisen from an association between the two 
coiled-coil regions within the S2 subunit, in which three N-terminal HRl helices 
interact with three C-terminal HR2 helices in an anti-parallel manner to form a 
stable six-helix coiled-coil bundle structure, which is designated as the 
SARS-CoV S protein fusion core. This "trimer of dimers" fusion core structure 
facilitates the juxtaposition of the SARS-CoV and target cell membranes into 
close proximity, destabilizes the membrane lipid bilayers, which ultimately causes 
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membrane fusion and release of SARS-CoV nucleocapsid into the target cell. 
Native pre-lusion Pre-tiairpin intermediate Post-fusion hairpin 
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Figure 1.6: Illustration of the conformational changes of SARS-CoV S protein fusion core 
during the membrane fusion process between the SARS-CoV and the target cell. 
In the native pre-fiision state, the SARS-CoV S protein is denoted SI and S2 subunits. In the 
pre-hairpin intermediate state, triggered by SI binding to the receptor, S2 changes its 
conformation by extending and inserting its fusion peptide (FP) into the target cell membrane, 
and exposing HRl and HR2 regions. In the post-fusion hairpin state, the HRl and HR2 
helices associate with each other to form a six-helix bundle and draw both viral and target cell 
membranes close together, resulting in the fiision between the viral and target cell membrane. 
(Modified from Liu et al, 2003) 
1.4 SARS-CoV S Protein Fusion Core 
1.4.1 Heptad repeat and coiled-coil 
The SARS-CoV S protein fusion core is a six-helix bundle formed by two 
coiled-coil regions, HRl and HR2. The basic element of each coiled-coil is the 
heptad repeat. 
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Heptad repeat is an occurrence of a group of seven aminoacids many times in 
a protein sequence. The seven amino acids are denoted "abcdefg", in which 
hydrophobic residues are frequent at positions "a" and "d", and the others are 
predominantly hydrophilic residues, especially positions "e" and "g" are often 
occupied by oppositely charged residues (Thomas et al, 1995; Liu et al., 2004). 
Coiled-coils are composed of amphipathic a-helices that have sequences based on 
the heptad repeats (Thomas et al, 1995). The high frequency with which Leu or 
He appear in positions "a" and "d" in the coiled-coil regions of many filamentous 
structural proteins, such as tropomyosin (Sodek et al, 1972), and certain 
DNA-binding proteins has led to the use of the descriptive term "leucine zipper" 
(Hope and Struhl, 1987; Landschulz et al., 1988). Coiled-coils occur in different 
oligomeric forms. While dimers predominate in the leucine zipper regions of 
DNA-binding proteins (Hope and Struhl, 1987; Landschulz et al., 1988)，many of 
the naturally occurring proteins preferentially assemble to trimeric as well as 
tetrameric structures (Thomas et al., 1995) (Figure 1.7). 
Viral membrane fusion proteins, including hemagglutinin protein of 
influenza virus, gp41 of HIV-1, glycoprotein of Ebola virus, and fusion protein of 
paramyxovirus (Eckert and Kim, 2001a; Hernandez et al., 1996), all are type I 
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membrane glycoproteins containing parallel homotrimeric coiled-coil regions. 
“衞0 
Figure 1.7: Representations of coiled-coil structures. 
(A) and (B) are helical wheel diagrams of dimeric and trimeric coiled-coils, respectively, 
"abcdefg" indicate the position of residues within the heptad repeat of the coiled-coil. The 
interactions between the coiled-coils are shown, hydrophobic interactions are indicated by 
solid arrows and potential electrostatic interactions by dotted arrows. (Modified from 
Adamson et al, 1993) 
Markedly, LeamCoil-VMF (Singh et a/., 1999), MultiCoil (Wolfer al.，1997) 
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and helical wheel analysis reveal that the SARS-CoV S protein fusion core 
consists of the same elements that were characterized in those type I viral 
membrane fusion proteins: the Leu/Ile heptad repeat coiled-coil regions. The 
LearnCoil-VMF, MultiCoil and helical wheel analysis of HRl and HR2 of 
SARS-CoV S protein fusion core are shown in chapter 3.1. Nevertheless, the 
high-resolution structure from x-ray crystallographic analysis of is now available 
for the heptad repeat coiled-coil regions of the SARS-CoV S protein fusion core 
(Duquerroy et al., 2005; Supekar et al, 2004; Xu et al.’ 2004a). 
1.4.2 The six-helix coiled-coil bundle structure 
The x-ray crystallographic structures of the post-fusion hairpin state of SARS 
CoV S protein fusion core have been solved at 1.6 A (PDB 2BEQ & PDB 2BEZ) 
(Supekar et al, 2004)，2.2 A (PDB IWYY) (Duquerroy et al., 2005) and 2.8 A 
(PDB IWNC) (Xu et al., 2004a) resolution (Figure 1.8). These structures 
validated conclusions drawn from the biophysical studies (Liu et al, 2004; Tripet 
et al., 2004; Xu et al.’ 2004b; Zhu et al., 2004). 
The first SARS-CoV S protein fusion core structure was constructed as a 
recombinant single-chain polypeptide by linking HRl (residues 900 - 948) and 
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HR2 (residues 1145 - 1184) via a linker (PDB IWNC) (Xu et al, 2004a). 
Another structure was prepared as a complex formed individually by HRl 
(residues 889 - 972) and HR2 (residues 1142 - 1185) synthetic peptides (PDB 
2BEZ) (Supekar et al, 2004). These two structures exhibit six-helix coiled-coil 
bundles in which three HRl helices form a central, parallel trimeric coiled-coil 
surrounded by three HR2 helices in an oblique anti-parallel orientation. Each HR2 
helix consists of a short five-turn a-helix (residues 1161 一 1175) and two 
extended regions (residues 1151 - 1160 and resides 1176 - 1185). The interaction 
between HRl and HR2 is largely hydrophobic, with each HR2 helix packs against 
a hydrophobic groove on the surface of the HRl central coiled-coil, in which the 
helical regions of HR2 pack exactly against the relatively deep grooves (residues 
909 — 927), and the extended regions of HR2 pack against the relatively shallow 
grooves (residues 928 - 947) (Xu et al.’ 2004b). 
Apart from the second-discovered structure (PDB 2BEZ), Supekar and 
co-workers also provided the structure of the fusion core complex consisting of 
smaller HRl peptides (residues 919 - 949) and HR2 peptides (residues 1149 -
1193) with extra C-terminal residues in proximity to TM (PDB 2BEQ) (Supekar 
et cd., 2004). The C-terminal part is a-helical and points away from the HRl 
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trimer axis, probably due to lack of stabilization by the corresponding HRl region. 
This structure was suggested to be an intermediate conformation adopted by S2 
subunit at the early stage of the fusion process or before the formation of the final 
post-fusion hairpin. 
A later structure was also constructed as a recombinant single-chain 
polypeptide by linking a longer HRl (residues 890 - 973) and HR2 (residues 
1145 — 1190) via a linker (PDB IWYY) (Duquerroy et al., 2005). It showed the 
hydrogen-bonding network formed by conserved Asp and Gin residues, together 
with two possible chloride ions, which could stabilize the conformation of the 
post-fusion hairpin. 
PDB 1WYY P D B 2 B E Z PDB 1WNC PDB 2BEQ 
I i i ^  
||i雪 
Figure 1.8: Current structural data of SARS-CoV S protein fusion core. 
The central HRl helices are shown in red, blue and green; the HR2 helices are shown in black. 
The N and C termini are labelled. (Modified from Bartlam et al, 2005) 
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1.5 3C-Iike Protease of SARS-CoV 
1.5.1 Extensive proteolytic processing of replicase polyproteins 
The SARS-CoV ORFla and ORFlb-encoded replicase polyproteins, ppla and 
pplab, can undergo extensive proteolytic processing by virus proteases to produce 
16 functional subunits, the 16 non-structural proteins (nsps), which are involved 
in the formation of the replicase complex that mediates viral replication and 
transcription (Table 1.2) (Snijder et al.，2003). 
Most of the coronaviruses express two papain-like proteases (PLlPr�and 
PL2Pro) and one major cysteine protease, called the main protease (M *^^ ") or the 
3C-like protease ( S C L ^ - Interestingly, SARS-CoV lacks the PLl^''^ (Marra et al., 
2004; Rota et al, 2003), but it can be assumed that its action is taken over by the 
PL2Pro: it is responsible for the cleavage of ppla and pplab at three sites near the 
amino-terminus, while the SCL'"^ ® cleaves at 11 conserved sites near the central 
and carboxyl-terminus (Thiel et al., 2003). 
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Table 1.1: Summary of SARS non-structural proteins (nsps). 
Protein ORF (location in genome sequence) Putative functional doinain(s) 
nspl ORF la (265 —804) --
nsp2 ORF la ( 8 0 5 - 2 7 1 8 ) --
nsp3 ORF 1 a (2719 - 8484) Ac, X’ PL2'''°, Y (TM 1 )，ADRP 
nsp4 O R F l a ( 8 4 8 5 - 9 9 8 4 ) TM2 
nsp5 ORF 1 a (9985 - 10902) 3CLP'° 
nsp6 O R F l a ( 1 0 9 0 3 - 11772) TM3 
nsp7 O R F l a ( 1 1 7 7 3 - 12081) --
nsp8 O R F l a ( 1 2 0 8 2 - 12615) --
nsp9 ORFla ( 1 2 6 1 6 - 12954) ssRNA binding 
nsplO O R F l a ( 1 2 9 5 5 - 13371) GFL 
nspl l O R F l a ( 1 3 3 7 2 - 13410) --
nspl2 O R F l b ( 1 3 3 9 8 - 16166) RdRp 
nspl3 O R F l b ( 1 6 1 6 7 - 17969) ZD, NTPase, HEL1 
nspl4 O R F l b (17970 — 19550) Exonuclease (ExoN homologue) 
nspl5 O R F l b (19551 - 2 0 5 8 8 ) NTD, endoribonuclease (XendoU 
homologue) 
nspl6 O R F l b ( 2 0 5 8 9 - 2 1 4 8 2 ) 2 ’ - 0 - M T 
Ac, acidic domain; ADRP, adenosine diphosphate-ribose 1 '-phosphatase; ExoN, 
3'-5'exonuclease; GFL, growth-factor-like domain; HELl , superfamily 1 helicase; Mpro, 
main (or 3C-like cysteine) protease; NTD, nidovirus conserved domain; NTPase, nucleoside 
triphosphatase; 20 -0 -MT, S-adenosylmethionine-dependent ribose 2‘-0-methyItransferase; 
PL2pro, papain-like protease 2; RdRp, RNA-dependent RNA polymerase; TM, 
transmembrane domain; X, Y, domains with unknown or hypothetical function; ZD, putative 
zinc-binding domain. (Modified from Bartlam et al, 2005) 
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1.5.2 SARS-CoV 3CL" 
The first structural models of SARS-CoV SCL^�were homology models built 
from the crystal structures of from HCoV-229E and TGEV (Anand et al., 
2003). The high-resolution X-ray crystal structure of SARS-CoV was 
solved at 1.9 A (PDB 1UK3) shortly after the peak of the SARS outbreak in 2003， 
which was the first crystal structure among the SARS-CoV proteins (Yang et al., 
2003). The reported SARS-CoV SCV"" structures provided important structural 
information for rational anti-SARS drug design (Anand et al.’ 2003; Yang et al., 
2003) (Figure 1.9). 
Monomer 1 Monomer 2 
一 Ml 
Domain II | ^ H f t ^ ^ u S n H 
^ H i t K m S m I ^ B 
Figure 1.9: The crystal structure of SARS-CoV 3CL''"'. 
SARS-CoV is a homodimer, in which each monomer comprises structural domains I， 
II and m . (Modified from PDB 1UK3) 
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SARS-CoV 3CLPr�is a 33.8-kDa dimeric enzyme with two perpendicularly 
arranged subunits. Each monomer consists of three domains: the N-terminal 
domains I (residues 8 — 101) and II (residues 102 - 184) resemble 
chymotrypsin-like p-barrel fold hosting the complete catalytic machinery, whereas 
the C-terminal domain III (residues 201 - 301) has a globular cluster of five 
mostly antiparallel a-helices and was shown to be essential for dimerization 
(Anand et aL, 2003; Yang et al, 2003). The active site for substrate recognition 
and catalysis of the enzyme is located in a cleft between domains I and II. In 
contrast to common serine proteases, which have the classical Ser-His-Asp 
catalytic triad at the active site, SARS-CoV 3CLP'° has a Cys-His catalytic dyad: 
the active nucleophile Cysl45 and the acid-base catalyst His41 (Thiel et al., 
2003). 
1.5.3 Substrate specificity of SARS-CoV SCI/*^ 
The substrate specificity of coronavirus SCL^^" is determined mainly by the PI, P2 
and PI，positions^^ (Hegyi and Ziebuhr, 2002). The PI position is usually a 
well-conserved Gin, P2 position seems to favour large hydrophobic residues, and 
PI’ position requires a small aliphatic residue. SARS-CoV cleaves the 
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replicase polyproteins at no less than 11 conserved sites, in which the substrate 
specificity involves preferentially the Leu-Gln i sequence in P2 and PI position at 
the cleavage site, respectively (Anand et al, 2003). Unlike other previously 
identified coronavirus 3CL''™, which have Leu/Ile at P2 position, SARS-CoV 
3CLpr° also tolerates Phe, Val and Met at P2 position. In order to understand the 
mechanism of substrate recognition and provide insights for rational anti-SARS 
drug design, a more comprehensive and valid interpretation on the substrate 
specificity preference of SARS-CoV 3CL''™ are necessary. 
1.6 SARS Drug Development 
1.6.1 Drug targets of SARS-CoV 
Till now, there are no approved antiviral drugs that are highly effective against 
SARS-CoV. However, many steps unique to SARS-CoV replication (Figure 1.4) 
could be targeted for development of antiviral drugs. 
'^The naming system for protease peptide substrate: The position (P) on the substrate is counted 
from the point of cleavage, PI is the position just before the cleavage site i , with PI, P2, ...etc. 
located at N-terminal to the cleavage site; and PI', P2', ...etc. located at C-terminal to the 
cleavage site (Berger and Schechter, 1970). 
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Step 1: Receptor binding 
Human monoclonal antibodies against the SARS-CoV SI subunit block the 
association of SARS-CoV with its receptor ACE2, indicating that the 
ACE2-binding site of S1 subunit could be a target for drug development (Sui et 
al, 2004). (5',5)-2-[l-carboxy-2-(3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl)-
ethylamino]-4-methy 1-pentanoic acid (MLN-4760) is the first small molecular-
weight inhibitor that was found to interact with the ACE2 active catalytic site 
(Towler et al, 2004), whether MLN-4760 inhibits SARS-CoV infection remains 
to be elucidated. Approximately 140,000 small molecules were screened by in 
silico molecular docking approach (Huentelman et al, 2004). This approach 
identified A^-(2-aminoethyl)-1 aziridine-ethamine (NAAE) as a novel ACE2 
inhibitor that is also effective in blocking the S protein-mediated cell fusion. 
Step 2: Membrane fusion 
Using a strategy similar to that utilized in the discovery of inhibitors of HIV 
gp41-mediated fusion that ultimately produced the drug enfuvirtide (T-20), 
peptides derived from the HRl and HR2 of S2 subunit of SARS-CoV were 
evaluated for their capacity to prevent infection of Vero-E6 cells (Bosch et al.， 
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2004; Liu et cd., 2004; Ni et al., 2004; Yuan et al., 2004; Zhu et al., 2004). 
Through the cell-based assays, the HR2-derived peptides showed inhibitory 
activities, but peptide derived from the HRl were not. However, the inhibitory 
potency of these HR2 peptides is considerably lower than similar inhibitors 
needed to prevent MHV and HIV-1 fusion (Bosch et al., 2004; Liu et al., 2004). 
Step 3: Replicase polyprotein processing 
As mentioned in the previous chapter, the cleavage of the SARS-CoV replicase 
polyproteins is processed by the SARS-CoV which is a key step for the 
replication of SARS-CoV making it an attractive target for the development of 
novel drugs against SARS. Both screening of currently available drugs and 
chemical libraries led to the identification of novel SARS-CoV 3CL''™ inhibitors. 
Binding pockets and affinities to SARS-CoV 3CLpro were predicted for clinically 
used anti-HIV (lopinavir and ritonavir), anti-psychotic (promazine), and 
anti-parasitic drugs (niclosamide) (Zhang and Yap, 2004). Screening of more 
than 10,000 agents led to the identification of a peptidic anti-HIV-1 agent that 
targets SARS-CoV 3(：1/*"�(Wu et al,, 2004a). The hexapeptidyl 
chloromethylketone (CMK), another peptidic inhibitor, binds irreversibly to 
CHAPTER 1. INTRODUCTION 35 
SARS-CoV 3CLPr。，s active site (Yang et al, 2003) whereas a bifunctional aryl 
boronic acid compound reversibly inhibits SARS-CoV SCL'"^ ® and appears to 
target a cluster of serine residues close to active site (Bacha et al, 2004). Several 
electrophilic keto-glutamine analogues with a phthalhydrazido group at the 
a-position were developed as reversible inhibitors of SARS-CoV 3CL''™ (Jain et 
al, 2004). Several non-covalent inhibitors of SARS-CoV SCL^ *^ ® was found using 
virtual screen by molecular docking of chemical databases (Liu et al, 2005). One 
of the most potent inhibitors was calmidazolium, a well known antagonist of 
calmodulin. The antiviral activities of these compounds against SARS-CoV 
3CLPr�in vitro and in vivo remain to be elucidated. 
Step 4: Viral RNA replication 
The intracellular SARS-CoV RNA replication displays further potential target for 
new therapeutic strategy. In this respect, the RNA-dependent RNA polymerase 
(SARS-CoV RdRp) maybe also a good target for anti-SARS drug design. Many 
nucleoside analogues were tested with the aim to inhibit SARS-CoV RNA 
polymerase (Xu et al.’ 2003). However, only P-D-A/^-hydroxycytidine showed 
activity against SARS-CoV replication in cell culture at a low level (Barnard et al. 
CHAPTER 1. INTRODUCTION 36 
2004). 
Step 5 and 6: Virus assembly and budding, and exocytosis 
Further potential targets are the SARS-CoV E and M proteins as they represent 
the minimum essential components for the assembly of coronaviruses which form 
the virus-like particles (Rota et al, 2003). Ultrastructurally, the process of 
SARS-CoV assembly is most likely localised to the ER-Golgi intermediate 
compartment (Klumperman et al, 1994). Together with strategies that may focus 
on the inhibition of virus assembly, the vims exit through exocytosis is also of 
interest for the development of new antiviral compounds. 
1.6.2 Current anti-SARS agents 
Due to the sudden and explosive emergence of SARS, empirical strategies were 
used to treat the SARS patients (Peiris et al, 2004; Fujii et al, 2004; Hui and 
Wong, 2004). These included various antibiotics, antiviral agents, corticosteroids, 
and interferons. Fusion inhibitors and natural products represent other therapeutic 
possibilities for SARS treatment. Table 1.2 shows the summary of the possible 
anti-SARS agents developed so far. 
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Table 1.2: Summary of current possible anti-SARS agents. 
Compounds Reported activity Anti-SARS activity References 
Aescin Active principle from SARS-CoV Wu et al, 2004a 
the horse chestnut replication inhibitor 
tree 
Aurintricarboxylic acid Vesicular stomatitis SARS-CoV He et al, 2004 
virus RNA replication inhibitor 
transcription inhibitor 
6-azauridine / orotidine SARS-CoV Cinatl et al, 2003a 
pyrazofurine monophosphate replication inhibitors 
decarboxylase 
inhibitors 
Baicalin Flavonoid derived SARS-CoV Chen et a/., 2004 
from Scutellaria replication inhibitor 
baicalensis 
P-D-V-hydroxycytidine - SARS-CoV RdRp Barnard et al, 
inhibitor 2004 
Calmidazolium Antigonist of SARS-CoV SCL"™ Liu et al.，2005 
calmodulin inhibitor 
Calpain inhibitors III Calpain inhibitors SARS-CoV Barnard et al., 
and VI replication inhibitors 2004 
Chloroquine -- SARS-CoV Keyaerts et al, 
replication inhibitor 2004 
CMK TGEV 3CLPr° SARS-CoV Yang et al.，2003 
inhibitor inhibitor 
Ginsenoside-Rbl Pharmacologically SARS-CoV Wu et a/., 2004a 
active compound of replication inhibitor 
Panax ginseng 
Glycyrrhizin and Anti-tumoural, SARS-CoV Cinatl et al, 2003a 
derivatives anti-inflammatory replication inhibitors 
and antiviral activities 
HR derived peptides -- SARS-CoV entry Bosch et a/., 2004; 
inhibitors Liu et a/., 2004; 
Yuan et al, 2004; 
Zhu et al, 2004 
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Interferons Antiviral activity SARS-CoV Cinatl et al, 
replication inhibitors 2003b 
Keto-glutamine -- SARS-CoV 3CV"° Jain et al., 2004 
analogues inhibitors 
Lopinavir / ritonavir HIV-1 protease SARS-CoV SCL*"" Chan et al.，2003 
inhibitors inhibitors 
Luteolin -- SARS-CoV entry Yi et a/., 2004 
inhibitor 
MLN-4760 -- ACE2 inhibitors Towler et al，2004 
N A A E ~ ACE2 inhibitors Huentelman et al., 
2004 
Niclosamide Anti-parasitic drug SARS-CoV Zhang and Yap, 
inhibitor 2004 
Nitric oxide Antiviral activity SARS-CoV Akerstrom et al, 
replication inhibitor 2005; Cinatl et al.’ 
2003a; Keyaerts et 
al., 2004 
Promazine Anti-psychotic drug SARS-CoV 3CLPr° Zhang and Yap, 
inhibitor 2004 
Reserpine Alkaloid produced by SARS-CoV Wu et al., 2004a 
Rauwolfia replication inhibitor 
Ribavirin Nucleoside analog SARS-CoV Koren et al, 2003; 
active against a replication inhibitor Morgenstem et al, 
diverse range of virus 2004 
TGG -- SARS-CoV entry Y i e / < 2 0 0 4 
inhibitor 
Quercetin -- SARS-CoV entry Yi et al, 2004 
inhibitor 
Vancomycin Antibiotic SARS-CoV Wu et al, 2004a 
replication inhibitor 
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1.7 Project Objectives 
In this project, we mainly focused on characterizing the SARS-CoV S protein 
fusion core and investigating the substrate specificity of SARS-CoV SCL''™. 
1.7.1 Characterization of SARS-CoV S protein fusion core 
As the SARS-CoV S protein fusion core plays a crucial role in the membrane 
fusion process between viral and target cells, it would be a good target for the 
drug development against SARS. In this study, we first investigated the structural 
basis of the fusion core via different biophysical techniques. We were particularly 
interested in characterizing the two different suggested sites of interaction 
between HRl and HR2: 1. Residues 902 - 952 of HRl and residues 1145 - 1184 
(Xu et al, 2004b); 2. Residues 916 - 950 of HRl and residues 1151 - 1185 of 
HR2 (Tripet et al., 2004). Drug development aims at inhibiting SARS-CoV entry 
by blocking the fusion core formation, which have been successfully applied in 
HIV-1 inhibitor development, maybe applicable to the inhibition of SARS-CoV 
on the basis of structural information provided here. The peptides derived from 
HR regions together with a series of small molecule compounds were screened 
using a HIV-luc/SARS pseudotyped virus entry inhibition assay. This study can 
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broaden our knowledge on the fusion mechanism of SARS-CoV and provide 
insights for the development of entry inhibitors targeted to the S protein fusion 
core. 
1.7.2 Characterization of SARS-CoV SCI/r� substrate 
specificity 
A better understanding of the specific enzyme substrate-binding mechanism 
during the SARS-CoV 3CL''™ proteolytic cleavage process is required for the 
rational design of an effective protease inhibitor with strong binding affinity to 
SARS-CoV 3CLPr�. To screen the substrate specificity of SARS-CoV in a 
rapid and highthroughput manner, we applied the matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 
combination with the novel "cartridge replacement" solid-phase peptide synthesis 
strategy to investigate the biological significance of amino acid residues in the P2, 
P3, P4, Pl,，P2，，and P3' positions that are flanking the conserved Gin residue in 
the PI position at the SARS-CoV SCL"""® cleavage site. Owing to the sensitivity of 
MALDI-TOF MS, the protease cleavage progress of a mixture of different peptide 
substrates can be monitored simultaneously to generate comprehensive data on the 
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substrate specificity of SARS-CoV 3CL'"'°. This study can provide insights into 
the molecular mechanism of the SARS-CoV SCL^ *"® cleavage process and reveal 
the feasibility of developing synthetic peptide-based protease inhibitors as 
potential drugs against SARS-CoV. 
End of chapter. 
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Chapter 2 
Materials and Methods 
2.1 Characterization of SARS-CoV S Protein Fusion 
Core 
2.1.1 Bioinformatics analyses of heptad repeat regions of 
SARS- CoV S protein 
The genome sequence of SARS-CoV S protein used for recombinant protein or 
synthetic peptide design in this study was based on the SARS-CoV CUHK-SulO 
complete genome sequence [GenBank accession no. AY282752] downloaded 
from GenBank^ (Appendix I). The protein sequence of S protein of the 
SARS-CoV CUHK-SulO strain was also downloaded from GenBank [GenBank 
accession no. AAP30713] (Appendix II) and submitted to different programs for 
heptad repeat analysis. LearnCoil-VMF program^ (Singh et al., 1999) was 
employed to identify coiled-coil regions in the SARS-CoV S protein. Multicoil 
program^ (Wolf et al, 1997) was employed to predict the heptad repeat patterns of 
http://www.ncbi.nlm.nih.gov/entrez 
^LearnCoil-VMF program (http://learncoil-vmf.lcs.mit.edu/cgi-bin/vmf) is a neural 
network-based program for detecting coiled-coil regions in viral membrane-fusion proteins. 
^Multicoil program (http://multicoil.lcs.mit.edu/cgi-bin/multicoil) is a neural network-based 
program for predicting the location of coiled-coil regions in amino acid sequences and classifies 
the predictions as dimeric or trimeric. 
CHAPTER 2. MA TERIALS AND METHODS 43 
HRl and HR2 of the SARS-CoV S protein. The helical wheel diagrams of HRl 
and HR2 were designed according to the results of LearnCoil-VMF and Multicoil. 
2.1.2 Recombinant protein approach 
Based on the bioinformatics analyses of heptad repeat regions of SARS-CoV S 
protein, recombinant proteins His6-HR1 (residues 899 - 958), GST-HR2 / 
GST-removed HR2 (residues 1145 - 1192) and HR-2-Helix (linking HRl and 
HR2 with a flexible linker) were constructed. 
2.1.2.1 Plasmids construction 
Design of primers for the cloning of HRl, HR2 and HR-2-Helix 
For the HRl construct (pET-28a-HRl), a pair of primers was designed for 
directional cloning of HRl DNA fragment into the pET-28a His6-tagged 
expression vector (Novagen) (Appendix III). 
Forward primer Ta = 52°C 
GC clamp 




Reverse primer Ta = 52°C 
GC clamp Stop condon 
5'- GGC GTC GAC TTA CAC ACT TGAAAT TGC ACC AAA ATT AG -3’ 
Y 
Sail site 
CHAPTER 2. MA TERIALS AND METHODS 44 
For the HR2 construct (pGEX-6P-l-HR2), a pair of primers was designed for 
directional cloning of HR2 DNA fragment into the pGEX-6P-l GST-fusion 
expression vector (GE Healthcare) (Appendix III). 
Forward primer Ta = 48�C 
GC clamp Flexible linker: N’- Gly-Ser-Gly-Gly - C 
r ^ . 入 ^ 
5'- AAT GAA TTC GGC AGC GGC GGC GAT GTT GAT CTT GGC GAC -3' 
、 一 J 
Y 
EcoRl site 
Reverse primer Ta = 47°C 
GC clamp Stop condon 
5'- GGC GTC GAC TTAAAT ATATTG CTCATATTT TCC CAA-3’ 
Y 
Sail site 
For HR-2-Helix construct, it was made by linking the HRl (residues 899 -
958) and HR2 (residues 1145 - 1192) with a ten-amino acid flexible linker (N'-
Gly-Gly-Ser-Gly-Glu-Phe-Gly-Gly-Ser-Gly - C ) . Two pairs of primers were 
designed for directional cloning of HRl (HRl (B/E)) and HR2 (HR2 (E/S)) DNA 
fragments into the pGEX-6P-l vector. 
Forward primer of HRl (B/E) Ta = 52^C 
GC clamp 
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Reverse primer of HRl (B/E) Ta = 46°C 
GC clamp Flexible linker: C - Gly-Ser-Gly-Gly -N' 
r ^ r 入 ^ 
5'- GGC GAATCC GCC GCT GCC GCC CAC ACT TGAAAT TGC ACC -3' V ) 
Y 
EcoRl site 
Forward primer of HR2 (E/S) 丁a = 48°C 
GC clamp Flexible linker: N’- Gly-Ser-Gly-Gly -C， 
r - ^ r 入 ^ 




Reverse primer of HR2 (E/S) Ta = 47°C 
GC clamp Stop condon 
5，- GGC GTC GAC TTA AAT ATA TTG CTC ATA TTT TCC CAA -3 ’ 
Sail site 
DNA amplification using Polymerase Chain Reaction (PCR) 
A standard PCR reaction mix was set with the following composition: 
Components Volume Final concentration 
DNA template (100 ng/|xL) 1 |iL 100 ng 
Forward primer (10 | iM) 1 |iL 0.2 |iM 
Reverse primer (10 _ ) 1 |j,L 0.2 |iM 
dNTPs mix (2 mM each nucleotide) 5 |j,L 200 |iM each nucleotide 
Pfu DNA polymerase (3 U/|aL) 1 |iL --
Pfu DNA polymerase 1 Ox reaction b u f f e / 5 |iL IX 
Autoclaved ddHzO 36 |iL -
Total 50 |iL ^ ‘ 
^Pfu DNA polymerase lOx reaction buffer: 200 mM Tris-HCl (pH8.8), 20 mM MgSOq, 100 mM 
KCl, 100 mM (NH4)2S04’ 1% Triton® X-100, 1 mg/mL nuclease-free bovine serum albumin 
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The DNA template, pS0S-S2 (pSOS vector containing the S2 (residues 
680 - 1255) DNA fragment, which was amplified from SARS-CoV CUHK-SulO 
strain cDNA), was kindly provided by Mr. Patrick Law T.W.). All the primers 
were synthesized by Invitrogen™. The Pfu DNA polymerase and Pfu DNA 
polymerase lOx reaction buffer were purchased from Promega. The PCRs were 
performed in a thermocycler (Eppendorf) equipped with a heat lid (105°C). The 
PGR temperature profile was set as following: 
Step 1 Preincubation 95°C 3 min 
Step 2 Denaturation 95°C 36 sec 
Step 3 Annealing 52 °C 45 sec 
Step 4 Extension 72 °C 1 min 
Steps 2 to 4 were repeated for 34 more cycles 
Step 5 Final extension 72 °C 10 min 
Amplification of the HRl , HR2 and HR-2-Helix DNA fragments were 
checked by running the PGR products in 1.5% agarose (USB) gel electrophoresis 
in TAE buffer (40 mM Tris, 0.1% (v/v) acetic acid, 1 mM EDTA, pH 8.0) under 
120 V for 20 min. The PGR products were visualized under UV trans-illumination 
after ethidium bromide (10 mg/mL, Invitrogen) staining. 
DNA extraction from agarose gels 
QIAquick Gel Extraction Kit (QIAGEN) was used to extract DNA from agarose 
gel. 
PGR products were excised out from the agarose gel with a scalpel. 800 jil of 
Buffer QG was added to dissolve the gel slice by incubation at 50°C. After the gel 
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slice was dissolved completely in the solution, the mixture was applied to the 
QIAquick column and centrifuged for 1 min at maximum speed (16,000 g) in a 
bench top centrifuge so that the DNA fragments can bind to the column. 
Flow-through was discarded. 750 |il Buffer PE was added to the column and 
centrifuged for 1 min again to wash. Flow-through was discarded and the 
QIAquick column was centrifuged for further 1 min to remove residual ethanol. 
30 III autoclaved ddHiO pre-warmed at 70°C was added to the centre of the 
column membrane and allowed to stand for 1 min. Finally, DNA was eluted by 
centrifugation for 2 min. 
Restriction digestion of purified PCR products and vectors 
The PCR products were subjected to two different restriction digestion profiles 
according to the primers used for PCR amplification. 
For pET-28a-HRl, the following reaction profile was used: 
Component HRl pET-28a (45 ng/^L) 
PCR product 25 ^L “ 
Vector - 7 |iL 
Bamm (15 U/|iL) 1 ^L 0.5 |iL 
Sail (15 U/|iL) 1 |iL 0.5 ^L 
1 Ox One-Phor-All PL US buffer; 8 |xL 2 |iL 
Autoclaved ddHzO 5 |iL -
Total 40 |iL 10 |iL 
^lOx One-Phor-All PLUS buffer: 100 mM Tris-acetate (pH7.5), 100 mM magnesium acetate, 
200 mM potassium acetate 
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For pGEX-6P-l-HR2, the following reaction profile was used: 
Component HR2 pGEX-6P-l (105 ng/^iL) 
PGR product 28 \ i L “ 
Vector ~ 6 |iL 
EcoRl (15 U / [ l L ) 1 |iL 1 |iL 
Sail (15 U/^L) 1 |iL 1 |xL 
1 Ox One-Phor-All P L U S buffer 8 iiL 2 |iL 
Autoclaved ddHsO 2 |iL -
Total 40 ^L 10 nL 
For HR-2-Helix construct, HRl (B/E) was first cloned into pGEX-6P-l 
vector. The following reaction profile was used to generate pGEX-6P-l-HRl (B/E) 
plasmid: 
Component HRl (B/E) pGEX-6P-l (105 ng/^L) 
PGR product 28 [iL “ 
Vector - 7 |iL 
5 a m H l ( 1 5 U / | a L ) 1 |iL 0.5 ^L 
EcoRl (15 U/|iL) 1 [iL 0.5 |iL 
lOx One-Phor-All PLUS buffer 8 \ i L 2 |iL 
Autoclaved ddHzO 2 |iL — 
Total 40 i^L 10 ^L 
HR2 (E/S) was first then cloned into the pGEX-6P-l-HRl (B/E) plasmid, the 
following reaction profile was used to generate pGEX-6P-1 -HR-2-Helix: 
Component HR2 (E/S) pGEX-6P-l-HRl 
PGR product 28 \xL “ 
Vector -- 7 i^L 
EcoRl (15 U/^iL) 1 i^L 0.5 ^L 
> M ( 1 5 U / ^ i L ) I |iL 0.5 |iL 
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lOx One-Phor-All buffer PLUS S^iL 
Autoclaved ddH20 2 |iL --
Total 40 [iL 10 |iL 
The lOx One-Phor-All buffer PLUS and the enzymes were purchased from 
GE Healthcare. The reaction mixtures were incubated at 37°C for 3 hours. The 
completion of digestion was checked by agarose gel electrophoresis and DNA 
was extracted and purified by QIAquick Gel Extraction Kit as described above. 
Ligation of PCR products into expression vectors 
The T4 DNA ligase together with the lOx ligation buffer was purchased from 
New England Biolabs Inc. The purified cohesive inserts from restriction digestion 
were ligated into the restricted vectors at 3:1 (insert : vector) molar ratio. The 
reactions were performed at 4°C overnight. The following table shows the 
composition of the reaction mixture: 
Component Ligation reactions Negative control 
Insert 14 |iL -
Vector 3fiL 
1 OX T4 DNA ligation buffer^ 2 [ i L 2 |iL 
T4 DNA ligase 1 |iL 1 |iL 
Autoclaved ddH20 -- 14 [iL 
Total 20 i^L 20 ^L 
'lOX T4 DNA ligation buffer: 500 mM Tris-HCl (pH 7.5), 100 mM MgCb, 100 mM DTT, 10 
mM ATP, 250 fig/mL bovine serum albumin 
Preparation of E. coli competent cells DH5a 
The RF I (100 mM RbCl, 50 mM MnCb, 30 mM Potassium acetate, 10 mM 
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CaCl2, 15% glycerol, pH 5.8) and RF II (10 mM MOPS, 10 mM RbCl, 75 mM 
CaCl2, 15% glycerol, pH 6.8) buffers were prepared prior to the preparation of 
competent cells. Frozen glycerol stock of Escherichia coil {E. coli) strain 
DH5a (GIBCO) stored at -80�C was streaked onto a LB agar plate (35 g/L LB 
agar, USB). The streaked plate was incubated at 37°C for 16 hours for the bacteria 
to grow. A single colony was picked and inoculated into 5 mL LB broth (20 g/L 
LB broth, USB) and cultured at 3 7 � C for 16 hours with shaking at 250 rpm. After 
that, the starter culture was inoculated into 250 mL LB broth. The culture was 
allowed to grow at 37°C with shaking at 250 rpm until OD at 600 nm reached 
0.3-0.5. The bacterial cells were harvested by centrifugation at 959 g for 10 min at 
4°C. The supernatant was discarded. The pellet was resuspended in 83 mL RF I 
buffer and chilled on ice for 15 min. The suspension was centrifuged again at 959 
g for 10 min at 4°C. The supernatant was discarded. The pellet was resuspended in 
20 mL RF II buffer and further incubated on ice for 15 min. The competent cells 
were then snap frozen in liquid nitrogen in 200 |j.l aliquots and stored at -80°C 
until use. 
Transformation of plasmids into DH5a competent cells 
200 jil aliquots of E. coli strain DH5a competent cells were thawed on ice for 10 
min. The ligation product or negative control was added into the each tube of 
competent cells and mixed gently. The mixtures were then incubated on ice for 20 
min followed by heat shock at 42°C for 1 min 30 sec. After that, the mixture was 
placed on ice for 2 min. 800 |il LB broth was added to each tube and the bacteria 
CHAPTER 2. MA TERIALS AND METHODS 51 
were allowed to recover at 37°C with shaking at 250 rpm for 45 min. Next, the 
bacterial cells were spun down at 9,820 g for 1 min. Most of the medium was 
removed and the transformed cell pellets were resuspended in the last drop of 
medium. The bacterial suspensions were spread onto LB agar plate supplemented 
with appropriate antibiotics (LB agar plates with 30 |ig/mL kanamycin for cloning 
into pET-28a vector and 100 |a.g/mL ampicillin for cloning into pGEX-6P-l 
vector). Finally, the plates were incubated at 37°C for 16 to 18 hours. 
Mini-preparation of plasmid DNA 
A single bacterial colony was inoculated from the agar plate into 5 mL LB broth 
supplemented with appropriate antibiotics. The culture was grown for 16 to 18 
hours at 37°C with shaking at 250 rpm. The bacterial cells were harvested by 
centrifugation at 16,000 g for 10 min. The plasmid DNA was isolated using the 
Marligen Biosciences CONCERT^'^ Rapid Plasmid Minipreps kit. The cell pellet 
obtained was resuspended in 250 chilled G1 buffer (50 mM Tris-HCl (pH 8.0), 
lOmM EDTA) containing RNase A. 250 [d G2 cell lysis solution (200 mM NaOH, 
1% SDS (w/v)) was further added and then mixed gently by inversion. The 
mixture was incubated at room temperature for 5 min. After that, 350 }il M3 
neutralizing buffer (contains acetate and guanidine hydrochloride) was added and 
mixed by inversion for five times. The mixture was centrifuged immediately at 
16,000 g at room temperature for 10 min. The supernatant obtained was loaded 
into the spin cartridge and centrifuged at 16,000 g for 1 min. The flow-through 
was discarded. The cartridge was washed by adding to it 700 G4 wash buffer 
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(contains NaCl, EDTA, Tris-HCl (pH 8.0) and ethanol) and then spun at 16,000 g 
for 1 min again. The flow-through was discarded. Residual ethanol was removed 
by further spinning at 16,000 g for 1 min. Finally, 60 |il autoclaved ddHiO 
pre-warmed at 70°C was added to the centre of the cartridge membrane and 
incubated at room temperature for 1 min. Finally, plasmids were eluted into clean 
sterile eppendorfs by spinning at 16,000 g for 2 min. The presence of the insert 
was checked by restriction digestion, PCR amplification and DNA sequencing. 
2.1.2.2 Protein expression and purification 
Preparation of E. coli competent cells BL21 
The procedures of preparation of E. coli competent cell strain BL21 (BL21 (DE3) 
pLysS) (Novagen) were the same as that of the preparation of DH5a except 17 
)ig/mL chloramphenicol was added to the LB agar plate as well as the LB broth 
during propagation. 
Protein expression of His6-HR1, GST-HR2, GST-removed HR2 and 
HR-2-Helix 
The pET-28a-HRl, pGEX-6P-l-HR2 and pGEX-6P-l-HR-2-Helix plasmids were 
transformed into E. coli strain BL21 competent cells for His6-HR1, GST-HR2 and 
HR-2-Helix protein expression. The plasmids were spread on LB agar plates 
containing appropriate antibiotics and chloramphenicol (17 jig/mL) (LB agar 
plates with 30 |Lig/mL kanamycin for cloning into pET-28a vector and 100 ^ig/mL 
ampicillin for cloning into pGEX-6P-l vector) and grown overnight at 37 A 
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single colony was inoculated into 50 mL of LB broth containing appropriate 
antibiotics and grown overnight at 37®C with shaking. This overnight culture was 
then transferred into 4 L of LB broth containing appropriate antibiotics for 
large-scale protein expression at 37°C with shaking. When the culture was grown 
to an ODeoonm of 0.6， it was induced with 0.1 mM 
isopropyl-1 -thio-P-D-galactopyranoside (IPTG) and grown for an additional 6 
hours at 37°C for Hisg-HRl and GST-HR2, and 2 5 � C for HR-2-Helix. Cells were 
harvested by centrifugation at 9,820 g at 4°C for 5 min. 
Purification of His6-HR1 
The bacterial cell pellet of His6-HR1 was resuspended in Phosphate-buffered 
Saline (PBS, 140 mM NaCl，2.7 mM KCl, 10 mM NazHPO*，1.8 mM KH2PO4, 
pH 7.4) containing 10 mM imidazole (USB) and 0.2 mM phenylmethylsulfonyl 
fluoride (PMSF) and homogenized by sonication. The lysate was then centrifuged 
at 48000 g for 45 min at 4 � C . The supernatant containing soluble His6-HR1 was 
loaded onto a His-Select Nickel Affinity Gel column (Sigma) equilibrated with 
PBS and incubated at 4°C for overnight for nickel affinity chromatography. The 
column was then washed with over 10 bed volumes of PBS containing 10 mM, 50 
mM and 100 mM imidazole respectively until no obvious protein can be detected 
by the Bradford protein assay (Bio-Rad). The His-tagged Hise-HRl protein was 
finally eluted with PBS containing 150, 200，250 and 300 mM imidazole 
respectively. 
The eluted His6-HR1 was concentrated by Macrosep® Centrifugal Device 
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3K MWCO Omega (Pall) and further purified by a preparative reverse-phase 
high-performance liquid chromatography (RP-HPLC) column (Alltima CI8 5|j., 
250 mm x 10 mm, Alltech) on the Agilent Technologies 1100 Series analytical 
and preparative RP-HPLC system using a linear gradient, 2% B/min, formed from 
the solvent systems A (0.05% trifluoroacetic acid (TFA, Riedel-de Haen) in H2O) 
and B (0.05 % TFA in acetonitrile (ACN)). The identity of His6-HR1 was 
confirmed by MALDI-TOF MS on an ABI 4700 MALDI TOF/TOF Analyzer 
(Applied Biosystems) in a linear-positive ion mode. Fractions of RP-HPLC 
containing the protein were lyophilized overnight and stored in desiccators at 
room temperature until use. The protein was finally dissolved in PBS and the 
purity was analyzed by an analytical RP-HPLC column (Alltima CI8 3)j_, 33 mm 
X 7 mm, Alltech) in a linear gradient of 2% B/min. 
Purification of GST-HR2 and GST-removed HR2 
The bacterial cell pellet of GST-HR2 was resuspended in PBS containing 0.2 mM 
PMSF and homogenized by sonication. The lysate was centrifuged at 48000 g for 
45 min at 4°C, and the supernatant was loaded onto a Glutathione Sepharose™ 4 
Fast Flow affinity column (GE Healthcare) equilibrated with PBS containing 0.2 
mM PMSF and incubated at 4°C for overnight with end-over-end rotation for 
glutathione affinity chromatography. The column was then washed with over 10 
bed volumes of PBS containing 0.2 mM PMSF until no obvious protein can be 
detected by the Bradford protein assay. 
For GST-fusion GST-HR2 protein, target protein was eluted with PBS 
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containing 10 mM reduced glutathione (Calbiochem) and 0.2mM PMSF, and 
subjected to size-exclusion chromatography (SEC). HiLoad"^^ 16/60 SuperdexTM 
75 Prep Grade column (GE Healthcare) was used for SEC and AKTAprimeTM 
plus (GE Healthcare) served as the pumping system. The column was firstly 
washed with 1 bed volume of dHiO (120 mL) and then equilibrated with PBS 
containing 0.2 mM PMSF for 1 bed volume. Protein sample was concentrated to 2 
mL by an Amicon Ultra-15 MWCO 5K filter (Millipore) and was injected and 
eluted at 2 mL/min by further running 1 bed volume of PBS. The whole process 
was carried out at 4°C. The dHzO and buffer were passed through 0.22 jxm filters, 
and protein samples were centrifuged to remove aggregates at 16,000 g for 5 min 
prior to injection. 
For GST-removed HR2, it was generated by cleaving the GST-tag from the 
GST-HR2 protein. PreScission Protease (GE Healthcare) was added into the 
Glutathione S e p h a r o s e T M 4 Fast Flow affinity column after the glutathione affinity 
chromatography, and the mixture was incubated overnight at 4°C. The GST 
removed HR2 protein was eluted with PBS, concentrated by Macrosep® 
Centrifugal Device 3K MWCO Omega and further purified by the preparative 
RP-HPLC column using a linear gradient, 2% B/min, formed from the solvent 
systems A and B. The identity of GST-removed HR2 was confirmed by 
MALDI-TOF MS on an Ettan MALDI-TOF Pro Mass Spectrometer (GE 
Healthcare) in a reflectron-positive ion mode. Fractions of RP-HPLC containing 
the protein were lyophilized overnight and stored in desiccators at room 
temperature until use. The protein was finally dissolved in PBS and the purity was 
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analyzed by the analytical RP-HPLC column in a linear gradient of 2% B/min. 
Purification of HR-2-Helix 
The bacterial cell pellet of HR-2-Helix was resuspended in PBS containing 0.2 
mM PMSF, and homogenized by sonication. The lysate was centrifuged at 48000 
g for 45 min at 4°C, and the supernatant was loaded onto a Glutathione 
S e p h a r o s e T M 4 Fast Flow affinity column equilibrated with PBS containing 0.2 
mM PMSF and incubated at 4°C for overnight with end-over-end rotation. The 
column was then washed with over 10 bed volumes of PBS containing 0.2 mM 
PMSF until no obvious protein can be detected by the Bradford protein assay. To 
cleave the GST-tag from the GST-fusion HR-2-Helix protein, PreScission 
Protease was added into the column, and the mixture was incubated overnight at 
4°C. The GST-cleaved HR-2-Helix protein was eluted with PBS, concentrated to 
2 mL by an Amicon Ultra-15 MWCO 5K filter and subjected to SEC in H i L o a d ™ 
16/60 SuperdexTM 75 Prep Grade column as described above. As HR-2-Helix was 
co-eluted with the GST-tag, the eluted fractions were poured together and the 
HR-2-Helix was re-purified by glutathione affinity chromatography to remove the 
GST-tag. 
The HR-2-Helix protein was eluted with PBS, concentrated by the Amicon 
Ultra-15 MWCO 5K filter and further purified by the preparative RP-HPLC 
column using a linear gradient, 0.5% B/min, formed from the solvent systems A 
and B. The identity of HR-2-Helix was confirmed by ABI 4700 MALDI 
TOF/TOF Analyzer in a linear-positive ion mode. Fractions of RP-HPLC 
CHAPTER 2. MA TERIALS AND METHODS 57 
containing the protein were lyophilized overnight and stored in desiccators at 
room temperature until use. The protein was finally dissolved in PBS and the 
purity was analyzed by the analytical RP-HPLC column in a linear gradient of 2% 
B/min. 
2.1.2.3 Amino acid analysis 
Acid hydrolysis and chromatographic separation 
About 10 mg of lyophilized proteins were dissolved in 0.5 mL PBS and subjected 
to acid hydrolysis. Each diluted sample was mixed with 1 mL 6N HCl (Sigma 
H0636) and introduced into the bottom reservoir of the 5-mL vacuum hydrolysis 
tube (Pierce) using a small-diameter glass pipette (disposable Pastuer). The 
Telflon® plug was inserted and screwed down just enough to leave a small 
passageway between the plug and the glass at the stricture point. The tube was 
then secured and the vacuum source was applied through the side arm. After the 
tube was evacuated, the united was sealed by slowly screwing the plug and 
detached from the vacuum source. The whole tube was then incubated at 110®C 
for 24 hours. 
After acid hydrolysis, the tube was allowed to cool down in an ice-bath. The 
sample was completely drawn out from the tube and "speedvac" dried at 50°C for 
3 hours. The dried sample pellet was then dissolved in 0.5 mL Beckman 6300 
higher performance amino acid sample dilution buffer, Na-S™, and filtered with a 
0.22 |Lxm nylon acrodisc filter (Gilman). The filtered sample was finally submitted 
for chromatographic separation by postcolumn derivatization method: a single 
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ion-exchange column system was employed in the Beckman Model 6300 high 
performance amino acid analyzer^. 
Quantitation of recombinant proteins 
The amount of proteins in each diluted sample was based on the yield of each 
well-recovered residue (Asx, Glx, Ala, Leu, Gly, or Lys). That amount is 
converted to a concentration (mg/mL) by multiplying the number of nmols 
(obtained from AAA) assayed by the molecular weight of the protein. 
2.1.2.4 GST-pulldown experiment 
For the analysis of His6-HR1 and GST-HR2, partial purified His6-HR1 was mixed 
with an equal molar concentration of partial purified GST-HR2 at room 
temperature for 1 hour. Then the mixture was loaded onto a Glutathione 
SepharoseTM 4 Fast Flow affinity column equilibrated with PBS and incubated at 
room temperature for another 1 hour with end-over-end rotation. The column was 
then washed with over 10 bed volumes of PBS containing 0.2 mM PMSF until no 
obvious protein can be detected by the Bradford protein assay and eluted by PBS 
containing 10 mM reduced glutathione. The collected samples were mixed with 
6X SDS gel-loading buffer (300 mM Tris-HCl (pH 6.8), 600mM DTT, 12% SDS, 
0.6% (w/v) bromophenol blue, 60% glycerol) and then loaded to a 10 cm X 1 cm 
20% Tris-tricine SDS gel (30 )jL each well) in Tris-tricine SDS running buffer 
Chromatographic separation was done by Tang Cho On Thomas (Technician) in Department of 
Biology, The Chinese University of Hong Kong. 
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(100 mM Tris-HCl, 100 mM Tricine, 0.1% (w/v) SDS). SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) was carried out with 125 V constant voltages at 
room temperature for 2 hours. The gel was then subjected to Coomassie blue 
staining and Western blotting analysis. 
Coomassie blue staining analysis 
The gel was stained with Coomassie blue (0.15% (w/v) Coomassie Brilliant Blue 
R-250 (Sigma), 3:6:1 (v/v) methanol : dH^O : glacial acetic acid) at room 
temperature for overnight with gentle shaking. The gel was then destained in 
de-staining solution (3:6:1 (v/v) methanol : dHiO : glacial acetic acid) at room 
temperature with gentle shaking until the background was completely removed 
and the peptide bands were visualized. 
Western blotting analysis 
A piece of transfer membrane (Immobilon-P PVDF 0.2 |j,m (Millipore)) was 
activated by 100% Methanol and pre-wet in transfer buffer (39mM glycine, 
48mM Tris-HCl (pH8.3), 0.037% SDS, 20% methanol) with four Whatman 3MM 
papers for 5 minutes. Proteins were transferred from the gel to the membrane in a 
semi-dry transfer unit at constant voltage of 15 V for 1 hour. After the transfer, the 
membrane was ready for Western blotting. In order to detect both His6-HR1 and 
GST-HR2 in the same membrane, the membrane was first probed with anti-His6 
antibody. Afterward, the anti-His6 antibody was stripped from the membrane and 
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re-probed with anti-GST antibody. 
To detect the His6-HR1, the membrane was first blocked in 5 mL blocking 
buffer (PBST (PBS containing 0.1% (v/v) Tween 20) containing 10% (w/v) 
non-fat dried milk powder) at room temperature for 1 hour, 25 fil of anti-Hise 
primary antibody (His-probe mouse monoclonal IgGi, 200 |ig/mL (Santa Cruz 
Biotechnology)) in 5 mL PBST containing 5% (w/v) non-fat dried milk powder 
(200-fold dilution) was added to the membrane and incubated at 4°C with 
end-over-end rotation for overnight. The membrane was then washed three times 
(10 minutes each) in wash buffer (PBST). Afterward, 2.5 \x\ of secondary antibody 
(anti-mouse IgG, Horseradish Peroxidase linked whole antibody (from sheep) 
(Santa Cruz Biotechnology)) in 5 mL PBST containing 5% (w/v) non-fat dried 
milk powder (2000-fold dilution) was added to the membrane and incubated at 
room temperature with end-over-end rotation for 1 hour and it was washed again 
with wash buffer. 1 mL Western Lightning® Western Blot Chemiluminescence 
Reagent Plus (0.5 mL oxidizing reagent and 0.5 mL enhanced luminol reagent) 
(Perkin Elmer) was then pipetted on to the membrane. The membrane was placed 
in an x-ray film cassette and brought into a dark room. A sheet of autoradiography 
film (Fuji) was placed on top of the membrane. The cassette was then closed and 
the film was exposed. Finally, the film was developed and fixed. 
To detect the GST-HR2, the bound anti-His6 antibody was first stripped from 
the membrane. The membrane was incubated in Restore™ Western Blot Stripping 
buffer (Pierce) at 3 T C with gentle shaking for 20 minutes and washed with wash 
buffer. The membrane was then re-probed with anti-GST antibody (GST (B-14) 
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mouse monoclonal IgGi, 200 |ig/mL (Santa Cruz Biotechnology)) as primary 
antibody. The same secondary antibody was used and the western blotting 
procedures were as described above. 
2.1.2.5 Laser light scattering 
Size-exclusion chromatography / light scattering (SEC / LS) 
His6-HR1 was incubated with an equal molar concentration of GST-removed HR2 
at 37°C for 1 hour (the final concentrations of His6-HR1 and GST-removed HR2 
were 1.25 mg/mL). After incubation, 150 fiL of sample was injected into 
SuperdexTM 75 10/300 GL Columns (GE Healthcare), which was connected 
in-line with the laser light scattering (LS) system (Wyatt Technology) with the 
following flow detectors: LS detector - WyattQELS™ 
(Quasi-Elastic-Light-Scattering) detector for combination with miniDAWN; 
refractive index (RI) detector - Optilab® DSP; and dynamic LS detector -
DynaProTM Titan. AKTAtmfPLCtm was served as the solvent delivery and 
pumping system. The column was equilibrated with PBS for 48 hours prior to 
sample injection. PBS was used as a mobile phase with a flow rate at 0.75 
mL/min. The whole process was carried out at room temperature. The buffer had 
been passed through 0.22 |im filter and protein sample was centrifuged at 16,000 
g for 5 min prior to injection. 
For HR-2-Helix, 150 ^iL of 1 mg/mL sample was also analyzed by SEC / LS 
as described above. 
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Molecular weight determination 
Molecular weights of His6-HR1, GST-removed HR2, the Hise-HRl / 
GST-removed HR2 complex and HR-2-Helix were determined using ASTRA 
calculations. The ASTRA software (Wyatt Technology) used data acquired across 
the entire peaks generated by the LS and RI detectors. A dn/dc value of 0.185 
mL/g was used. The molar mass distribution plots of Hise-HRl, GST-removed 
HR2, the His6-HR1 / GST-removed HR2 complex and HR-2-Helix were finally 
generated. 
2.1.2.6 Size-exclusion chromatography 
For the analysis of HR-2-Helix, purified protein (5 mg/mL) was loaded onto 
HiLoadTM 16/60 Superdex™ 75 Prep Grade column as described above. Gel 
Filtration Low Molecular Weight Calibration Kit consisting of Bovine Serum 
Albumin (67000 Da), Ovalbumin (43000 Da), Chymotrypsinogen A (25000 Da) 
and Ribonuclease A (13700 Da) was used. The whole process was carried out at 
room temperature. The buffer had been passed through 0.22 p,m filter and protein 
sample and standard were centrifuged at 16,000 g for 5 min prior to injection. 
2.1.2.7 Circular dichroism spectroscopy 
His6-HR1 was incubated with an equal molar concentration of GST-removed HR2 
in PBS at 37�C for 1 hour (the final concentrations of His6-HR1 and 
GST-removed HR2 were 25 ^iM). After incubation, circular dichroism (CD) 
spectra of His6-HR1, GST-removed HR2 and His6-HR1 / GST-removed HR2 
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complex were measured on a JASCO J-810 spectropolarimeter equipped with a 
peltier-type temperature control unit. Wavelength spectra scanning from 260 -
190 nm at 20 nm min'' at 37°C using a 1-mm pathlength rectangular quartz 
cuvette (llOQS, Hellma®) were recorded. 
The stability measurement of His6-HR1 from thermal denaturation was 
followed by molar ellipticity at 222 nm. The protein sample (25 |j,M) was 
thoroughly degassed before CD measurements. The sample was heated in a 
cuvette from 37 to 100°C at a heating rate of 1° min"^ The cuvette was securely 
stoppered to ensure that there was no loss in the volume of the protein solution 
because of evaporation. Wavelength spectrum scanning from 260 - 190 nm at 
100°C was also recorded. For the thermal reversible reaction of His6-HR1, the 
temperature was then immediately decreased from 100 to 37°C. Wavelength 
spectrum scanning from 260 - 190 nm at 37°C was recorded. 
For the stability measurement of the His6-HR1 / GST-removed HR2 complex 
from thermal denaturation, it was also followed by molar ellipticity at 222 nm. 
The protein sample was thoroughly degassed before CD measurements. The 
sample was heated in the cuvette from 37 to 100°C at a heating rate of 1° min"'. 
Wavelength spectrum scanning from 260 - 190 nm at 100°C was also recorded. 
For the thermal reversible reaction of the complex, the temperature was then 
immediately decreased from 100 to 37®C. Wavelength spectra scanning from 
260 - 190 nm at 37°C were recorded at 0 hour and 24 hour. 
For HR-2-Helix (50 in PBS, wavelength spectrum scanning from 260 -
190 nm at 20 nm min'' at 37°C were recorded. The stability measurement of the 
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HR-2-Helix protein from thermal denaturation was followed by molar ellipticity 
at 222 nm. The sample was heated in the cuvette from 25 to 110°C at a heating 
rate of 1° mi r f�Wave leng th spectrum scanning from 260 - 190 nm at 110°C was 
also recorded. For the thermal reversible reaction of HR-2-Helix, the temperature 
was then immediately decreased from 110 to 25°C. Wavelength spectra scanning 
from 260 - 190 nm at 25°C were recorded at 0 hour and 24 hour. 
2.1.3 Synthetic peptide approach 
Based on the bioinformatics analyses of heptad repeat regions of SARS-CoV S 
protein, peptides HRl-a (residues 899 - 926), HRl-b (residues 916 - 950) and 
HR2 (residues 1151-1185) were synthesis. 
2.1.3.1 Peptide synthesis 
All peptides were synthesized by the solid-phase technique with an in-house 
Applied Biosystems 433A Peptide Synthesizer on amide resins using standard 
9-fluorenylmethoxycarbonyl (Fmoc) synthesis chemistry with piperidine (Sigma) 
deprotection and 2-( 1 H-benzotriazole-1 -yl)-1，1,3,3 -tetramethyluronium 
hexafluorophosphate (HBTU) / N-hydroxybenzotriazole (HOBt) (Applied 
Biosystems) activation. The amino termini of peptides were acetylated on the 
resin with acetic anhydride capping solution containing 0.5 M acetic anhydride 
(Sigma), 0.125 M N,N-diispopropylethylamine (DIEA) (Applied Biosystems), 
0.015M N-hydroxybenzotriazole (HOBt) in N-methylpyrrolidone (NMP) 
(Applied Biosystems). The acetylated peptides were cleaved from the resins, and 
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side-chain protecting groups were removed by cleavage solution containing 25 
g/L ethanedithiol (EDT) (Fluka) and 50 g/L thioanisole (Fluka) in TFA. The 
peptides were then precipitated with cold diethyl ether, washed, and lyophilized. 
The cleaved peptides were purified with a preparative RP-HPLC column using a 
linear gradient, 0.5% B/min, formed from the solvent systems A (0.05% TFA in 
H2O) and B (0.05 % TFA in ACN). The identities of the synthetic peptides were 
confirmed by MALDI-TOF MS on an ABI 4700 MALDI TOF/TOF Analyzer. 
Fractions of RP-HPLC containing the peptides were lyophilized overnight and 
stored in desiccators at room temperature until use. The peptides were finally 
dissolved in PBS and the homogeneities were analyzed by the analytical 
RP-HPLC column in a linear gradient of 2% B/min. The concentrations of the 
synthetic peptides were quantified by AAA as described in Chapter 2.1.2.3. 
2.1.3.2 Native polyacrylamide gel electrophoresis 
HRl-a and HRl-b were incubated with an equal molar concentration of HR2 
respectively at 37°C for 1 hour (the final concentrations of HRl-a, HRl-b and 
HR2 were 50 p-M). After incubation, the samples were mixed with 6X native 
gel-loading buffer (300 mM Tris-HCl (pH 6.8), 0.6% (w/v) bromophenol blue, 
60% glycerol) and were then loaded to a 10 cm x 1 cm 20% Tris-tricine gel in 
Tris-tricine running buffer. Gel electrophoresis was carried out with 100 V 
constant voltages at room temperature for 2 hours. The gel was stained with 
Coomassie blue at room temperature for overnight with gentle shaking. The gel 
was then destained in de-staining solution at room temperature with gentle 
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shaking until the background was completely removed and the peptide bands were 
visualized. 
2.1.3.3 Size-exclusion high-performance liquid chromatography 
HRl-a and HRl-b were incubated with an equal molar concentration of HR2 
respectively at 37®C for 1 hour (the final concentrations of HRl-a, HRl-b and 
HR2 were 50 |aM). After incubation, 20 \xL of sample was injected into Shodex 
PROTEIN KW-802.5 SE-HPLC column (1 bed volume = 24 mL) (Shodex) 
connected to the Agilent Technologies 1100 Series analytical and preparative 
HPLC systems. The column was equilibrated with PBS for overnight prior to 
sample injection. PBS was used as a mobile phase with a flow rate at 0.75 
mL/min. The UV absorbance 210 nm was recorded. Gel Filtration Low Molecular 
Weight Calibration Kit consisting of Bovine Serum Albumin (67000 Da), 
Ovalbumin (43000 Da) and Ribonuclease A (13700 Da) was used as a standard 
for determination of the molecular weights of the protein samples. The whole 
process was carried out at room temperature. The buffer had been passed through 
0.22 |im filter and degassed, and protein sample and standard were centrifuged at 
16,000 g for 5 min prior to injection. 
2.1.3.4 Laser light scattering 
Size-exclusion chromatography / light scattering (SEC / LS) 
HRl-b was incubated with an equal molar concentration of HR2 at room 
temperature for 1 hour (the final concentrations of HRl-b and HR2 were 6.5 
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mg/mL). After incubation, 150 |LIL of sample was injected into SuperdexTM 75 
10/300 GL Columns, which was connected in-line with the laser light scattering 
(LS) system as described in Chapter 2.1.2.5. Peptide sample was centrifuged at 
16,000 g for 5 min prior to injection. 
Molecular weight determination 
Molecular weights of HRl-b, HR2 and HRl-b / HR2 complex were determined 
using ASTRA calculations. A dn/dc value of 0.185 mL/g was used. The molar 
mass distribution plots of HRl-b, HR2 and HRl-b / HR2 complex were finally 
generated. 
2.1.3.5 Circular dichroism spectroscopy 
HRl-a was incubated with an equal molar concentration of HR2 in PBS at 37°C 
for 1 hour (the final concentrations of HRl-a and HR2 were 50 [iM). After 
incubation, Wavelength spectra of HRl-a, HR2 and HRl-a / HR2 complex 
scanning from 260 - 190 nm at 20 nm min'' at 3TC using a 1-mm pathlength 
rectangular quartz cuvette (llOQS, Hellma®) were recorded. 
HRl-b was incubated with an equal molar concentration of HR2 in PBS at 
37°C for 1 hour (the final concentrations of HRl-b and HR2 were 50 jiM). After 
incubation, Wavelength spectra of HRl-b, HR2 and HRl-b / HR2 complex 
scanning from 260 - 190 nm at 20 nm min"^ at 37°C were recorded. 
The stability measurement of HR2 from thermal denaturation was followed 
by molar ellipticity at 222 nm. The protein sample (50 jiM) was thoroughly 
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degassed before CD measurements. The sample was heated in the cuvette from 20 
to 78°C at a heating rate of 1° min"'. The cuvette was securely stoppered to ensure 
that there was no loss in the volume of the protein solution because of evaporation. 
Wavelength spectrum scanning from 260 - 190 nm at 78�C was also recorded. For 
the thermal reversible reaction of the complex, the temperature was then 
immediately decreased from 78 to 20°C. Wavelength spectrum scanning from 
260 - 190 nm at 20�C was recorded. 
For the stability measurement of the HRl-b / HR2 complex from thermal 
denaturation, it was followed by molar ellipticity at 222 nm. The samples were 
heated in the cuvettes from 37 to 78°C at a heating rate of 1° min"^ Wavelength 
spectrum scanning from 260 - 190 nm at 78°C was also recorded. For the thermal 
reversible reaction of the complex, the temperature was then immediately 
decreased from 78 to 37°C. Wavelength spectra scanning from 260 - 190 nm at 
37°C were recorded at 0 hour and 24 hour. 
For the time course measurement of the complex, it was followed by molar 
ellipticity at 222 nm at 37°C for 60 min with a data pitch of 10 sec. HRl-b and 
HR2 peptides were pre-warmed at 37°C for 30 min respectively. Then HRl-b was 
incubated with an equal molar concentration of HR2 and injected into the cuvette 
immediately for the time course measurement. 
For the stability measurement of the complex from guanidine-induced and 
urea-induced denaturation, HRl-b was first incubated with an equal molar 
concentration of HR2 at 37°C for 1 hour and the mixture was then equilibrated 
with 0 — 7.25 M GdnHCl or urea in PBS and 37°C for 30 min before CD 
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measurements. Molar ellipticity at 222 nm was measured at 37°C. The final 
GdnHCl / urea concentrations were made by varying the ratios of PBS and 8 M 
GdnHCl / urea solution. The concentration of GdnHCl was determined from 
refractive index measurements using a Leica AR200 refractometer. 
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2.2 Identification of SARS-CoV entry inhibitors 
2.2.1 HIV-luc/SARS pseudotyped virus entry inhibition assay 
HIV-luc/SARS pseudotyped virus production and purification 
To produce HIV-luc/SARS pseudotyped virus (HIV/SARS^), HIV-1 luciferase 
reporter vector pNL4.3丄uc-E'R—luc (HIV-luc) and codon optimized SARS-CoV S 
protein expression plasmids (pcTSh) were co-transfected into 293T cells; by 
calcium phosphate coprecipitation. The constructions of the plasmids^ have been 
described previously (Connor et al, 1995; Nie et al.’ 2004). One day prior to 
transfection, the 298T cells were seeded to 10 cm dishes that they were 50-60% 
confluent at the time of transfection. For transfection, two sets of 1.5 mL 
eppendorf tubes were prepared as follows: 
“Tube Content Volume (^ iL) 
1 2x HEPES buffered saline (HBS) 500~ 
2 DNA/CaCb mixture: 
10 |ig pcTSh 3.5 
10 ^g HIV-luc 2 
2.5M CaCb 50 
H2O 444.5 
Total ^ 
'°2x HBS: 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HP04.2H20，50 mM HEPES, pH 7.05 
Note that Tube 2 with HIV-luc only (3.5 nL H2O was added instead ofpcTSh) 
was performed as the negative control (Mock virus). 
®HIV/SARS: Codon-optimzed ftill-length SARS-CoV S protein was assembled and incorporated 
into HIV-1-like particles using an e«v-defective, luciferase gene-containing HIV-1 reporter viral 
expression system. 
9八11 cell lines in this assay (298T and Vero-E6), and pNL4.3.Luc.E"R'luc and pcTSh plasmids, 
were provided by our collaborator Dr. Deng Hongkui's team in Department of Cell Biology and 
Genetics, College of Life Sciences, Peking University. 
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The DNA/CaCh mixture was added dropwise to the 2x HBS while shaking 
the tube by fingertip (to generate air into the solution). The mixture was allowed 
to incubate at room temperature for 20 min. A fine opalescent precipitate appeared. 
The coprecipitate was then added dropwise to the surface of the complete 
Dulbecco's Modified Eagle's Medium (DMEM) (4500 mg/L glucose and 
L-glutamine, 25 mM HEPES, (Sigma, D1152) supplemented with 7.5% (w/v) 
sodium bicarbonate (pH 7.0), 10% fetal bovine serum, penicillin G50 (100 U/ml) 
and streptomycin (100 |ig/ml)) containing 298T cells and incubated at 37°C in a 
5% CO2 incubator. After 12 hour-posttransfection, the coprecipitate containing 
medium was removed from the cells and replaced by fresh complete DMEM. 
After additional 36 hours of 37°C incubation, the medium was removed and the 
transfected cells were washed with PBS twice before harvesting. 
To purify the HIV/SARS from the transfected cells, 1 mL Ix Luciferase Cell 
Culture Lysis Reagent (Promega) was added to the cells and the cell suspension 
was shaken slightly for 20 min. The cell lysate was then centrifuged by 
ultracentrifugation through a CsCl density gradient at 5,0000 g for 4 hours (Type 
70 Ti fixed-angle rotor, Beckman Coulter Ultracentrifuge). The supernatant 
containing the HIV/SARS was collected, filtered through a 0.45 fiM 
Millipore-sized membrane and stored at To check the luciferase activity of 
the pseudotyped virus, 20 |LIL aliquots was tested by the addition of 100|AL 
Luciferase Assay Reagent (Luciferase Assay Substrate pre-mixed with Luciferase 
Assay Buffer, Promega) and measured for 10 sec in a Wallac Multilabel 1450 
Counter (Perkin-Elmer). 
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HIV-luc/SARS pseudotyped virus entry inhibition assay - in vivo screening 
One day prior to perform the HIV-luc/SARS pseudotyped virus entry inhibition 
assay, 96-well plates were seeded with 8 x 10^ Vero-E6^ cells/well. To screen the 
inhibitory activities of the 5 peptides derived from SARS-CoV S protein HRl and 
HR2 regions and 39 small molecule compounds (Table 2.1), the lyophilized or 
solid samples were first dissolved in PBS or dimethyl sulfoxide (DMSO)" at 10 
mg/mL. The 10 mg/mL samples were further diluted in complete DMEM to the 
desired concentration: for the peptides, the concentration gradient was 25, 10，4, 
1.6, 0.64 and 0.256 jiM; for the small molecules, the concentration gradient was 
500, 200，80，32, 12.8 and 5.12 jjM. 50 )iL aliquots of samples were serially 
diluted in complete DMEM and incubated with 50 ^iL of 5 ng HIV/SARS at 3TC 
for 30 min. Then the mixtures were transferred into the 96-well plates seeded with 
Vero-E6 cells. HIV/SARS only without samples acted as the positive control. 
1 , 
Mock virus was also added onto the Vero-E6 cells to act as the negative controls. 
After incubation at 37°C for 12 hours, the sample containing medium was 
replaced with fresh complete DMEM and the cells were incubated for additional 
36 hours at 37°C. Finally, the cells were lysed and measured for luciferase 
activities as described above. 
"The concentration of DMSO should be less than 5% (v/v) in the assay. 
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2.2.2 Recombinant protein- and synthetic peptide-based 
biophysical assays - in vitro screening 
Recombinant protein-based biophysical assay - GST-pull down aided in vitro 
screening 
His6-HR1 was incubated with 1500 ^iM ADS-Jl or XTT^^ or PBS at 37�C for 1 
hour, followed by addition of GST-HR2 (the final concentration of His6-HR1 and 
GST-HR2 was 50|aM). After incubation at 37�C for another 1 hour, PBS 
equilibrated Glutathione S e p h a r o s e T M 4 Fast Flow affinity resin was loaded into 
the mixtures and incubated at room temperature for 1 hour with end-over-end 
rotation. The resin was then washed with 10 bed volumes of PBS and eluted by 
PBS containing 10 mM reduced glutathione. The collected samples were mixed 
with 6X SDS gel-loading buffer and then loaded to a 10 cm X 1 cm 20% 
Tris-tricine SDS gel (30 |jL each well) in Tris-tricine SDS running buffer. 
SDS-PAGE was carried out with 125 V constant voltages at room temperature for 
2 hours. The gel was then subjected to Western blotting analysis as described in 
Chapter 2.1.2.4. 
Synthetic peptide-based biophysical assay - Native-PAGE and SE-HPLC 
aided in vitro screening 
For Native-PAGE aided screening, HRl-b was incubated with 1500 ^M / 3000 
|LIM ADS-Jl or 1500 ^iM XTT or PBS at 3TC for 1 hour, followed by addition of 
…ADS-Jl was the most effective small molecules in the HIV-luc/SARS pseudotyped virus entry 
inhibition assay. XTT was used as a negative control, as it was one of the small molecules with no 
inhibitory activity. 
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HR2 (the final concentrations of HRL-b and HR2 were 50 |LIM). After incubation 
at ？>TC for another 1 hour, the mixtures were mixed with 6X native gel-loading 
buffer and were then loaded to a 10 cm x 1 cm 20% Tris-tricine gel in Tris-tricine 
running buffer. Gel electrophoresis was carried out with 100 V constant voltages 
at room temperature for 2 hours. The gel was then stained with Coomassie blue. 
For SE-HPLC aided screening, HRl-b was incubated with 1500 \xM ADS-Jl 
or XTT or PBS at 37°C for 1 hour, followed by addition of HR2 (the final 
concentrations of HRl-b and HR2 were 50 |iM). After incubation at 37°C for 
another 1 hour, 20 [iL of each sample was injected into Shodex PROTEIN 
KW-802.5 SE-HPLC column. PBS was used as a mobile phase with a flow rate at 
0.75 mL/min. The UV absorbance 210 nm was recorded. 
2.2.3 Molecular modeling 
Docking of ADS-Jl to the hydrophobic deep pocket of the SARS-CoV S 
protein fusion core 
All 3D molecular modeling studies were performed on an Insight II molecular 
modeling platform (Accelrys Software Inc., USA) running on Silicon Graphics 
Octane2 workstations (Silicon Graphics Inc., USA). The consistent valence 
forcefield (CVFF) was selected in all the simulations. The structure of the 
anti-HIV-1 agent ADS-Jl was constructed with the BUILDER module (Figure 
2.1). In this module, the tool SKETCHER was used to draw the two-dimensional 
image of ADS-Jl and this image was automatically converted into a 
three-dimensional model by another tool CONVERTER. 
CHAPTER 2. MA TERIALS AND METHODS 76 
SO3H 
/ H HO3S 
-谢 H I Xx 
h 厂H3 K A A s o h CH3 
N�H SO3H 
Figure 2.1: Chemical structure of ADS-J 1. 
The X-ray crystal structure of the SARS-CoV S protein fusion core (PDB ID: 
IWNC) was downloaded from the Protein Data Bank (PDB) 
(http://www.rcsb.org/pdb/) and used as a starting model. One of the HRl helices 
from the six-helix coiled-coil bundle was extracted to generate the target site on 
the HRl for docking of ADS-Jl. Hydrogen atoms were added for the HRl 
structure in the BUILDER module. Forcefield potentials and partial charges were 
then assigned for both of the structures of HRl and ADS-Jl. Both of them were 
subsequently energy minimized using the DISCOVER module and used as the 
pre-docking structures. A distance-dependent dielectric constant of 80.0 (aqueous 
solvent) and non-bonded distance cutoff of 20 人 were used throughout the energy 
minimization and molecular dynamics simulation. Initially, the structures of HRl 
and ADS-Jl were minimized for 5000 iterations of steepest descent energy 
minimization. The resulting structures were then subjected to molecular dynamics 
simulations. The energy-minimized structures were equilibrated at 300 K for 10 
picoseconds (ps). Following this, a 100 ps dynamics simulation was carried out at 
300 K, and structures were sampled at a time step of 1 femtosecond (fs). 
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According to the information from the X-ray crystallographic structure of 
fusion core (Duquerroy et al., 2005; Supekar et al., 2004; Xu et al, 2004), four 
hydrophobic residues from the HR2 (Leull68, ValllTl, Leul l75 and Leu 1179) 
penetrate into one of the three hydrophobic deep pockets or cavities formed 
between Phe909 and Leu920 on the deep groove region of HRl (Figure 3.45). 
Therefore, the region containing all residues (5.0 A radius) around this deep pocket 
was selected as the target site (named HRl-DP) and set up as a grid with the 
DOCKING module. The nonbonded energetics of this region was pre-calculated 
on the grid. ADS-Jl was first docked into HRl-DP by manual docking using the 
DOCKING module. The best docking position was based on the docking energy 
of the ADS-Jl/HRl-DP complex. Thousand of orientations of ADS-Jl were 
searched by maneuvering it in the HRl-DP manually until reaching the energy 
minimum. The resultant complex was subjected to energy minimization and 
molecular dynamics simulation using the DISCOVER module. An 8.0 A cutoff 
for the calculation of non-bonded interactions and the distance-dependent 
dielectric constant of 80.0 (aqueous solvent) and non-bonded distance cutoff of 20 
A were used throughout the energy minimization and molecular dynamics 
simulation. Initially, the complex was minimized for 5000 iterations of steepest 
descent energy minimization. The resulting structure was then used as a starting 
point for sampling conformational space using molecular dynamics. The 
energy-minimized complex was equilibrated at 300 K for 10 ps. Following this, a 
100 ps dynamics simulation was carried out at 300 K, and the structure was 
sampled at a time step of 1 fs. The sampled structure was subsequently energy 
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minimized using conjugate gradient minimization. Ultimately, the total docking 
energy between ADS-Jl and HRl-DP in the energy minimized complex was 
calculated using the DOCKING module. The docking energy included the van der 
Waals and electrostatic energies, which were the components of the 
intermolecular energy. 
The in silico derivation of ADS-Jl and docking of its derivatives to HRl-DP 
Based on the docking study between ADS-Jl and HRl-DP, the structure of 
ADS-Jl was analyzed and a cluster of chemical groups was identified that may 
not be required for the anti-SARS activity. ADS-Jl was then subjected to in silico 
derivation. The resultant derivatives were constructed by the BUILDER module. 
SKETCHER was used to generate the two-dimensional images of derivatives and 
the images were automatically converted into three-dimensional models by 
CONVERTER. Forcefield potentials and partial charges were then assigned for 
the structures of the derivatives. They were subsequently energy minimized using 
the DISCOVER module as described in the last section. Finally, the 
energy-minimized derivatives were docked into HRl-DP and the docking poses 
were evaluated by the total docking energy between them and the HRl-DP using 
the DOCKING module. 
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2.3 Characterization of SARS-CoV SCL '^^  substrate 
specificity 
2.3.1 Protein expression and purification 
The plasmid containing the coding sequence of SARS-CoV SCL^™ was 
pGEX-3CLPr° (Appendix III)，which was kindly provided by Dr. Zihe Rao's 
research team at Tsinghua University. The construction of the pGEX-3CLPr� 
plasmid has been described previously by Yang and colleagues (Yang et al, 
2003). The pGEX-3CL''™ plasmid was transformed into E. coli strain BL21 
competent cells and spread on LB agar containing ampicillin (100 |ag/mL) and 
chloramphenicol (17 |Lig/mL) and grown overnight at 37 A single colony was 
inoculated into 50 mL of LB broth containing ampicillin (100 }ig/mL) and grown 
overnight at 37°C with shaking. This overnight culture was then transferred into 5 
L of LB broth containing ampicillin (100 ^ig/mL) for large-scale protein 
expression at 3TC with shaking. When the culture was grown to an ODeoonm of 
0.6, it was induced with 0.1 mM IPTG and grown for an additional 6 hours at 25 
Cells were harvested by centrifugation at 9,820 g at 4°C for 5 min, and the 
bacterial cell pellet was resuspended in lysis buffer containing 10 mM Tris-HCl 
(pH 7.5), 500 mM NaCl, 1 mM DTT, 0.5 mM EDTA, and 0.2 mM PMSF, and 
homogenized by sonication. The lysate was centrifuged at 48000 g for 45 min at 4 
and the supernatant was loaded onto a Glutathione Sepharose™ 4 Fast Flow 
affinity column equilibrated with the lysis buffer. The column was then washed 
with 10 bed volumes of lysis buffer until no obvious protein can be detected by 
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the Bradford protein assay. 
To cleave the GST-tag from the GST-3CLP™ fusion protein, PreScission 
Protease was added into the column, and the mixture was incubated overnight at 4 
The GST-removed SCL^™ protein was eluted with the lysis buffer, 
concentrated to 2 mL by an Amicon Ultra-15 MWCO 5K filter and subjected to 
SEC in HiLoadTM 16/60 SuperdexTM 200 Prep Grade column. The purified 
SARS-CoV 3CLPro protein was finally concentrated to 10 mg/mL and stored at 
-80°C until use. 
2.3.2 "Cartridge replacement" solid-phase peptide synthesis 
The sequence of peptide substrate used in this study was based on one of the 
SARS-CoV 3CLPro cleavage sites on the SARS-CoV BJOl''^ polyprotein pplab 
(residues 3232-3247) (Table 1). The biological significance of amino acid 
residues in the P2, P3, P4, PI , , P2', and P3' positions that are flanking the 
conserved Gin residue in the PI position at the cleavage site was investigated one 
at a time using the novel "cartridge replacement" solid-phase peptide synthesis 
strategy (Chu et al., 2006). In a standard procedure of solid-phase peptide 
synthesis, each amino acid cartridge that contains a particular type of amino acid 
is placed side-by-side in the peptide synthesizer according to the target peptide 
sequence, and the peptide synthesis begins with the cartridge containing the first 
amino acid at the carboxyl terminus of the sequence. In this study, we utilized 
flexibility in changing the contents of each amino acid cartridge and designed a 
"SARS-CoV BJOl strain: GenBank accession no. AY278488 
CHAPTER 2. MA TERIALS AND METHODS 81 
novel peptide synthesis strategy that we named as the "cartridge replacement" 
solid-phase peptide synthesis. Our "cartridge replacement" strategy consisted of 
two screening procedures: primary and secondary screening. 
Primary screening 
Prior to peptide synthesis, the corresponding amino acid cartridge at the target 
position under investigation was replaced by another cartridge containing a 
mixture of 20 standard amino acids in equal molar ratio, such that a mixed pool of 
20 synthetic peptides differing by a single amino acid residue was generated as 
the end product after complete synthesis of the substrate sequence. Six sets of 
such peptide substrate pools together with the original peptide substrate were 
synthesized with this approach (Table 2.2) using the solid-phase peptide synthesis 
technique as described in chapter 2.1.3.1. 
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Table 2.2: Amino acid sequence of the seven synthetic peptide substrates. 
Peptide"““ Sequence 丨 > 
substrate ~ P 9 ？ S P 7 P 6 ？ 5 P 4 P3 P2 PI P1' P2' P3' P4, P5' P6' P7' 
p s m ^ T S i T S A V L Q S G F R i c M a T 
PS02 T S I T S A V X20 口 Q S G F R K M A 
PS03 T S I T S A 乂20丨7 L Q S G F R K M A 
PS04 T S I T S X20I7 V L Q S G F R K M A 
PS05 T S I T S A V L Q Xzo'^ G F R K M A 
PS06 T S I T S A V L Q S Xjo'^ F R K M A 
PS07 T S I T S A V L Q S G Xjo'^ R K M A 
'^The amino acids flanking the SARS-CoV SCL/"�cleavage sites are labeled from the amino 
terminus to the carboxyl terminus as follows: -P3-P2-P1 | Pl’-P2，-P3’ as described previously 
(Schechter et al. 1967). 
'^The control peptide substrate is based on the amino acid sequence of one of the SARS-CoV 
3CLPr�cleavage site on the SARS-CoV BJOl polyprotein pplab (residues 3232 - 3247). 
"The corresponding amino acid at this position is substituted by a mixture of 20 standard 
amino acids in equal molar ratios. 
Secondary screening 
The PS02 and PS06 peptide substrates require further analysis by a secondary 
screening. For the PS02 peptide substrates, the peptides with close masses were 
separated into three batches: PS02-1, PS02-2, and PS02-3. For the peptide 
synthesis of the PS02-1 batch, the corresponding Leu cartridge at the P2 position 
was replaced by a cartridge containing a mixture of Cys, Glu, Leu, and Pro in an 
equal molar ratio. For the peptide synthesis of the PS02-2 batch, the 
corresponding Leu cartridge at the P2 position was replaced by a cartridge 
containing a mixture of Asn, Lys，and Val in an equal molar ratio. For the peptide 
synthesis of the PS02-3 batch, the corresponding Leu cartridge at the P2 position 
was replaced by a cartridge containing a mixture of Asp, Gin, lie, and Thr in an 
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equal molar ratio. For the PS06 peptide substrates, only the lie and Leu 
substitutions were further investigated and separated into two batches: PS06-I and 
PS06-L. For the peptide synthesis of PS06-I and PS06-L batches, the 
corresponding Gly cartridge at the P2' position was replaced by a cartridge 
containing lie or Leu, respectively. 
2.3.3 Peptide cleavage assay and MS analysis 
The in vitro peptide cleavage assay was performed in a total reaction volume of 
25 i^L, containing 1.5 mM recombinant SARS-CoV SCLP'®, 0.5 mM sum total 
concentration of the peptide substrate batch, 20 mM NazHPO*, 200 mM NaCl, 1 
mM EDTA, 1 mM DTT, pH 7.6, with overnight incubation at 25 Cleavage 
products were desalted by ZipTipu-cis (Millipore), and the corresponding peptide 
peaks before and after the cleavage reactions were resolved by mass spectrometry 
on the Ettan MALDI-TOF Pro Mass Spectrometer or the ABI 4700 MALDI 
TOF/TOF Analyzer. For acquisition of mass spectra, 0.5 [iL aliquots of samples 
were dispensed onto the MALDI-plate, followed by a 0.5 |iL matrix solution (5 
g/L a-cyano-4-hydroxycinnamic acid in 50% ACN/0.1% TFA). All spectra were 
acquired in a reflectron-positive ion mode and accumulated from 1000 laser shots 
with acceleration of 20 kV and pulsed extraction. Angiotensin III (m/z value of 
897.523) and adrenocorticotropic hormone (m/z value of 2465.199) were used as 
standards for internal calibration of MALDI-TOF MS spectra. 
End of chapter. 
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Chapter 3 
Results 
3.1 Characterization of SARS-CoV S Protein Fusion 
Core 
3.1.1 Bioinformatics analyses of heptad repeat regions of 
SARS- CoV S protein 
The coiled-coil regions of SARS-CoV S protein were predicted by 
LearnCoil-VMF program. As shown in Figure 3.1，SARS-CoV S protein is a 
typical type I membrane glycoprotein. The HRl region appears on residues 900 -
1005, whereas HR2 region appears on residues 1151 - 1185. 
On the other hand, Multicoil program was used to predict the heptad repeat 
patterns "abcdefg" of HRl and HR2. It predicted that the HRl starts from a = 
Y899 to g = KlOlO, which covers 16 heptad repeats, however HR2 starts from b = 
D1145 to g = 11192, which covers approximately 7 heptad repeats (Figure 3.2). 
Based on the heptad repeat patterns analyzed by Multicoil program, the 
helical wheel diagrams of SARS-CoV HRl and HR2 were built (Figure 3.3). 
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Amino Acid Residue Number of SARS-CoV S Protein 
Figure 3.1: LeamCoil-VMF analysis of SARS-CoV S protein. 
HRl region appears on residues 900 - 1005, whereas HR2 region appears on residues 1151 -
1185, in the SARS-CoV S protein amino acid sequence. Likelihood: The probability of heptad 
repeat occurrence in a protein sequence. 
899 YENQKQI ANQFNKA ISQIQES LTTTSTA LGKLQDV VNQNAQA LOTL VKQLSSN FGAISSV 
abcdefg abcdefg abcdefg abcdefg abcdefg abcdefg abed abcdefg abcdefg 
LNDILSR LDKVEAE VQIDRLI TCJRLQ SLQTY VTQQLIR AAEIRAS ANLAATK 1010 
abcdefg abcdefg abcdefg abcde cdefg abcdefg abcdefg abcdefg 
1145 DVDLGD ISGINAS WNIQKE IDRLNEV AKNLNES LIDLQEL GKYEQYI 1192 
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Figure 3.2: Multicoil analysis of SARS-CoV S protein. 
Heptad repeat pattern of HRl starts from residues 899 - 1010, which covers 16 heptad repeats, 
heptad repeat pattern of HR2 starts from residues 1145 - 1192, which covers approximately 7 
heptad repeats. Likelihood: The probability of heptad repeat occurrence in a protein sequence. 




A1008 V990 L983 KlOlO 
RlOOl T980 D976 S1003 
L994 V973 V969 R996 
Q987 L966 1962 Y989 
Q984 L959 1955 L986 
R977 F952 L948 1979 
E970 V945 L944 E972 
L963 L941 N937 R965 E1189 
S956 V934 L930 V958 G1186 L1182 
S949 L927 T923 N951 L1179 L1175 
A938 L920 1916 A940 Q1190 A1172 L1168 11192 
Q931 1913 F909 V933 Q1183 11165 11161 L1185 
S924 A906 Q902 A926 N1176 V1158 11154 S1178 
Q917 Y899 Q895 S919 N1169 11151 D1147 V1171 
N910 A912 Q1162 ^ ^ ^ ^ E1164 
K903 f a l T d J 1905 N1155 ( a l T d ) S1157 
V893 f f j ^ T 8 9 4 D1145 ( f ) ^ V 1 1 4 6 
E900 ^ ^ N901 S1152 ^ ^ G1153 
N907 V897 Q908 V1159 G1149 N1160 
S914 Q904 Q915 D1166 A1156 RII67 
T921 K911 T922 K1173 K1163 N1174 
G928 E918 K929 11180 E1170 D1181 
N935 T925 Q936 K1187 E1177 Y1188 
N942 D932 T943 E1184 
K946 Q939 Q947 Y1191 
G953 S950 A954 
N960 S957 D961 
D967 S964 K968 
Q974 A971 1975 
G981 L978 R982 
T991 S985 Q992 
A998 T988 £999 
N1005 1995 L1006 
A1002 
T1009 
Figure 3.3: Helical wheel diagrams of HRl and HR2 of SARS-CoV S protein fusion core. 
The amino acid sequence is displayed end-to-end down the axis of a schematic helix, 
"abcdefg" indicate the position of residues within the heptad repeat of the coiled-coil. 
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3.1.2 Recombinant protein approach 
3.1.2.1 Plasmids construction of pET-28a-HRl, pGEX-6P-l-HR2 
and pGEX-6P-l-HR-2-Helix 
For construction of pET-28a-HRl, the HRl DNA fragment of the size of 180 bp 
was amplified from pS0S-S2 (Figure 3.4). The PGR product and pET-28a vector 
were restriction digested by BamUl and Sail (Figure 3.4). After ligation and 
transformation, positive clones were screened by PGR amplification (Figure 3.5). 
For construction of pGEX-6P-l-HR2, the HR2 DNA fragment of the size of 
144 bp was amplified from pS0S-S2 (Figure 3.6). The PGR product and 
pGEX-6P-l vector were restriction digested by and Sail (Figure 3.7). After 
ligation and transformation, positive clones were screened by PGR amplification 
(Figure 3.8). 
For construction of pGEX-6P-l-HR-2-Helix, the HRl (B/E) and HR2 (E/S) 
DNA fragments of the size of 180 bp and 144 bp were amplified from pS0S-S2 
(Figure 3.9). The HRl (B/E) PGR product and pGEX-6P-l vector were first 
restriction digested by BamRl and EcoRl (data not shown). After ligation and 
transformation, positive clones were identified by DNA sequencing. Then the 
pGEX-6P-l-HRl (B/E) plasmid and HR2 (E/S) PGR product were restriction 
digested by and Sail (Figure 3.10). After ligation and transformation, 
positive clones were screened by both PGR amplification and restriction digestion 
(Figure 3.11). 
All of plasmid constructs were finally confirmed by DNA sequencing and the 
DNA inserts were matched against the GenBank nr database through the BLAST 
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p r o g r a m w i t h 1 0 0 % c o r r e c t n e s s w i t h r e f e r e n c e t o t h e o r i g i n a l s e q u e n c e . 
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丨丨 : 
Figure 3.4: PCR products of HRl and restriction digestion of HRl and pET-28a vector. 
(A) Lane M-GeneRulerTM lOObp D N A Ladder Plus; Lane 1 to 3 - H R l PCR products. (B) 
Lane M ' - GeneRuler™ Ikb D N A Ladder; Lane 4 - pET-28a vector digested by BamHl and 
Sail; Lane 5 , 6 - H R l PCR products digested by BamHl and Sail. 
M 1 2 3 4 5 6 
200 ~ | | | ‘ U y p i W p W | ( l i | i m “ H R l 
100 • _ _ O I H I H H H M ， 1 8 0 bp 
Figure 3.5: S c r e e n i n g o f p o s i t i v e p E T - 2 8 a - H R l c l o n e s b y P C R a m p l i f i c a t i o n . 
Lane M — G e n e R u l e r ™ lOObp D N A Ladder Plus; Lane 1 to 6 - Positive clones with HRl 
D N A inserts amplied by PCR. 
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Figure 3.6: PCR products of HR2. 
Lane M - GeneRuler™ lOObp DNA Ladder Plus; Lane 1 to 3 - HR2 PCR products. 
A ^ ^ ^ ^ ^ ^ ^ ^ B 二 。 
4900 bp m f s m _ 
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Figure 3.7: Restriction digestion of HR2 and pGEX-6P-l vector. 
(A) Lane 1 to 3 - HR2 PCR products digested by EcoRl and Sail; Lane M - GeneRulerTM 
lOObp DNA Ladder Plus. (B) Lane 4 - pGEX-6P-l vector digested by EcoRl and Sail; Lane 
M' - GeneRuler™ ikb D N A Ladder. 
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Figure 3.8: Screening of positive pGEX-6P-l -HR2 clones by PCR amplification. 
Lane M - GeneRuler™ lOObp D N A Ladder Plus; Lane 1 to 6 - Positive clones with HR2 
DNA inserts amplied by PCR. 
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Figure 3.9: PCR products of HRl (B/E) and HR2 (E/S). 
Lane M - G e n e R u l e r ™ lOObp DNA Ladder Plus; Lane 1 to 3 - HRl PCR products; Lane 4 
to 6 - HR2 PCR products. 
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Figure 3.10: Restriction digestion of pGEX-6P-l -HRl (B/E) plasmid and HR2 (E/S). 
Lane 1 一 pGEX-6P- l -HRl (B/E) plasmid digested by EcoRl and Sail; Lane 2 to 4 - HR2 
PCR products digested by 份oRI and Sail, Lane M - GeneRuler^^ lOObp D N A Ladder Plus. 
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Figure 3.11: Screening of positive pGEX-6P-1 -HR-2-Helix clones by PCR amplification and 
restriction digestion. 
(A) Lane 1 to 7 - Positive clones with HR-2-Helix D N A inserts amplied by PCR. (B) Lane 8 
to 14 - Positive clones with HR-2-Helix D N A inserts digested from the recombinant plasmids 
pGEX-6P-l-HR-2-Helix by BamHl and Sail Lanes M - GeneRuler'^^^ lOObp D N A Ladder 
Plus. 
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3.1.2.2 Protein expression and purification 
Purification of His6-HR1 
Bacterial cells expressing His6-HR1 was lysed. Soluble fraction was passed 
through nickel affinity chromatography. Most of the His6-HR1 could bind to the 
resin, but a small amount was washed out in 100 mM imidazole. The majority of 
His6-HR1 was eluted in 200 mM and 250 mM imidazole. The purity was not high 
as shown in Figure 3.12 as the bacterial proteins bound and eluted with His6-HR1, 
thus further purification was required. An over 90% purity of Hise-HRl was 
obtained after passing through RP-HPLC (Figure 3.13 (A)). Hise-HRl was eluted 
at 23.3 min and the corresponding fraction was analyzed by MALDI-TOF MS. 
The eluted fraction was shown to have the matched mass-to-charge ratio (m/z) 
value of 9910 to His6-HR1 (Figure 3.13 (B)). The AAA calculated concentration 
of the His6-HR1 protein stock was 7.10 mg/mL (720 |iM). 
9 8 7 6 5 4 3 2 I M k D a 
20.1 
His6-HR1 “ s i •似 I m i ^ i r f B N I P I ^ 6 5 
-10 kDa “ • • ^ ^ g l 3 5 
Figure 3.12: Purification of Hise-HRl by nickel affinity chromatography. 
The bacterial cell lysate supernatant containing Hise-HRl was loaded onto a His-Select 
Nickel Affinity Gel column for nickel affinity chromatography. The unbound proteins were 
eluted as flow-through. The column was washed with PBS containing 10 mM, 50 mM and 
100 mM imidazole, respectively. The His-tagged His6-HR1 protein was finally eluted with 
PBS containing 150，200, 250 and 300 mM imidazole respectively. Lane M - Low-range 
Rainbow Molecular Weight Marker; Lane 1 - Flow-through; Lane 2 — Washing (buffer with 
10 mM imidazole); Lane 3 - Resin after washing; Lane 4 - Washing (buffer with 50 mM 
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imidazole); Lane 5 - Washing (buffer with 100 mM imidazole); Lane 6 - Elution of 
His6-HR1 in 150 mM imidazole; Lane 7 - Elution of Hise-HRl in 200 mM imidazole; Lane 
8 - Elution of Hise-HRl in 250 mM imidazole; Lane 9 - Elution of Hise-HRl in 300 mM 
imidazole. The samples were subjected to Tris-tricine 20% SDS-PAGE analysis. 
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Figure 3.13: Purification ofHis6-HRl by RP-HPLC. 
His6-HR1 was purified by RP-HPLC using a linear gradient of 2% B (0.05% TFA in ACN) 
/min. (A) His6-HR1 analytical RP-HPLC profile showing changes in ODaionm. His6-HR1 with 
over 90% purity was eluted at 23.3 min. (B) The identity of the 23.3 min peak was confirmed 
by ABI 4700 MALDI TOF/TOF Analyzer. Mass spectrum showed the RP-HPLC purified 
His6-HR1 with its exact m/z = 9910. The sequence of Hise-HRl was shown {insert). 
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Purification of GST-HR2 and GST-removed HR2 
For GST-HR2, bacterial cells expressing GST-HR2 was lysed. Soluble fraction 
was passed through glutathione affinity chromatography. Most of the GST-HR2 
could bind to the resin and eluted out although a small amount was still bound 
onto the resin after washing (Figure 3.14 (A)). The purity of GST-HR2 showed 
little improvement after passing through SEC (Figure 3.14 (B)). The dim bands 
shown in Figure 3.14 (A) at about 28kDa were the GST-tags, which were 
co-expressed with the GST-HR2. 
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Figure 3.14: Purification of GST-HR2 by glutathione affinity chromatography and SEC. 
The bacterial cell lysate supernatant containing GST-HR2 was loaded onto a Glutathione 
Sepharose™ 4 Fast Flow affinity column for glutathione affinity chromatography. Target 
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protein was eluted with 10 mM reduced glutathione and subjected to SEC. (A) 
Elution fractions of SEC of GST-HR2. Lane 1 to 7 - Corresponding to fraction number 20 to 
26 of elution profile in (B); Lane 8 - Resin after washing from glutathione affinity 
chromatography; Lane 9 - Sample from glutathione affinity chromatography before being 
subjected to SEC; Lane M - High-range Rainbow Molecular Weight Marker. The samples 
were subjected to Tris-glycine 15% SDS-PAGE analysis. (B) GST-HR2 SEC elution profile 
showing changes in OD280nm (blue) and the collected fractions (red). 
For GST-removed HR2, bacterial cells expressing GST-HR2 was lysed. 
Soluble fraction was firstly passed through glutathione affinity chromatography. 
Most of the GST-HR2 can bind onto the column, but a small amount was lost in 
the flow-through and washing (Figure 3.15). The resin bound with GST-HR2 was 
then incubated with GST-tagged PreScission Protease. GST-HR2 was cleaved into 
GST-tag and HR2 protein, and GST-removed HR2 was eluted from the column as 
the flow-through. Although most of the GST-tags were remained bound onto the 
resin, some of them were eluted out as the flow-through together with the 
GST-removed HR2. The purity of GST-removed HR2 was quite low as shown in 
Figure 3.15 and thus required further purification. An over 98% purity of 
GST-removed HR2 was obtained after passing through RP-HPLC (Figure 3.16 
(A)). GST-removed HR2 was eluted at 23.1 min and the corresponding fraction 
was analyzed by MALDI-TOF MS. The eluted fraction was shown to have the 
matched m/z value of 6430 to GST-removed HR2 (Figure 3.16 (B)). The AAA 
calculated concentration of the GST-removed HR2 protein stock was 3.25 mg/mL 
(500 
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Figure 3.15: Purification of GST-removed HR2 by glutathione affinity chromatography. 
PreScission Protease was added into the Glutathione Sepharose™ 4 Fast Flow affinity column 
after the glutathione affinity chromatography of GST-HR2. Lane M - Low-range Rainbow 
Molecular Weight Marker; Lane 1 - Total bacterial lysate before IPTG induction; Lane 2 -
Soluble fraction of the bacterial cell lysate after IPTG induction; Lane 3 - Flow-through; 
Lane 4 - Washing; Lane 5 - GST-HR2 bound resin before adding PreScission Protease; 
Lane 6 - Elution of GST-removed HR2; Lane 7 - Resin after adding PreScission Protease. 
The samples were subjected to Tris-tricine 20% SDS-PAGE analysis. 
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Figure 3.16: Purification of GST-removed HR2 by RP-HPLC. 
GST-removed was purified by RP-HPLC using a linear gradient of 2% B (0.05% TFA in ACN) 
/min. (A) GST-removed HR2 analytical RP-HPLC profile showing changes in OD i^onm. 
GST-removed HR2 with over 98% purity was eluted at 23 .1 min. (B) The identity of the 23.1 
min peak was confirmed by Ettan MALDI-TOF Pro Mass Spectrometer. Mass spectrum 
showed the RP-HPLC purified GST-removed HR2 with its exact m/z = 6430. The sequence of 
GST-removed HR2 was shown {insert). 
Purif ication o f H R - 2 - H e l i x 
Bacterial cells expressing GST-HR-2-Helix was lysed. Soluble fraction was firstly 
passed through glutathione affinity chromatography. The resin bound with 
GST-HR-2-Helix was then incubated with GST-tagged PreScission Protease. 
GST-HR-2-Helix was cleaved into GST and HR-2-Helix proteins, and 
HR-2-Helix was eluted from the column as the flow-through. Although some of 
the GST-tags were remained bound onto the resin, large amount of them were 
eluted out as the flow-through together with the HR-2-Helix (Figure 3.17). The 
purity of HR-2-Helix showed little improvement after passing through SEC, 
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however, the GST-tags were still co-eluted with HR-2-Helix (Figure 3.17 (B)). So 
the HR-2-Helix was re-purified by glutathione affinity chromatography and the 
GST-tags were finally removed. 
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Figure 3.17: Purification of HR-2-Helix by glutathione affinity chromatography and SEC. 
The bacterial cell lysate supernatant containing GST-HR-2-Helix was loaded onto a 
Glutathione Sepharose™ 4 Fast Flow affinity column for glutathione affinity chromatography. 
PreScission Protease was added into the column after the glutathione affinity chromatography 
and the GST-cleaved HR-2-Helix was subjected to SEC. (A) Purification by 
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glutathione affinity chromatography. Lane M - Low-range Rainbow Molecular Weight 
Marker; Lane 1 - Elution 1 of GST-removed HR-2-Helix; Lane 2 - Soluble fraction of the 
bacterial cell lysate after IPTG induction; Lane 3 - Elution 2 of GST-cleaved HR-2-Helix; 
Lane 4 一 Resin after adding PreScission Protease. The samples were subjected to Tris-tricine 
15% SDS-PAGE analysis. (B) Purification by SEC. Left panel: Elution fractions of SEC of 
HR-2-Helix. Lane M - Low-range Rainbow Molecular Weight Marker; Lane 1 to 9 -
Corresponding to fraction number 30 to 38 of elution profile in (C). The samples were 
subjected to Tris-glycine 15% SDS-PAGE analysis. Right panel: Re-purification of 
HR-2-Helix by glutathione affinity chromatography. Lane M - Low-range Rainbow 
Molecular Weight Marker; Lane 1 - Elution 1 of re-purified HR-2-Helix; Lane 2 - Elution 2 
of re-purified HR-2-Helix; Lane 3 - Resin after complete elution. (C) HR-2-Helix SEC 
elution profile showing changes in OD280nm (blue) and the collected fractions (red). 
An over 98% purity of HR-2-Helix was obtained after passing through 
RP-HPLC (Figure 3.18 (A)). HR-2-Helix was eluted at 25.991 min and the 
corresponding fraction was analyzed by MALDI-TOF MS. The eluted fraction 
was shown to have the matched m/z value of 13170 to HR-2-Helix. The AAA 
calculated concentration of the HR-2-Helix protein stock was 5 mg/mL (3800 
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Figure 3.18: Purification ofHR-2-Helix by RP-HPLC. 
HR-2-Helix was purified by RP-HPLC using a linear gradient of 0.5% B (0.05% TFA in ACN) 
/min. (A) HR-2-Helix analytical RP-HPLC profile showing changes in ODsionm. HR-2-Helix 
with over 98% purity was eluted at 25.991 min. (B) The identity of the 25.991 min peak was 
confirmed by ABI 4700 MALDI TOF/TOF Analyzer. Mass spectrum showing the RP-HPLC 
purified HR-2Helix with its exact m/z = 13170. The sequence of HR-2-Helix was shown 
{insert). The italic letters within the HR-2-Helix sequence are the ten amino adds of the 
flexible linker. 
CHAPTER 3. RESULTS 13 8 
3.1.2.3 GST-pulldown experiment 
The GST-pulldown experiment showed that His6-HR1 bound to GST-HR2. For 
the negative controls, individual Hise-HRl and GST-HR2 were incubated with 
PBS respectively, instead of mixing the two proteins together. For Hise-HRl only, 
the protein was only detected in the flow-through and washing fractions (Figure 
3.19 (A)), indicated that it could not bind to the Glutathione SepharoseTM 4 Fast 
Flow affinity column by itself. For GST-HR2 only, most of the protein was 
detected in the elution fraction although a small amount was found in the 
flow-through (Figure 3.19 (A)). It indicated that GST-HR2 could bind to the 
column with some of it lost in the flow-through. For the His6-HR1 - GST-HR2 
mixture sample, both the Hise-HRl and GST-HR2 can be detected in the elution 
fractions, although a small amount of them were found in the flow-through 
(Figure 3.19 (B)). It indicated that His6-HR1 bound tightly to GST-HR2. Note that 
all the contaminant proteins of the partially purified His6-HR1 and GST-HR2 (dim 
bands shown in lane 1 and 2 of Figure 3.19 (B)) were removed in the 
flow-through and the washing steps, which meant that the interaction between 
His6-HR1 and GST-HR2 was specific. The western blotting analysis showed the 
same results (Figure 3.20). Note that the lower bands shown in Figure 3.20 (B) 
were the Hise-HRl. His6-HR1 was also detected together with GST-HR2 because 
of using the same secondary antibody after the incomplete western blot stripping. 
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Figure 3.19: Coomassie blue staining analysis of GST-pulldown experiment. 
(A) Negative control. Lane 1 - Partially purified GST-HR2; Lane 2 - Partially purified 
His6-HR1 ； Lane 3 - Flow-through of GST-HR2 only; Lane 4 - Washing of GST-HR2 only; 
Lane 5 - Elution of GST-HR2 only; Lane 6 - Flow-through of Hise-HRl only; Lane 7 -
Washing of His6-HR1 only; Lane 8 - Elution of HiSg-HRl only. (B) Hisg-HRl - GST-HR2 
mixture sample. Lane 1 - Partially purified GST-HR2; Lane 2 - Partially purified Hise-HRl ； 
Lane 3 - Flow-through; Lane 4 - Washing; Lane 5 - First elution; Lane 6 - Second elution. 
The samples were subjected to Tris-tricine 20% SDS-PAGE analysis. 
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Figure 3.20: Western blotting analysis of GST-pulldown experiment. 
(A) Western blot probed with anti-His6 antibody. Lane 1 — Flow-through; Lane 2 — First 
elution; Lane 3 - Second elution. (B) Western blot probed with anti-GST antibody. Lane 1 -
Flow-through; Lane 2 — First elution; Lane 3 - Second elution. 
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3.1.2.4 Laser light scattering 
The light scattering experiment was employed to determine the MW of His6-HR1, 
GST-removed HR2, the Hise-HRl / GST-removed HR2 complex and HR-2-Helix. 
For His6-HR1, the molar mass distribution plot showed that the eluting peak at 
about 15 min was monodisperse with an average MW of 38610 Da, which was 
close to the value expected for a tetramer of His6-HR1 (4 x 9910.26 = 39641.04 
Da) (Figure 3.21 (A)). For GST-removed HR2, the plot showed that the eluting 
peak between 15 and 20 min was also monodisperse and with an average MW of 
6142 Da, which was close to the value expected for a monomer of GST-removed 
HR2 (6430.24 Da) (Figure 3.21 (B)). For the His6-HR1 / GST-removed HR2 
complex, the plot showed the eluting peak between 10 and 15 min was 
monodisperse with an average MW of 49050 Da, which was close to the value 
expected for a hexameric complex (3 x 9910.26 (Hise-HRl) + 3 x 6430.24 
(GST-removed HR2) = 49021.5 Da) (Figure 3.21 (C)). For HR-2-Helix, the molar 
mass distribution plot showed that the eluting peak at about 14 min was 
monodisperse with an average MW of 40110 Da, which was close to the value 
expected for a trimer ofHR-2-Helix (3 x 13170.77 = 39512.31 Da) (Figure 3.22). 
Note that the early eluting peaks at about 10 min in all plots corresponded to the 
protein aggregates. 
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Figure 3.21: Molar mass distribution plots o fHise -HRl , GST-removed HR2 and Hise-HRl / 
GST-removed HR2 complex. 
The solid lines indicate the trace from the refractive index detector, and the dots are the 
weight-average molecular weights for each peak. (A) Hise-HRl showed the eluting peak at 
about 15 min was monodisperse with MW of 38610 Da, which was a tetramer. (B) 
GST-removed HR2 showed the eluting peak between 15 and 20 min was monodisperse with 
MW of 6142 Da, which was a monomer. (C) Hise-HRl / GST-removed HR2 complex showed 
the eluting peak between 15 and 20 min was monodisperse with M W of 49050 Da, which was 
shown to be a 3 X Hise-HRl / 3 x GST-removed HR2 hexameric complex. 
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Figure 3.22: Molar mass distribution plot of HR-2-Helix. 
The solid line indicate the trace from the refractive index detector, and the dots are the 
weight-average molecular weights for the peak at about 14 min. HR-2-Helix showed the 
eluting peak at about 14 min was monodisperse with MW of 40110 Da, which was a trimer. 
3.1.2.5 Size-exclusion chromatography 
To estimate the molecular weight (MW) of HR-2-Helix, SEC analysis was 
performed. The four standard proteins, bovine serum albumin, ovalbumin, 
chymotrypsinogen A and ribonuclease A, included in the Gel Filtration Low 
Molecular Weight Calibration Kit were used. The plot of logarithmic MW against 
retention time showed a good linear correlation (y = -0.0254x + 6.1154; R = 
0.9971) (Figure 3.21 (A)). Under the same condition, HR-2-Helix was analyzed. 
The purified HR-2-Helix was eluted at 60 min with a calculated MW about 39000 
Da, which was close to the value expected for a trimer of HR-2-Helix (3 x 
13170.77 = 39512.31 Da) (Figure 3.21 (B)). 
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Figure 3.23: SEC analysis of HR-2-Helix. 
(A) The plot of logarithmic molecular weight of gel filtration standards against retention time. 
Gel filtration standard: Bovine serum albumin (67000 Da) — 51.08 min; Ovalbumin (43000 
Da) - 57.81 min; Chymotrypsinogen A (25000 Da) - 68.53 min; and Ribonuclease A (13700 
Da) - 77.71 min. (B) SEC profile of purified HR-2-Helix. HR-2-Helix was eluted at 60 min, 
which corresponded to the estimated MW of -39000 Da that determined in comparison with 
the gel filtration standards shown in (A). 
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3.1.2.6 Circular dichroism spectroscopy 
The secondary structure of His6-HR1, GST-removed HR2 and the Hise-HRl / 
GST-removed HR2 complex were examined by CD spectroscopy. His6-HR1 
displayed an a-helical spectrum with double minima at 208 and 222 nm, while 
GST-removed HR2 exhibited a random coil spectrum (Figure 3.23). Thermal 
denaturation of Hise-HRl showed the a-helical structure with a transition 
midpoint temperature (Tm)^  at 62.94°C (Figure 3.24 (A)). The thermal reversible 
reaction indicated that the thermal unfolding of His6-HR1 was reversible. The CD 
spectra recorded before thermal denaturation and after refolded from thermal 
unfolded state were more or less the same with the comparable molar ellipticities 
at 222 nm (Figure 3.24 (B)). 
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Figure 3.24: The CD spectra ofHise-HRl, GST-removed HR2 and the HiS6-HRl / 
GST-removed HR2 complex. 
His6-HR1 displayed an a-helical spectrum, while GST-removed HR2 exhibited a random coil 
spectrum. The Hise-HRl / GST-removed HR2 complex showed a strong a-helical spectrum. 
“'Tm is the transition midpoint temperature at which there is 50% decrease in molar ellipticity at 
222 nm compared with the fully folded peptide. 
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Figure 3.25: The thermal denaturation and thermal reversible reaction profiles of His6-HR1. 
(A) Thermal denaturation curve. The Tm was 62.94°C. (B) Thermal reversible reaction: CD 
spectra were recorded before thermal denaturation (at 37"C), at unfolded state (at 100°C), at 
refolded state (at 37°C). 
The His6-HR1 / GST-removed HR2 complex showed a strong a-helical 
spectrum (Figure 3.24), suggesting that His6-HR1 showed a strong complex 
interaction with GST-removed HR2. Thermal denaturation of complex showed the 
a-helical structure had high stability with a Tm at 86.15°C (Figure 3.25 (A)). The 
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thermal reversible reaction indicated that the thermal unfolding of the complex 
was reversible. The CD spectra recorded before thermal denaturation and after 
refolded from thermal unfolded state were more or less the same with the 
comparable molar ellipticities at 222 nm (Figure 3.25 (B)). 
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Figure 3.26: The thermal denaturation and thermal reversible reaction profiles of His6-HR1 / 
GST-removed HR2 complex. 
(A) Thermal denaturation curve. The T^ was 86.15°C. (B) Thermal reversible reaction: CD 
spectra were recorded before thermal denaturation (at 37°C), at unfolded state (at 100°C), at 
refolded state (at 37°C). 
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The secondary structure of HR-2-Helix was also examined by CD 
spectroscopy. The CD profile of HR-2-Helix showed the characteristic a-helical 
spectrum with double minima at 208 and 222 nm (Figure 3.26). Thermal 
denaturation of HR-2-Helix showed the a-helical structure had high stability with 
a Tm at 100.95°C (Figure 3.27 (A)). The thermal reversible reaction indicated that 
the thermal unfolding of HR-2-Helix was reversible. The CD spectra recorded 
before thermal denaturation and after refolded from thermal unfolded state were 
more or less the same with the comparable molar ellipticities at 222 nm (Figure 
3.27 (B)). 
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Figure 3.27: The CD spectrum of the HR-2-Helix. 
HR-2-Helix showed the characteristic a-helical spectrum double minima at 208 
and 222 nm. 
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Figure 3.28: The thermal denaturation and thermal reversible reaction profiles of HR-2-Helix. 
(A) Thermal denaturation curve. The Tm was 100.95°C. (B) Thermal reversible reaction: CD 
spectra were recorded before thermal denaturation (at 25°C)’ at unfolded state (at 110°C), at 
refolded state (at 25°C) after 0 min and overnight. 
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3.1.3 Synthetic peptide approach 
3.1.3.1 Peptide synthesis 
H R l - a 
The lyophilized HRl-a peptide was dissolved in PBS. The homogeneity of the 
purified HRl-a peptide was verified by analytical RP-HPLC and MALDI-TOF 
MS. The analytical RP-HPLC profile showed that the purity of HRl-a was over 
90% (Figure 3.29 (A)). Note that the peaks before 5 min were corresponded to the 
salts in PBS. The identity of the 27.2 min peak of the analytical RP-HPLC was 
matched the HRl-a theoretical m/z value of 3197.59. 
The AAA calculated concentration of the HRl-a peptide stock was 0.5 
mg/mL (150 
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Figure 3.29: Purification of HRl-a by RP-HPLC. 
HRl-a was purified by RP-HPLC using a linear gradient of 0.5% B (0.05% TFA in ACN) 
/min. (A) HRl-a analytical RP-HPLC profile showing changes in OD280nnv HRl-a with over 
90% purity was eluted at 27.2 min. (B) The identity of the 27.2 min peak was confirmed by 
ABI 4700 MALDI TOF/TOF Analyzer. Mass spectrum showing the RP-HPLC purified 
HRl-a with its exact m/z = 3197. The sequence of HRl-a was shown {insert). 
HRl-b 
The lyophilized HRl-b peptide was dissolved in PBS. The homogeneity of the 
purified HRl-b peptide was verified by analytical RP-HPLC and MALDI-TOF 
MS. The analytical RP-HPLC profile showed that the purity of HRl-b was over 
98% (Figure 3.30 (A)). Note that the peaks before 5 min corresponded to the salts 
in PBS. The identity of the 23.9 min peak of the analytical RP-HPLC was 
matched with the HRl-b theoretical m/z value of 3755.00. The AAA calculated 
concentration of the HRl-b peptide stock was 6.93 mg/mL (1845 i^M). 
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Figure 3.30: Purification of HRl-b by RP-HPLC. 
HRl-b was purified by RP-HPLC using a linear gradient of 0.5% B (0.05% TFA in ACN) 
/min. (A) HRl-b analytical RP-HPLC profile showing changes in OD2ionm- HRl-b with over 
98% purity was eluted at 23.9 min. (B) The identity of the 23.9 min peak was confirmed by 
ABI 4700 MALDI TOF/TOF Analyzer. Mass spectrum showing the RP-HPLC purified 
HRl-b with its exact m/z = 3755. The sequence of HRl -b was shown {insert). 
HR2 
The lyophilized HR2 peptide was dissolved in PBS. The homogeneity of the 
purified HR2 peptide was verified by analytical RP-HPLC and MALDI-TOF MS. 
The analytical RP-HPLC profile showed that the purity of HR2 was over 98% 
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(Figure 3.31 (A)). Note that the peaks before 5 min corresponded to the salts in 
PBS. The identity of the 23.7 min peak of the analytical RP-HPLC was matched 
with the HR2 theoretical m/z value of 3733.11. The AAA calculated concentration 
of the HR2 peptide stock was 4.4 mg/mL (1120 |iM). 
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Figure 3.31: Purification of HR2 by RP-HPLC. 
HR2 was purified by RP-HPLC using a linear gradient of 0.5% B (0.05% TFA in ACN) /mm. 
(A) HR2 analytical RP-HPLC profile showing changes in ODiionm- HR2 with over 98% 
purity was eluted at 23.7 min. (B) The identity of the 23.7 min peak was confirmed by ABI 
4700 MALDI TOF/TOF Analyzer. Mass spectrum showing the RP-HPLC purified HR2 with 
its exact m/z = 3933. The sequence of HR2 was shown {insert). 
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3.1.3.2 Native polyacrylamide gel electrophoresis 
Native polyacrylamide gel electrophoresis (Native-PAGE) was used to analyze the 
complex formation between HRl-a / HRl-b and HR2 peptides. In Figure 3.32, 
Lanes 1 to 5 were the controls. HRl-a and HRl-b showed no band since both of 
them carry net positive charges, thus they may migrate up and off the gel. HR2 
peptide showed one band as it carries net negative charges. 
The mixture of HRl-b and HR2 showed two bands: the lower one located at 
the same position as that of HR2 and the upper band with a higher molecular 
weight was suggested to be the HRl-b / HR2 complex. When the HRl-b to HR2 
ratio was 1 : 2，the intensity of the lower HR2 band was higher, while the intensity 
of upper complex band was lower. When the HRl-b to HR2 ratio was 1 : 1，the 
intensity of the lower HR2 band was very low, while the intensity of upper 
complex band was much higher. It indicated that the complex formation between 
HRl-b and HR2 was probably in a one-to-one molar ratio. Note that although 
HRl-b and HR2 were mixed at equimolar concentration, there was a surplus of 
HR2 in disassociated form. It maybe due to the possibility of a small portion of 
HRl-b was in an aggregate form. 
In the mixture of HRl-a and HR2, either with the HRl-a to HR2 ratio being 
2 : 1 or 1 : 1 ratio, showed one band only, which was located at the same position 
as that of HR2. It indicated that there was no complex formation between HRl-a 
and HR2 under these conditions. 
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Figure 3.32: Determination of the complex formation between HRl and HR2 peptides by 
Native-PAGE. 
Lane 1 - 50 ^M HR2 only; Lane 2 - 100 |iM HRl-b only; Lane 3 - 50 ^M HRl-b only; 
Lane 4 - 100 nM HRl-a only; Lane 5 - 50 i^M HRl-a only; Lane 6 - 50 i^M HRl-b + 100 
^M HR2 (HRl-b : HR2 = 1 : 2 ) ; Lane 7 - 50 ^M HRl-b + 50 ^M HR2 (HRl-b : HR2 = 1 : 
1); Lane 8 - 100 i^M HRl-a + 50 i^M HR2 (HRl-a : HR2 = 2 : 1 ) ; Lane 9 - 50 i^M HRl-a + 
50 loM HR2 (HRl-a : HR2 = 1 : 1 ) . The peptide samples were run from negative pole (-) to 
positive pole (+). 
3.1.3.3 Size-exclusion high-performance liquid chromatography 
The three standard proteins, bovine serum albumin, ovalbumin and ribonuclease 
A, included in the Gel Filtration Low Molecular Weight Calibration Kit were 
effectively separated (Figure 3.33 (A)). The plot of logarithmic molecular weight 
(MW) against retention time showed a good linear correlation (y = -0.221 Ix + 
6.9064; r2 = 0.9981) (Figure 3.33 (B)). Under the same condition, the complex 
formation between HRl peptides (HRl-a / HRl-b) and HR2 peptide was analyzed. 
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Figure 3.33: Gel filtration standards of SE-HPLC. 
(A) SE-HPLC profile of gel filtration standards: Bovine serum albumin (67000 Da) - 9.468 
min; Ovalbumin (43000 Da) - 10.204 mm; and Ribonuclease A (13700 Da) - 12.546 min. (B) 
The plot of logarithmic molecular weight against retention time. 
HRl-a showed a single peak at 13.2 min with an apparent MW about 9700 
Da, which was close to the value expected for a trimer of HRl-a (3 x 3197 = 9591 
Da) (Figure 3.34 (A)). HR2 peptide showed a single peak at 12.4 min with an 
apparent MW about 14600 Da, which was close to the value expected for a 
tetramer of HR2 (4 x 3933 = 15732 Da) (Figure 3.34 (B)). However, the HRl-a / 
HR2 mixture showed two peaks: the first one was eluted at the same time as the 
HR2 and the second one was eluted at the same time as HRl-a (Figure 3.34 (C)). 
Thus, there was no high MW complex formed between HRl-a and HR2. 
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Figure 3.34: Determination of the complex formation between HRl-a and HR2 by SE-HPLC. 
(A) SE-HPLC profile of HRl-a. HRl-a showed a single peak at 13.2 min with an apparent 
MW about 9700 Da, which was a trimer. (B) SE-HPLC profile of HR2. HR2 showed a single 
peak at 12.4 min with an apparent MW about 14600 Da, which was a tetramer. (C) SE-HPLC 
profile of HRl-a and HR2 mixed at equimolar concentration. Peak at 12.4 min was 
corresponded to HR2, whereas peak at 13.2 min was corresponded to HRl-a, revealing that 
there was no high MW complex formed between HRl-a and HR2. 
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HRl-b showed a single peak at 12.8 min with an apparent MW about 11920 
Da, which was close to the value expected for a trimer of HRl (3 x 3755 = 11265 
Da) (Figure 3.35 (A)). HR2 peptide showed a single peak at 12.4 min with an 
apparent MW about 14600 Da, which was close to the value expected for a 
tetramer of HR2 (4 x 3933 = 15732 Da) (Figure 3.35 (B)). However, the HRl-b / 
HR2 mixture showed three peaks: the first one at 10.9 min with the apparent MW 
about 31000 Da, the second one was eluted at the same time as the HR2 and the 
third one was eluted at the same time as HRl-b (Figure 3.35 (C)). These results 
suggested that HRl-b can form complex with HR2. However, the apparent MW of 
the complex was unexpectedly large - larger than the expected value of 26997 Da 
(11265 Da + 15732 Da). 
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Figure 3.35: Determination of the complex formation between HRl-b and HR2 by SE-HPLC. 
(A) SE-HPLC profile of HRl-b. HRl-b showed a single peak at 12.8 min with an apparent 
MW about 11920 Da, which was a trimer. (B) SE-HPLC profile of HR2. H R 2 peptide 
showed a single peak at 12.4 min with an apparent MW about 14600 Da, which 
was a tetramer. (C) SE-HPLC profile of the complex (10.9 min peak) formed by HRl-b and 
HR2 mixed at equimolar concentration. 
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3.1.3.4 Laser light scattering 
The light scattering experiment was employed to determine the MW of HRl-b, 
HR2 and the HRl-b / HR2 complex. For HRl-b, the molar mass distribution plot 
showed that the eluting peak at about 20 min was monodisperse with an average 
MW of 3665 Da, which was close to the value expected for a monomer of HRl 
(3755 Da) (Figure 3.36 (A)). For HR2, the plot showed that the eluting peak 
between 15 and 20 min was polydisperse and contained a mixture of molecules 
with different molar mass. There were two populations of molecules with average 
MWs of �7800 to 11000 Da and �3900 to 7800 Da respectively, in which the 
former one was the dominant population. The �7800 to 11000 Da fractions were 
c lose to the MW v a l u e s e x p e c t e d for dimer (2 x 3933 = 7866 Da) and trimer (3 x 
3933 = 11799 Da) of HR2, whereas the -3900 to 7800 Da fractions were close to 
the MW values expected for monomer (3933 Da) and dimer (Figure 3.36 (B)). For 
the HRl-b / HR2 complex, the plot showed two eluting peaks at about 15 and 20 
min respectively. The peak at 15 min was monodisperse with an average MW of 
about 22830 Da, which was close to the value expected for a hexameric complex 
(3 X 3755 (HRl-b) + 3 x 3933 (HR2) = 23064 Da). The peak at 20 min was also 
monodisperse with an average MW of 3668 Da, which was close to the value 
expected for a monomer of HRl (3755 Da) (Figure 3.36 (C)). Note that the early 
eluting peaks at about 10 min in all plots corresponded to the peptide aggregates. 
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Figure 3.36: Molar mass distribution plots of HRl-b, HR2 and H R l - b / HR2 complex. 
The solid lines indicate the trace from the refractive index detector, and the dots are the 
weight-average molecular weights for each peak. (A) HRl -b showed the eluting peak at about 
20 min was monodisperse with MW of 3665 Da, which was a monomer. (B) HR2 showed the 
eluting peak between 15 and 20 min was polydisperse with M W of 7800 to 11000 Da and 
3900 to 7800 Da respectively, which was shown to be in a monomer-dimer-trimer equilibrium. 
(C) HRl -b / HR2 complex showed the eluting peak at 15 min was monodisperse with MW of 
22830 Da, which was shown to be a 3 x HRl -b / 3 x HR2 hexameric complex. 
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3.1.3.5 Circular dichroism spectroscopy 
The secondary structures of HRl-a, HRl-b, HR2, the HRl-a / HR2 mixture and 
HRl-b / HR2 complex were examined by CD spectroscopy. Both HRl-a and 
HRl-b exhibited a random coil spectrum, while HR2 displayed an a-helical 
spectrum with double minima at 208 and 222 nm (Figure 3.37). Thermal 
denaturation of HR2 showed the a-helical structure with a Tm at 36.30°C (Figure 
3.38 (A)). The thermal reversible reaction indicated that the thermal unfolding of 
HR2 was reversible. The CD spectra recorded before thermal denaturation and 
after refolded from thermal unfolded state were more or less the same with the 
comparable molar ellipticities at 222 nm (Figure 3.38 (B)). 
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Figure 3 .37: The CD spectra of HRl and HR2 peptides. 
(A) The CD spectra of HRl-a, HR2 and HRl-a / HR2 mixture. HRl-a exhibited a random 
coil spectrum, while HR2 displayed an a-helical spectrum. The HRl-a / HR2 mixture showed 
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a very weak a-helical spectrum. (B) The CD spectra of HRl-b, HR2 and HRl-b I HR2 
complex. HRl-b exhibited a random coil spectrum, while HR2 displayed an a-helical 
spectrum. The HRl-b / HR2 mixture showed a very strong a-helical spectrum. 
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Figure 3.38: The thermal denaturation and thermal reversible reaction profiles of HR2. 
(A) Thermal denaturation curve. The T^ was 36.30�C. (B) Thermal reversible reaction: CD 
spectra were recorded before thermal denaturation (at 20°C), at unfolded state (at 78�C)，at 
refolded state (at 20°C). 
The HRl-a / HR2 mixture showed a very weak a-helical spectrum (The 
slightly increase in molar ellipticity at 222 nm was probably due to the 
superimposition between the HRl-a and HR2 signals) (Figure 3.37 (A)), 
suggesting that HRl-a cannot form complex with HR2, as assessed by SE-HPLC. 
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The HRl-b / HR2 complex showed a very strong a-helical spectrum (Figure 3.37 
(B))，suggesting that HRl-b showed a strong complex interaction with HR2, as 
assessed by SE-HPLC. Thermal denaturation of the HRl-b / HR2 complex 
showed the strong a-helical structure had high stability with a Tm at 59.46�C 
(Figure 3.39 (A)). The thermal reversible reaction indicated that the thermal 
unfolding of the complex was reversible. Surprisingly, the CD spectra recorded 
before thermal denaturation and after refolded from thermal unfolded state were 
different: the molar ellipticity at 222 nm was gradually increasing from 0 min to 
15 min in the refolding state, with a value (at 15 minute) lower than that of the 
before thermal denaturation, however, the value obtained after refolded overnight 
was even higher (Figure 3.39 (B)). This indicated that the complex did not refold 
to its original a-helical structure simultaneously and the complex formation might 
not have occurred on a nanosecond or microsecond time scale. So a time course 
measurement of the complex formation followed by molar ellipticity at 222 nm 
was performed. It showed that the molar ellipticity at 222 nm was gradually 
increasing with time (Figure 3.39 (C)). To assess the contribution of the heptad 
repeats to the stability of the coiled-coil HRl-b / HR2 complex, 
guanidine-induced and urea-induced denaturation were performed. The 
guanidine-induced denaturation curve showed a GdnHCl midpoint of transition 
([GdnHCl]i/2) of 1.25 M (Figure 3.40 (A)). The urea-induced denaturation curve 
showed a urea midpoint of transition ([Urea] 1/2) of 2.16M (Figure 3.40 (B)). 
^[GdnHCl] 1/2 and [Urea] "2 are the GdnHCl and urea midpoints of transition, respectively, at 
which there is a 50% decrease in molar ellipticity at 222 nm compared with that of the fully folded 
peptide. 
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Figure 3.39: The thermal denaturation, thermal reversible reaction, t ime COUTSe 
measurement of the HRl -b / HR2 complex. 
(A) Thermal denaturation curve. The Tn, was 59.46�C. (B) Thermal reversible reaction: CD 
spectra of the HRl-b / HR2 complex were recorded before thermal denaturation (at 25°C), at 
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unfolded state (at 110°C), at refolded state (at 25°C) after 0 min, 15 min and overnight. The 
thermal unfolding of HRl-b / HR2 complex was reversible. (C) Time course measurement. 
The molar ellipticity at 222 nm was increased with time. 
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Figure 3.40: The chemical denaturation curves of the HRl-b / HR2 complex. 
(A) Guanidine-induced denaturation curve. The [GdnHCl] 1/2 was 1.25 M. (B) Urea-induced 
denaturation curve. The [Urea] 1/2 was 2.17 M. 
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3.2 Identification of SARS-CoV Entry Inhibitors 
3.2.1 HIV-luc/SARS pseudotyped virus entry inhibition assay -
in vivo screening 
The SARS-CoV entry inhibition activities of the HR recombinant proteins and 
synthetic peptides, which had been characterized in the last chapters, were 
detected by the HIV-luc / SARS pseudotyped virus entry inhibition assay. For the 
peptides derived from the HRl region, only HRl-a showed antiviral activity with 
an EC50 of 1.61 |iM (Figure 3.41). For the peptides derived from the HR2 region, 
both GST-removed HR2 and HR2 showed antiviral activities: EC50 of 
GST-removed HR2 was 2.15 |liM, while EC50 ofHR2 was 0.34 |iM (Figure 3.41). 
Apart from the peptides derived from SARS-CoV S protein HR regions, 39 
small molecule compounds were also tested to identify effective anti-SARS 
agents. Amongst the 39 small molecules, only 5 were found to have relatively 
potent inhibitory activities when compared with that of the positive control, 
quceretin, with an EC50 of 64.8 |iM, they are HKC-5, HKC-21, HKC-24, HKC-25 
and ADS-Jl, with EC50 values of 38.38, 35.94, 32.60, 18.74 and 3.89 |aM, 
respectively (Figure 3.41). 
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Figure 3.41: The HIV-luc / SARS pseudotyped virus entry inhibition activities of the peptides 
derived from SARS-CoV S protein HR regions and small molecule compounds. 
For the peptides, the EC50 values of HRl-a, GST-removed HR2 and HR2 were 1.61, 2.15 and 
0.34 |iM, respectively; His6-HR1 and HRl-b showed no effect. For the effective small 
molecules, the EC50 values of HKC-5 HKC-21, HKC-24, HKC-25 and ADS-Jl were 38.38, 
35.94, 32.60, 18.74 and 3.89 |iM, respectively; Quceretin with an EC50 of 64.80 i^M was the 
positive control and XTT was shown as one of the other 33 small molecules with no 
inhibitory activity. All the values are averages of triplicate determinations and the bars 
indicate the standard deviations. 
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3.2.2 Recombinant protein- and synthetic peptide-based 
biophysical assays 一 in vitro screening 
Amongst the 5 small molecule compounds with potent antiviral activities against 
the HIV-luc / SARS pseudotyped virus, only ADS-Jl was chosen for further 
analysis in the recombinant protein- and synthetic peptide-based biophysical 
assays - in vitro screening, as it had the highest inhibitory activities and it was one 
of the two PBS well-dissolved compounds. XTT, which had no effect in the in 
vivo screening, acted as a negative control. 
Recombinant protein-based biophysical assay 一 GST-pull down aided in vitro 
screening 
For the positive control (His6-HR1 was pre-incubated with PBS before the 
addition of GST-HR2), His6-HR1 was only detected in the elution fractions 
(Figure 3.42 (A)). It indicated that His6-HR1 bound tightly to GST-HR2. In the 
presence of ADS-Jl, His6-HR1 was only detected in the flow-through, but not in 
the elution fractions (Figure 3.42 (A)). It indicated that ADS-Jl may interact with 
His6-HR1 and block the binding between His6-HR1 and GST-HR2. In the 
presence of XTT, His6-HR1 was only detected in the elution fractions (Figure 3.42 
(B)). This result was the same as the positive control, which indicated that 
His6-HR1 could still bind tightly to GST-HR2, without the interference from XTT. 
The differences in the intensity and purity between the samples from ADS-Jl and 
XTT were due to the different batches of purified His6-HR1 and GST-HR2 
proteins. 
CHAPTER 3. RESULTS 13 8 
A 
M 1 2 3 4 5 6 7 8 kDa 
H i S f i - H R l � . ^ m ^ ' - m ^ t t t k — 14.3 
-10 kDa ^ ^ ^ ^ p i _ . : \__ 6.5 
D 
“ 1 2 3 4 5 6 kDa 
•,- ？•-•. •-， . 1 — * — 
His6-HR1 “ ? : � : : : ‘ • ... K 14.3 
-10 kDa 剛 .。、； P i ^ . 一.. . . .. . 1_ 6.5 
Figure 3.42: Western blotting analysis of GST-pull down aided in vitro screening. 
(A) Western blot analysis of ADS-Jl probed with anti-His6 antibody. Lanes 1 — 4 correspond 
to the samples from positive control, Hise-HRl was pre-incubated with PBS, whereas Lanes 
5 - 8 correspond to the samples from Hise-HRl pre-incubated with 1500 ^M ADS-Jl. Lane 
1 - Flow-through; Lane 2 - First elution; Lane 3 - Second elution; Lane 4 - Third elution; 
Lane 5 - Flow-through; Lane 6 - First elution; Lane 7 - Second elution; Lane 8 — Third 
elution. (B) Western blot analysis of XTT probed with anti-His6 antibody. Lanes 1 - 3 
correspond to the samples from positive control, whereas Lanes 4 - 6 correspond to the 
samples from negative control, His6-HR1 was pre-incubated with 1500 |xM XTT. Lane 1 -
Flow-through; Lane 2 - First elution; Lane 3 - Second elution; Lane 4 - Flow-through; 
Lane 5 - First elution; Lane 6 - Second elution. 
Synthetic peptide-based biophysical assay - Native-PAGE and SE-HPLC 
aided in vitro screening 
For Native-PAGE aided screening, the positive control (HRl-b was pre-incubated 
with PBS before the addition of HR2), a band corresponded to the HRl-b / HR2 
complex was detected in the gel (Figure 3.43). In the presence of ADS-Jl or XTT, 
the bands corresponded to the HRl-b / HR2 complex were still detected in the gel 
(Figure 3.43). It indicated that both ADS-Jl and XTT had no effect on the HRl-b / 
HR2 complex formation under these conditions. 
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Figure 3.43: Native-PAGE aided in vitro screening. 
Lane 1 - 50 ^M HRl-b only; Lane 2 - 50 i^M HR2 only; Lane 3 - 50 ^M HRl-b + PBS + 
50 i^M HR2; Lane 4 - 50 |iM HRl-b + 3000 ^M ADS-Jl + 50 ^M HR2; Lane 5 - 50 ^M 
HRl-b + 1500 |iM ADS-Jl + 50 ^M HR2; Lane 6 - 5 0 \iM HRl-b + 1500 jiM X T T + 5 0 i^M 
HR2. The samples were run from negative pole ( - ) to positive pole (+). 
For SE-HPLC aided screening, the positive control (HRl-b was 
pre-incubated with PBS), a peak corresponded to the HRl-b / HR2 complex was 
shown (Figure 3.44 (A)). In the presence of ADS-Jl or XTT, the peaks 
corresponded to the HRl-b / HR2 complex were still shown (Figure 3.44 (B) and 
(C)). It indicated that both ADS-Jl and XTT had no effect on the HRl-b / HR2 
complex formation. 
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Figure 3.44: SE-HPLC aided in vitro screening. 
HRl-b was pre-incubated with (A) PBS (positive control), (B) 1500 i^M ADS-Jl, and (C) 
1500 [xM XTT (negative control), before the addition of HR2. The 10.9 min peak 
corresponded to the HRl-b / HR2 complex formation. 
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3.2.3 Molecular modeling 
Drug target: The hydrophobic deep pocket in the SARS-CoV S protein fusion 
core 
From the X-ray crystal structure of the SARS-CoV S protein fusion core, there are 
two deep pockets composing the relatively deep grooves on the surface of central 
HRl coiled-coil. The two deep pockets are located within Phe909 to Leu920 and 
Leu920 to Leu927. According to our experimental results, the most effective 
antiviral small molecule compound, ADS-Jl, may bind to the deep pocket formed 
between Phe909 to Leu920. The X-ray crystal structure demonstrated that four 
hydrophobic residues from the HR2 (Leull68, Valll71，Leull75 and Leull79) 
penetrate into the deep pocket from Phe909 to Leu920 of HRl and make 
extensive hydrophobic contacts (Figure 3.45(A) and (B)). This region was chosen 
to be the drug target site for our molecular modeling in silico studies. 
Docking of ADS-Jl to the hydrophobic deep pocket 
From close inspection on the docking model of the ADS-Jl / HRl-DP complex , 
ADS-Jl was positioned in such a way that its hydrophobic groups, phenyl and 
naphthalene groups, can penetrate into the deep pocket and interact with the 
hydrophobic residues, Phe909, Ile913，Ile916 and Leu920, in it, and even with 
Ala906 outside it (Figure 3.47(B)). Besides, we monitored the total docking 
energy (Table 3.1) of ADS-Jl / HRl-DP complex as an indicator of the ligand 
placement and activity. The van der Waals energy term showed in favor of the 
position of ADS-Jl in the deep pocket. This substantial favorable energy state 
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(-37.05 kcal mol'') revealed that hydrophobic force was the major interactive 
force between ADS-Jl and HRl-DP. This interaction probably hinders the normal 
HRl and HR2 pairing in the early stage of SARS-CoV infection. 
In addition, the small favorable electrostatic energy (-4.41 kcal mol"') 
indicated the existence of an ionic interaction. Close visual inspection of the 
model revealed that a negative charged sulfonic acid group (SO3H) was proximal 
(8.65 A) to a positively charged group of Lys911 outside the deep pocket (Figure 
3.47(B)). 
Figure 3.45: Interaction ofHR2 with the deep pocket in the relative deep groove region of 
HRl in the SARS-CoV S protein fiision core. 
(A) Hydrophobic residues (Leu 1168 (light green). Vail 171 (orange), Leull75 (light blue) and 
Leull79 (pink)) of the HR2 helix (yellow) penetrating deep into the deep pocket on the 
surface of HRl (violet solid surface). (B) Interaction of the hydrophobic residues (Phe909, 
Ile913, Ile916 and Leu920) (red) in the deep pocket formed by the HRl central coiled-coil 
(violet ribbon) with the hydrophobic residues of the HR2 helix (yellow ribbon). Note that 
there is a peripheral ionic HRl / HR2 interaction between Lys911 (orange) on the HRl helix 
(violet ribbon) and Glull77 (blue) on the HR2 helix (white ribbon). 
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The in silico derivation of ADS-Jl and docking of its derivatives to HRl-DP 
In the docking study, we discovered that a cluster of chemical groups of ADS-Jl 
were clearly projected out of the deep pocket region and made no noticeable 
interaction with HRl (Figure 3.47(B)). Therefore, we employed in silico 
derivatization to modify ADS-Jl. Ten derivatives, ADS-Jl a to ADS-Jlj, were 
designed by extracting the significant interacting groups from the ADS-Jl and 
incorporated with different hydrophobic groups at appropriate chemically viable 
positions as shown in Figure 3.46. 
The docking simulations of ADS-Jl a to ADS-Jlj were shown in Figure 3.47 
and their corresponding docking energies were listed in Table 3.1. Hydrophobic 
groups (phenyl and naphthalene) of ADS-Jl a could interact with the hydrophobic 
residues in the deep pocket and its SO3H is in close proximity to Lys911. 
Hydrophobic groups (triazine ring and 5-methoxy-2-methylphenyl) of ADS-Jlb 
could interact with the hydrophobic residues in the deep pocket and its SO3H was 
close to Lys911. Only the hydrophobic naphthalene group of ADS-Jlc could fit 
into the deep pocket, but its SO3H was in close proximity to Lys911. Almost the 
whole ADS-Jld could not fit into the deep pocket except its naphthalene group 
and its SO3H was projected away from Lys911. The whole ADS-Jle also could 
not fit into the deep pocket and its SO3H was also projected away from Lys911. 
Hydrophobic groups (4-amino-5-methoxy-2-methylphenyl and dichlorotriazin) of 
ADS-Jlf could interact with the hydrophobic residues in the deep pocket, but its 
SO3H was far away from Lys911. Hydrophobic groups (4-amino-5-methoxy-
2-methylphenyl and phenyl) of ADS-Jlg could interact with the hydrophobic 
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residues in the deep pocket and its SO3H was in close proximity to Lys911. The 
whole ADS-Jlh could not fit into the deep pocket, but its SO3H was close to 
Lys911. The whole ADS-Jli could fit into the deep pocket, but its SO3H was 
projected away from Lys911. The whole ADS-JIj could also fit into one of the 
deep pocket, but its SO3H was also projected away from Lys911. 
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Figure 3.46: Chemical structures of in silico derivatives of A D S - J l . 
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Figure 3.47: Interaction of HR2, ADS-Jl and its derivatives with the deep pocket of the 
relatively deep groove region of HRl. 
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All ADS-Jl derivatives, with their carbon, nitrogen, oxygen and sulfur atoms that are shown 
in green, blue, pink and yellow, respectively, were docked into the deep pocket. The 
hydrophobic residues in deep pocket of the HRl helix (violet ribbon) are shown in red and 
Lys911 is shown in orange with its amino group shown in blue. (A) Hydrophobic interaction 
between Leu 1168 (light green), Vail 171 (orange), Leu 1175 (light blue) and Leu 1179 (pink) of 
HR2 (yellow ribbon) and the hydrophobic residues (red) in the deep pocket. (B) ADS-J1. (C) 
ADS-Jl a. (D) ADS-J lb. (E) ADS-J Ic. (F) ADS-J Id. (G) ADS-J le. (H) ADS-J If. The 
chlorine atoms in the dichlorotriazin ring are shown in white. (I) ADS-JIg. (J) ADS-JIh, (K) 
ADS-Jli. (L) ADS-JIj. 
Table 3.1: Quantitative docking results of ADS-J 1 and its derivatives. 
Docking Energy (kcal mol' ) Distance 
Candidate MW(Da) ‘ : � 
vdW' Elect' Total' (A) 
ADS-J l 1079.07 -37 .05 ^ ^ -41 .46 ^ 
ADS-J la 652.12 -31 .36 -2 .08 -33 .44 11.83 
ADS-J lb 762.74 -29 .80 -1 .31 -31 .10 12.97 
ADS-J lc 702.72 -26.61 -4 .90 -31.51 12.09 
ADS-J ld 878.83 -19.21 -0 .45 -19 .66 17.11 
ADS-J le 760.80 -17.01 -0 .83 —17.84 16.44 
ADS-J l f 615.42 -14 .42 0.45 -13 .97 15.73 
ADS-J lg 543.57 -27 .97 -1 .38 -28 .35 10.33 
ADS-J lh 593.63 -13 .43 -0 .94 -14 .37 12.97 
ADS-J l i 467.47 -21 .86 0.62 -21 .24 15.90 
ADS-J l j 319.30 -8 .90 -0 .04 - 8 . 9 4 22.51 
""" v^an der Waals energy 
'^Electrostatic energy 
^Total intermolecular energy 
^Distance between Lys911 and SO3H of each candidate on HRl-DP. Note that the distance 
between Lys911 and Glull77 is 5.91 A. 
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3.3 Characterization of SARS-CoV 3CLP™ Substrate 
Specificity 
3.3.1 Protein expression and purification 
Bacterial cells expressing GST-SCL^ """ was lysed. Soluble fraction was firstly 
passed through glutathione affinity chromatography. The resin bound with 
GST-3CLPr�was then incubated with GST-tagged PreScission Protease. 
GS丁-3CLP™ was cleaved into GST and proteins, and 3CLP'° was eluted 
from the column as the flow-through. The purity of SCL^ '"® showed great 
improvement after passing through SEC (Figure 3.48 (A)). 
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Figure 3.48: Purification of SCL*"^ " by glutathione affinity chromatography and SEC. 
(A) Lane M — Low-range Rainbow Molecular Weight Marker; Lane 1 - Concentrated elution 
of GST-removed 3CLpro from glutathione affinity chromatography; Lane 2 to 9 -
Corresponding to fraction number 38 to 45 of elution profile in (B). The samples were 
subjected to Tris-glycine 10% SDS-PAGE analysis. (B) SEC elution profile showing 
changes in OD280nm (blue) and the collected fractions (red). 
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3.3.2 Substrate specificity preference of SARS-CoV 3(：1/'� 
The PSOl peptide was amidated and acetylated at the C and N’ termini 
respectively. The corresponding amino acid sequence of PSOl was based on one 
of the SARS-CoV cleavage sites on the SARS-CoV BJOl polyprotein 
pplab (residues 3232-3247) and was used as the positive control in the enzymatic 
cleavage assay to assess the activity of 3CLPr�. The original PSOl peptide peak 
with m/z value of 1739.03 before the enzymatic assay was absent from the mass 
spectrum after the cleavage reaction (Figure 3.49 (A)), which validated the 
enzymatic activity of our recombinant SARS-CoV 
3.3.3 Primary and secondary screening using the "cartridge 
replacement strategy" 
Primary screening 
The results from the primary screening of the in vitro enzymatic cleavage assay of 
the six batches of synthetic peptide substrates (namely PS02, PS03, PS04, PS05, 
PS06 and PS07) with amino acid substitutions in their corresponding target 
positions are shown in Figure 3.49 and summarized in Table 3.2. 
Before the enzymatic assay, the corresponding peaks of the 20 peptides in 
each substrate pool were resolved on the mass spectrum with their exact m/z 
values, which demonstrated the validity of solid-phase peptide synthesis using the 
"cartridge replacement" approach to generate a pool of 20 peptides with single 
amino acid difference at the target position. The results also demonstrated the 
capability of MALDI-TOF MS to discriminate most of the peptide species with a 
CHAPTER 3. RESULTS 13 8 
single amino acid difference. 
For PS02 peptide substrates with amino acid substitutions in P2 position, 
only the original peptide (m/z value of 1739.03) and the peptide with Phe 
substitution for Leu in P2 position (m/z value of 1773.01) were cleaved, with their 
corresponding peptide peaks absent from the mass spectrum after the enzymatic 
assay, whereas all other peptides were not cleaved, with their corresponding peaks 
remaining. For PS03 peptide substrates with amino acid substitutions in P3 
position, only the peptide with Pro substitution for Val in P3 position (m/z value 
of 1737.01) was not cleaved, with its corresponding peptide peak remaining in the 
mass spectrum after the enzymatic assay, whereas all other peptides were cleaved 
successfully. For PS04 peptide substrates with amino acid substitutions in P4 
position, all the 20 peptides were cleaved completely, with their corresponding 
peaks absent from the mass spectrum after the enzymatic assay. 
For PS05 peptide substrates, only three peptides with Pro substitution (m/z 
value of 1749.05)，Asp substitution (m/z value of 1767.02) and Glu substitution 
(m/z value of 1781.04) for Ser in PI ' position, respectively, were not cleaved. For 
PS06 peptide substrates, only two peptides with Pro substitution (m/z value of 
1779.06) and Ile/Leu substitution (m/z value of 1795.09) for Gly in P2' position, 
respectively, were not cleaved. For PS07 peptide substrates with amino acid 
substitutions in P3' position, all the 20 peptides were cleaved completely, with 
their corresponding peaks absent from the mass spectrum after the enzymatic 
assay. 
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Figure 3.49: Primary screening: Mass spectrometry analysis of SARS-CoV 3CL''™ cleavage 
products. 
(A) Positive control. PSOl peptide peak (*) was resolved before cleavage assay (A-1) and was 
absent from the mass spectrum after the reaction (A-2). (B) P2 position. For PS02 peptide 
substrates, all 20 peptide peaks were resolved on the mass spectrum before cleavage assay 
(B-1), and only the peptide peaks corresponding to Leu (*) and Phe (**) substitutions in P2 
position were absent, whereas all other peaks remained after the cleavage reaction (B-2). (C) 
P3 position. For PS03 peptide substrates, all 20 peptide peaks were resolved on the mass 
spectrum before cleavage assay (C-1), and only the peptide peak with Pro (*) substitution in 
P3 position remained after the reaction (C-2). (D) P4 position. For PS04 peptide substrates, all 
20 peptide peaks were resolved on the mass spectrum before cleavage assay (D-1), which 
were all absent from the mass spectrum after the reaction (D-2). (E) PI，position. For PS05 
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peptide substrates, all 20 peptide peaks were resolved on the mass spectrum before cleavage 
assay (E-l), and the peptide peaks with Pro (*), Asp (**) and Glu (***) in PI，position 
remained after the reaction (E-2). (F) P2' position. For PS06 peptide substrates, all 20 peptide 
peaks were resolved on the mass spectrum before cleavage assay (F-1), and the peptide peaks 
with Pro (*) and Ile/Leu (*•) in P2' position remained after the reaction (F-2). (G) P3' 
position. For PS07 peptide substrates, all 20 peptide peaks were resolved on the mass 
spectrum before cleavage assay (G-1), which were all absent from the mass spectrum after the 
reaction (G-2). 
Table 3.2: Summary of results from primary screening. 
Peptide Target Corresponding Amino acid substitution 
substrate Position' amino acid® Cleaved peptides Uncleaved peptides 
PS02 ？2 L ^ Leu, Phe others'" 
PS03 P3 Val others" Pro 
PS04 P4 Ala all" — 
PSOS P1' Ser others'' Pro, Asp, Glu 
PS06 P2' Gly others丨 1 Pro, Ile/Leu 
PS07 P3' Phe alli2 
~^The positions flanking the SARS-CoV SCL^ ™ cleavage sites are labeled from the amino 
terminus to the carboxyl terminus as follows: -P3-P2-P1 [ Pl’-P2，-P3’ as described previously 
(Schechter et al. 1967). 
®The original amino acid residue in the position under investigation before the substitution with 
20 standard amino acids. 
^The identity of the amino acid in the particular peptide that substituted the residue at the 
position under investigation. 
'°A11 peptides other than those in the opposite column were not cleaved by SARS-CoV 3CL''™. 
"All peptides other than those in the opposite column were cleaved by SARS-CoV SCL^ ™. 
'^ AIl the 20 peptides were cleaved by SARS-CoV 
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Secondary screening 
After the primary screening procedure, we generated the comprehensive 
cleavage profiles of the corresponding 20 peptide substrates of each target amino 
acid position simultaneously, based on the 'cartridge replacement' strategy. 
However, there were peptides (carrying ambiguous residues like He / Leu and Gin 
/ Lys that carry the identical or close masses) in which true cleavage might not be 
identified with absolute confidence. A secondary screening procedure was 
necessary, and we proceeded to the synthesis of target peptides substrates into 
defined batches, particularly for those peptides with identical or close molecular 
masses, which resulted in ambiguous peaks for detection on the mass spectra in 
the primary screening procedure. The results of the in vitro enzymatic cleavage 
assay of five peptides batches (namely PS02-1, PS02-2, PS02-3, PS06-I and 
PS06-L) are shown in Figure 3.50 and summarized in Table 3.3. 
For PS02-1 peptide batches, only the original peptide with Leu in P2 position 
(m/z value of 1739.03) was cleaved, with its corresponding peptide peaks absent 
from the mass spectrum after the enzymatic assay, whereas the other three 
peptides with Pro, Cys and Glu substitutions for Leu in P2 position were not 
cleaved, with their corresponding peaks remaining. For PS02-2 and PS02-3 
peptide batches, all the peptides were not cleaved, with their corresponding peaks 
remaining. For PS06-I and PS06-L peptide batches, both the peptides with lie 
substitution (m/z value of 1795.09) and Leu substitution (m/z value of 1795.09) 
for Gly in P2' position, respectively, were not cleaved, with their corresponding 
peaks remaining. 
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Figure 3.50: Secondary screening: Mass spectrometry analysis of SARS-CoV SClJ""�cleavage 
products. 
The monoisotopic peaks of each peptide can be clearly shown. (A) PS02-1 peptide batch. The 
four peaks of peptides with Pro (P; m/z = 1722.90), Cys (C; m/z = 1728.86), Leu (L; m/z = 
1739.03) and Glu (E; m/z = 1754.89) substitutions were resolved on the mass spectrum before 
cleavage assay (A-1); only the peptide peaks corresponding to Leu ( • ) substitutions was 
absent, whereas all other peaks remaining after the reaction (A-2). (B) PS02-2 peptide batch. 
The three peaks of peptides with Val (V; m/z = 1724.92), Asn ( N ; m / z = 1739.89) and Lys (K; 
m/z = 1753.95) substitutions were resolved on the mass spectrum before cleavage assay (B-1), 
which were all remaining after the reaction (B-2). (C) PS02-3 peptide batch. The four peaks 
of peptides with Thr (T; m/z = 1726.90), lie (I; m/z = 1739.03), Asp (D; m/z = 1740.88) and 
Gin (Q; m/z = 1753.91) substitutions were resolved on the mass spectrum before cleavage 
assay (C-1), which were all remaining after the reaction (C-2). The 1740.88 monoisotopic 
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peak with high intensity ( • ) belongs to the mother peak of the peptide with Asp (D) 
substitution. (D) PS06-I peptide batch. The peak of peptide with He (I; m/z = 1795.09) 
substitution was resolved on the mass spectrum before cleavage assay (D-1), which was 
remained after the reaction (D-2). (E) PS06-L peptide batch. The peak of peptide with Leu (L; 
m/z = 1795.09) substitution was resolved on the mass spectrum before cleavage assay (E-1), 
which was remained after the reaction (E-2). 
Table 3.3: Summary of results from secondary screening. 
Peptide batch Amino acid substitution Cleaved peptides Uncleaved peptides 
PS02-1 Pro", Cys", Leu", Glu" L ^ Pro, Cys, Glu 
PS02-2 V a l " ， A s n i 6 ’ 丨 7 ， . . . Val, Asn, Lys 
PS02-3 Thfio, He", A s p ' \ Gln^® — Thr, He, Asp, Gin 
PS06-I Ilei9 ~ lie 
PS06-L Leu 丨 9 — Leu 
'"Pro (m/z value of 1722.90) and Val (m/z value of 1724.92) substitutions with close masses 
were separated into PS02-1 and PS02-2 peptide batches, respectively. 
'^Cys (m/z value of 1728.86) and Thr (m/z value of 1726.90) substitutions with close masses 
were separated into PS02-1 and PS02-3 peptide batches, respectively. 
'^Leu (m/z value of 1739.03), Asn (m/z value of 1739.89) and lie (m/z value of 1739.03) 
substitutions with close masses were separated into PS02-1, PS02-2 and PS02-3 peptide batches, 
respectively. 
"Asp (m/z value of 1740.88) and Asn (m/z value of 1739.89) substitutions with close masses 
were separated into PS02-2 and PS02-3 peptide batches, respectively. 
i8g1u (m/z value of 1754.89)，Lys (m/z value of 1753.95) and Gin (m/z value of 1753.91) 
substitutions with close masses were separated into PS02-1, PS02-2 and PS02-3 peptide batches, 
respectively. 
'^Ile and Leu substitutions with identical masses (m/z value of 1795.09) were separated into 
PS06-I and PS06-L peptide batches, respectively. 
End of chapter. 
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Chapter 4 
Discussion 
4.1 Characterization of SARS-CoV S Protein Fusion 
Core 
The six-helix coiled-coil bundle formation is a critical conformational change of 
the S protein during the membrane fusion of SARS-CoV and target cell. Therefore, 
characterization of the SARS-CoV S protein fusion core is important for studying 
the mechanism by which SARS-CoV induces membrane fusion and for 
identification of SARS-CoV fusion inhibitors targeting the fusion core. 
4.1.1 Design of recombinant proteins and synthetic peptides of 
HR regions 
In this study, we defined the HR regions within the SARS-CoV S protein using 
both LearnCoil-VMF and Multicoil programs. Although LeamCoil-VMF was 
designed as a specialized program for identifying coiled-coil-like regions in viral 
membrane-fusion proteins, the sequences of the SARS-CoV HR regions in this 
study were based on the prediction of Multicoil. When comparison to 
LeamCoil-VMF, Multicoil showed that the HRl coiled-coil has a more complete 
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heptad repeat pattern from a = Y899 to g = KlOlO and HR2 coiled-coil from b = 
D1145 to g = 11192, as shown in Figure 3.2. Therefore, we designed the 
recombinant proteins and synthetic peptides of HR regions on the basis of the 
Multicoil analysis. 
From the Multicoil analysis, HRl covers 112 amino acid residues, and it is 
unlikely that the whole region would interact with HR2, which only covers 48 
amino acid residues. Yet, two research groups have proposed two different sites of 
interaction between HRl and HR2: 1. Residues 902 - 952 of HRl and residues 
1145 - 1184 (Xu et al, 2004b); 2. Residues 916 - 950 of HRl and residues 
1151 — 1185 of HR2 (Tripet et al., 2004). In order to compare the suggested sites 
of interaction of HRl and HR2, and provide more detailed information for the 
SARS-CoV S protein fusion core to identify peptide inhibitors, we designed three 
recombinant proteins on the basis of the definition of Xu's group, namely 
His6-HR1 (residues 899 — 958), GST-removed HR2 (residues 1145 - 1192) and 
HR-2-Helix (HRl (899 — 958) - linker - HR2 (1145 - 1192)); and three synthetic 
peptides including HRl-a (residues 899 - 926)，HRl-b (residues 916 - 950) and 
HR2 (residues 1151 - 1185), which are the sites of interaction between HRl and 
HR2 suggested by Tripet's group. As it is important that the HR coiled-coils 
should remained intact, all the constructs except HRl-b peptide, contained the 
complete heptad repeat patterns (Figure 4.1). 
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899 958 
a d a d a d a d a d a d a d a d a d 
His6-HR1 YENQKQI ANQFNKA ISQIQES LTTTSTA LGKLQDV VNQNAQA LNTL VKQLSSN FGAISSV 
HRl-a YENQKQI ANQFNKA ISQIQES LTTTSTA 
HRl-b IQES LTTTSTA LGKLQDV VNQNAQA LNTL VKQLSS 
1145 1192 
d a d a d a d a d a d a d 
GST-removed HR2 DVDLGD ISGINAS WNIQKE IDRLNEV AKNLNES LIDLQEL GKYEQYI 
HRl ISGINAS WNIQKE IDRLNEV AKNLNES LIDLQEL 
HiSfi-HRl 
I ^ 1 
HR-2-HeIix YENQKQI ANQFNKA ISQIQES LTTTSTA LGKLQDV VNQNAQA LNTL VKQLSSN FGAISSV 
^SGEFGSGG DVPLGD ISGINAS WNIQKE IDRLNEV AKNLNES LIDLQEL GKYEQYI 
Linker GST-removed HRl 
Figure 4.1: Amino acid sequences of recombinant proteins and synthetic peptides 
used in this study. 
His6-HR1 (residues 899 - 958) and GST-removed HR2 (1145 - 1192) are recombinant 
proteins, whereas HRl-a (residues 899 - 926), HRl-b (residues 916 - 950) and HR2 (residues 
1151 - 1185) are synthetic peptides. The hydrophobic a and d positions of the predicted 
heptad repeat patterns are shown above the amino acid sequences. 
4.1.2 Recombinant protein approach 
HRl binds to HR2 to form a complex 
The GST-pulldown experiment showed the tight binding of His6-HR1 to 
GST-HR2. Although this experiment rapidly proved that there was interaction 
between HRl (residues 899 - 958) and HR2 (residues 1145 - 1192), it could not 
give the molar ratio of the two proteins within the complex. Therefore, the 
GST-tag of GST-HR2 was cleaved and the complex formation between His6-HR1 
and GST-removed HR2 was further investigated by LS and CD spectroscopy. 
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Oligomeric state of the HR regions 
LS was carried out to determine the absolute molecular weight and oligomeric 
states of His6-HR1 and GST-removed HR2. His6-HR1 was shown exclusively to 
be tetrameric. It was consistent with the CD analysis of His6-HR1, which 
displayed a strong a-helical structure. This result concluded that HRl from 
reisudes 899 - 958 can undergo self-associated oligomerization to form a 
homotetrameric a-helical coiled-coil structure in the native pre-fusion state. 
In contrast, LS showed that GST-removed HR2 was monomeric. This result 
was also consistent with the CD analysis, which shown that GST-removed HR2 
displayed a random coil structure. 
Six-helix coiled-coil bundle formation 
When His6-HR1 was mixed with equal molar GST-removed HR2, the 
monodisperse eluting peak was detected by LS, which corresponded to its 
molecular weight of 49050 Da. This matched the calculation of 3 x His6-HR1 and 
3 X GST-removed HR2, implying the formation of a three-to-three hexameric 
complex - the six-helix bundle. 
CD analysis of the Hise-HRl / GST-removed HR2 complex showed a strong 
a-helical structure. Thermal denaturation profiles showed the HR1-HR2 complex 
has a Tm of 86.15�C，a 23.21°C rise relative to His6-HR1 alone (Tm= 62.94°C). 
Indeed, the His6-HR1 tetrameric structure started to be unfolded at about 40°C, 
but, the His6-HR1 / GST-removed HR2 complex started to be unfolded at 80�C. It 
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indicated that the six-helix coiled-coil bundle was extremely stable. 
Our results showed that HRl from residues 899 - 958 and HR2 from 
residues 1145 - 1192 interacted with each other to form a typical stable six-helix 
coiled-coil bundle. Based on this result, these HRl and HR2 regions were chosen 
to construct a single-chain polypeptide HR-2-Helix: HRl (residues 899 - 958) 
and HR2 (residues 1145 — 1192) were connected with a flexible linker. 
HR-2-Helix was designed to mimic the real SARS-CoV S protein in which HRl 
and HR2 are connected with an interdomain loop (Figure 1.5). 
Both LS and SEC analysis showed that HR-2-Helix formed a trimer - it 
self-associated to form a six-helix bundle. This HR-2-Helix trimer also displayed 
a strong a-helical coiled-coil structure by CD spectroscopy. HR-2-Helix was 
extremely stable to thermal denaturation: it had a Tm of 100.95°C, which was 
14.8°C higher than that of the six-helix bundle formed by individual HRl and 
HR2. These properties suggested that the HR-2-Helix trimeric coiled-coil bundle 
represents the SARS-CoV S protein fusion core structure of the post-fusion 
hairpin state. 
4.1.3 Synthetic peptide approach 
HRl binds to HR2 to form a complex 
The complex formation between the HRl and HR2 synthetic peptides was 
demonstrated with Native-PAGE. This experiment rapidly showed that there was 
interaction between HRl-b (residues 916 一 950) and HR2 (residues 1151 - 1185)， 
but no interaction between HRl-a (residues 899 - 926) and HR2. In the 
CHAPTER 4. Discussion 154 
Native-PAGE analysis, although we mixed the peptides at equimolar 
concentration, due to the aggregation of HRl-b, the one-to-one molar ratio 
complex could not give a single band in the gel. So the complex formation 
between the HRl and HR2 peptides was further investigated by SE-HPLC. 
SE-HPLC further verified that there was complex formation between HRl-b, 
not HRl-a, and the HR2 peptide. The retention times of HRl-a, HRl-b, HR2 and 
HRl-b / HR2 mixture, relative to the MW standards, gave the apparent MWs of 
them. HRl-a and HRl-b were shown to be trimers，and HR2 was shown to a 
tetramer. However, the apparent MW of the HRl-b / HR2 complex was 
unexpectedly large, which indicated that the MW estimation by SE-HPLC might 
not be accurate. Therefore, LS was employed for MW and oligomer determination 
for the HRl-b, HR2 and HRl-b / HR2 complex. 
Oligomeric state of the HR regions 
LS results showed that HRl-b was exclusively monomeric, instead of trimeric as 
estimated by SE-HPLC. This result was also consistent with the CD analysis, 
which shown that HRl-b displayed a random coil structure. 
In contrast, the peak of HR2 in LS was polydisperse and contained a mixture 
of molecules with different MW. Although the polydispersity of the HR2 peak 
resulted from incomplete SEC separation, LS accurately detected the presence of 
the HR2 monomer-dimer-trimer equilibrium: HR2 tended to be trimeric. It was 
consistent with the CD analysis of HR2, which displayed an a-helical structure. 
This result concluded that HR2 from residues 1151 - 1185 can undergo 
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self-associated oligomerization to form a homotrimeric a-helical coiled-coil 
structure in the native pre-fusion state. 
Six-helix coiled-coil bundle formation 
When HRl-b was mixed with equal molar HR2, two monodisperse eluting peaks 
were detected by LS. The majority was the eluant with a molecular weight of 
22830 Da, which matched the calculation of 3 x HRl-b and 3 x HR2, implying 
the formation of a three-to-three hexameric complex - the six-helix bundle. 
Besides, LS showed that a large proportion of aggregate was formed by HRl-b or 
HR2 alone, which can explain why there is always a surplus of either HRl-b or 
HR2 in the one-to-one molar ratio complex, as shown in Native-PAGE, SE-HPLC 
and LS. 
CD analysis of the HRl-b / HR2 complex showed a very strong a-helical 
structure. Thermal denaturation profiles showed the HRl-b / HR2 complex has a 
Tmof 59.46°C, a 23.16°C rise relative to HR2 alone (Tm= 36.30°C). It indicated 
that the six-helix coiled-coil bundle was very stable. Indeed, the HR2 trimeric 
structure started to be unfolded at about 20°C, even lower than the room 
temperature, implying that the energy expenditure to dissociate the HR2 trimer 
was very low. So the random coil monomeric HRl-b could easily interact with 
individual HR2 and stabilize HR2 by forming the six-helix bundle. 
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Table 4.1: Summary of biophysical analysis of the HR peptides and complexes formation in 
the present study. 
“ “ SEC/ ‘ a ? 
HR Peptide / complex Native-PAGE* , LS' , , 
SE-HPLC^ (deg cm^ mol'^) 
His6-HR1 “ “ T e t r a m e r - 2 . 1 1 x 10' 
GST-removed HR2 “ “ M o n o m e r - 3 . 8 3 x 1 0 ' “ 
HiSfi-HRl / GST-removed HR2 ~ ~ 
-- -- Hexamer -2 .85 x 10 
complex 
HR-2-Helix “ Trimer Trimer' -6 .35 x 10' 
HRl-a “ Trimer “ -3 .00 x 10^ 
HRl-b “ Trimer M o n o m e r - 3 . 0 9 x 1 0 ' “ 
H ^ “ Tetramer Trimer -1 .17 X lO'' 
H R l - a / H R 2 mixture x x “ -2.13X 10' 
H R l - b / H R 2 complex 7 7 H e x a m e r - 3 . 0 4 x 10^ 
'This column shows the results of Native-PAGE analysis in the complex formation. = 
Complex formation occurred; x = Complex formation did not occur. 
^This column shows the results of SE-HPLC / SEC in the oligomeric state of the peptides and 
the complex formation. "/= Complex formation occurred; X = Complex formation did not occur. 
^This column shows the results of LS in the oligomeric state of the peptides and the complexes. 
4This column shows the results of CD in molar ellipticity at 222 nm of the peptides and the 
complexes. 
^HR-2-Helix was shown to be a dimer of trimer. 
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4.1.4 Summary of the present and previous studies in the 
SARS-CoV S protein fusion core 
Comparison between the six-helix bundles formed by recombinant protein 
and synthetic peptide approaches in the present study 
In our present study, the six-helix coiled-coil bundle formed by HRl (residues 
899 - 958) and HR2 (residues 1145 - 1192) was shown to be stronger and more 
stable than that formed by HRl (residues 916 - 950) and HR2 (residues 1151 -
1185): the Tm and molar ellipticity at 222nm of HR-2-Helix were 100.95°C 
and -6.7x10^ deg cm^ mol"^ respectively, as compared to 59.46°C and -3.3x10^ 
1 1 
deg cm mol" of the HRl-b / HR2 complex respectively. The most significant 
differences between the two constructs are the N-terminal residues 899 - 916 of 
HRl and the C-terminal residues 1185 - 1192 of HR2. Indeed, these two regions 
are particularly important for the interaction between HRl and HR2 to form the 
fusion core structure. 
X-ray crystallographic studies of the SARS-CoV S protein fusion core have 
demonstrated that three HR2 helices pack against the hydrophobic grooves on the 
surface of the HRl central coiled-coil to form the six-helix coiled-coil bundle, in 
which the helical regions of HR2 (resiudes 1161 - 1175) pack exactly against the 
relatively deep grooves (residues 909 - 927), and the extended regions of HR2 
(residues 1151 - 1160 and resides 1176 - 1185) pack against the relatively 
shallow grooves (residues 928 - 952) (Duquerroy et al, 2005; Xu et al., 2004a). 
In our study, the N-terminal HRl residues 899 - 916 of HR-2-Helix actually form 
half of the relatively deep groove region for the binding of the HR2 helical 
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regions and make extensive interaction with the residues 1161 — 1192. This 
finding also agrees with the structural analyses by Duquerroy and Supekar 
(Duquerroy et al” 2005; Supekar et al., 2004). The C-terminal of HR2 (residues 
1176 - 1193), which is extended in the six-helix bundle conformation (PDB 
IWYY), becomes helical (PDB 2BEQ) while it lacks interaction with the 
corresponding HRl residues 899 - 916. It indicates the importance of the 
N-terminal HRl residues 899 - 916 to presumably stabilize the fusion core 
structure in the final post-fusion state. 
U 穷 Extekded 柳 
寸 m » 丁 卿 
Helical j ^ Z f l B B B j ^ Relative deep 
region 
1161 ^ H ^ B 927 
Extended • ^ H ^ S n Relative 
region ^ T ^ ^ ^ K I K ^ shallow groove 
1 1 4 5 ~ ^ M ^ i X r W ^ E ~ 9 5 2 
Figure 4.2: Structure model of SARS-CoV S protein fusion core in this study. 
Three HR2 helices pack against the hydrophobic grooves on the surface of the HRl central 
coiled-coil to form the six-helix coiled-coil bundle. Left panel: The extended regions (residues 
1145 - 1161 and residues 1175 - 1192) and helical region of HR2 (Blue helices). Right panel: 
The relative deep groove (resides 909 - 927) and shallow groove (residues 927 - 952) regions 
of HRl (Red solid). (Modified from Xu et al., 2004b) 
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In addition to the strong hydrophobic interaction between the N-terminal 
HRl residues 899 - 916 and C-terminal HR2 residues 1185 - 1192, the structure 
analysis by Duquerroy showed that the interaction between Lys903 and Glull89 
is one of the important peripheral ionic HRl / HR2 interactions and these two 
oppositely charged residues can participate in the formation of the salt bridge 
(Figure 4.3). In fact, such ionic pair can contribute to the interhelical stability in 
an a-helical coiled-coil and promote the formation of the trimeric structure: by 
minimizing the number of interhelical electrostatic repulsions and maximizing the 
number of interhelical electrostatic attractions (Kohn et al., 1998). 
H H 
Figure 4.3: Inter-chain salt bridge formed between HRl and HR2 helices. 
The interaction between HRl (residues 899 - 909) and HR2 (residues 1 1 7 9 - 1189) is shown. 
Glul l89 (white) with its carboxylate group (the oxygen atoms are shown in pink) of HR2 
(yellow ribbon) is in close proximity to its ion pairing partner, Lys903 (orange) of the HRl 
(violet ribbon) with its amino group shown in blue. The white dotted line shows the distance 
of the salt bridge which is 5.29 A. In addition to the ionic interaction, hydrophobic interaction 
is also important between HRl (residues 899 - 909) and HR2 (residues 1179 - 1189). The 
hydrophobic residues (Leull79, Hell80, Leu 1182 and Leul l85) of HR2 are shown as light 
green, orange, light blue and pink respectively. The hydrophobic residues (Tyr899, Gln902, 
Ala906, Phe909) of HRl are shown as red. (Modified from PDB IWYY) 
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The guanidine-induced and urea-induced denaturation studies showed that 
the HRl-b / HR2 complex had a very low [GdnHCl] 1/2 and [Urea] 1/2 values of 
1.25M. and 2.17M, respectively. The result from thermal denaturation study was 
consistent with the urea denaturation data of the HRl-b / HR2 complex, which 
indicated that the net stability of the HRl-b / HR2 complex, that is, the sum of the 
stabilizing effect of hydrophobic interaction and electrostatic attraction, was 
relatively low comparing with that of HR-2-Helix. The guanidine denaturation 
data further implied that the HRl-b / HR2 complex had a low stabilizing effect 
contributed by the electrostatic interaction. It may due to the lack of the important 
peripheral ionic HRl / HR2 interaction between Lys903 and Glul l89 in the 
complex. On the contrary, HR-2-Helix, consisted of both Lys903 and Glull89, 
was expected to have a higher stabilizing effect contributed by the electrostatic 
interaction. 
Besides, the analysis of the currently available HR sequences from the 
SARS-CoV isolates found that both the Lys903 and Glul l89 respectively in the 
HRl and HR2 regions are strictly conserved. Out of 116 sequences analyzed, 
100% of the sequences contain both the Lys903 and Glul l89 (Figure 4.4 shows 
11 of them). These two residues are also highly conserved among coronaviruses 
(Duquerroy et al, 2005). These data suggested that these strictly conserved, 
oppositely charged residues located in the N-terminal HRl and C-terminal HR2 
regions of the fusion core probably play a crucial role in SARS-CoV S-mediated 
membrane fusion, which imply the importance of the C-terminal HR2 residues 
1185- 1192. 
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• •• • • " ,I I • 
c fgcdsabcdc f cabc<k:fpabcdc fgabcdc ffiab 
HR2 i 
bcdertabcdersabcdefsabcdefsabcdefsabcdefsabcdeffi 
GZ02 1145 DVCtJQD丨SG丨fMSWNIQEEIDfiUCVAIOUESLinjQElXXYtjQin 1192 
BJ302 1U5 IMm)ISGimSVVNK|EIWUCVAK)l>eSUajQEUXYHQVI 丨 192 
CUK-A003 1145 DVDLCDISGINI^SWNIQ EIDSUCV'AKNUCSLIOLQEUXYtiA I 1192 
CUK-SulO 1145 DVnjGDISGINASWNIQ EIWUCVAIOUCSUDUlEUXYilTn 丨 192 
OIK-WI I US DVDUQDISGimSVWIC EIDH>e\'AOl>e!iUIlJQEUXYHQIYI 1192 
FSA 1M5 IMlJGDISGItMSWNIQ EIDKUCVAnVCSUnjQEUXYHQiri IW2 
Tiiwai TO 1145 WajODlSOltSWNIC EIDRUCV'AnUCSLlDUXLGKYrQYI 1192 
Tor2 1145 WXGDISGINdSVWIC EIDBUe'AKKUtSLIDUlEUSnHQfiri 1192 
m 1145 OVOJCDISGimSWNK] tIDRLWrVAKHJCSUUmxXYrQYl 丨 192 
•m 1M5 WOJDD丨SOlNWVWiq E丨MUev«MJ€SUDU»aCV.H(?fl 1192 
ZJOl 1145 C^UjQHSGINflSVWI^IDRUCVAiaUESUnjQEUXYHQVI 1192 
HIV-1 >04 628 •GBBEIHNnSLIBSUISSQNnBNS-aU. 661 
abcde fsabcde fgabcde fgabcdc fgab cdef 
Figure 4.4: Sequence alignments of the HRl and HR2 regions of 11 selected SARS-CoV 
isolates and the HTV-l. 
Letters above the sequences indicate the predicted heptad repeat pattern ‘abcdefg’. Eleven out 
of 116 sequences of different SARS-CoV isolates are shown to align with the sequence of 
GZ02. In HRl, the boxes with light blue and yellow backgrounds indicate the sequences of 
the relatively deep groove and shallow groove regions, respectively. Vertical light green 
background column identifies a HR2 residue which is the only variable residue among the 116 
SARS-CoV isolates. All the sequences mentioned above are strictly conserved among all the 
116 SARS-CoV isolates. The orange letter 'K', Lys903 (orange arrow) and the pink letter 'E', 
d u l l 8 9 (pink arrow), in which these two residues can form a salt bridge, are strictly 
conserved also. The last lines of the sequences (grey background) in both HRl and HR2 are 
the HIV-1 N-terminal helix (N36) and C-terminal helix (C34) respectively. These two 
sequences are aligned with the SARS-CoV HRl and HR2 sequences, respectively, using 
Clustal X (1.83). The alignment is symbol-coded according to sequence conservation: '*', 
identical; ‘:’，highly conserved; ‘.’，slightly conserved. The alignment result revealed high 
sequence similarity between fflV-l-N36 and SARS-CoV HRl and between HIV-1-C34 and 
SARS-CoV HR2 (45% and 50%, respectively). Thus, the HRl and HR2 regions in 
SARS-CoV and HIV-1 may share certain structural and functional features. The lines under 
the alignment symbols in HRl and HR2 are the heptad repeat pattern of HIV-1 N36 and C34 
respectively (blue letters). 
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Comparison to previous studies in SARS-CoV S protein fusion core 
Previous studies in the SARS-CoV S protein fusion core by Tripet's group showed 
that the site of interaction between HRl and HR2 is between HRl residues 916 -
950 and HR2 residues 1151 - 1185 (Tripet et al,, 2004). However, our results 
showed that the six-helix coiled-coil bundle formed by these regions was 
relatively unstable, in terms of both hydrophobic and electrostatic interaction, 
comparing with the complex formed by HRl residues 899 - 958 and HR2 
residues 1145 - 1192. Our findings were consistent with the previous studies by 
Xu's group, who showed that the binding regions of HRl and HR2 are residues 
902 - 952 in HRl and 1145 - 1184 in HR2 (Xu et al.’ 2004b). Indeed, the 
six-helix coiled-coil bundle formed by HRl (residues 899 - 958) and HR2 
(residues 1145 - 1192) was even stronger and more stable than that formed by 
HRl (residues 902 - 952) and HR2 (residues 1145 - 1184): the T^ of HR-2-Helix 
in this study was 100.95°C, when comparison to 90�C of the 2-Helix analysed by 
Xu's group (Xu et al., 2004b). The 10.95°C difference was probably due to the 
strong hydrophobic and electrostatic interaction between N-terminal HRl residues 
899 - 916 and C-terminal HR2 residues 1185 - 1192，as discussed in the last 
section. Therefore, we identified that residues 899 - 958 in HRl and residues 
1145 - 1192 in HR2 are the major interacting regions for the formation of the 
six-helix coiled-coil bundle, which represents the SARS-CoV S protein fusion 
core structure of the post-fusion hairpin state. 
In addition to providing more detailed information for the site of interaction 
between HRl and HR2, we had presented several methods and results which were 
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different from the previous studies in the SARS-CoV S protein fusion core. 
First, we are the first and only research group to employ LS techniques for 
the determination of MW and protein oligomerization for the SARS-CoV S 
protein HR regions. Traditionally, researchers use SEC and analytical 
centrifugation to determine MW of proteins and their complexes in solution; there 
is no exception in the previous studies of SARS-CoV S protein fusion core. In fact, 
SEC coupled with LS provides the capability of determining the absolute MW and 
it depends only on the readings obtained from the LS and RI detectors. The 
resulting MW is independent of the SEC elution position. However, SEC is just an 
empirical approach for MW estimation that relies on external calibration based on 
the elution position (or retention time), which is readily altered by non-globular 
shape and interaction with the matrix of the SEC column. This interpretation is 
true for our present study. We revealed that the results in MW determination of 
HRl-b, HR2 and the HRl-b / HR2 complex were quite different between 
SE-HPLC and LS; we could accurately obtain the precise MW of the HRl-b / 
HR2 complex in LS, but not in SE-HPLC. Furthermore, compared with analytical 
centrifugation, LS is rapid and samples can be analyzed easily at various pH 
values, ionic strengths and temperatures (Folta-Stogniew and Williams, 1999). 
Therefore, LS offers an accurate and rapid tool for the characterization of the 
SARS-CoV HR regions and the six-helix coiled-coil bundle. In our results, HRl 
from residues 899 - 958 (His6-HR1) was shown to be a tetramer in the LS 
experiment, which was consistent to the result of Tripet's group who showed that 
a similar HRl peptide from residues 882 - 973 (HR-Nl) was also a tetramer in 
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the analytical centrifugation experiment (Tripet et al., 2004) (Table 4.2). HR2 
from residues 1151 - 1185 was in a monomer-dimer-trimer equilibrium and it 
tended to be a trimer in the present LS experiment. However, the oligomeric state 
of a similar HR2 peptide from residues 1150 - 1185 (C36) could not be resolved 
by analytical centrifugation in a previous study (Deng et al.’ 2006) (Table 4.2). It 
was quite surprising that HR2 from residues 1145 - 1192 (GST-removed HR2) 
was shown to be monomeric in the LS experiment. Our CD analysis further 
revealed that GST-removed HR2 displayed a random coil structure, which was 
incompatible with the result of Deng's group who showed that a similar HR2 
peptide from residues 1150 - 1193 (C44) exhibited an a-helical tetrameric 
structure (Deng et al, 2006) (Table 4.2). The deviation from the a-helical 
structure was likely due to the difference in analysis condition. In our study, all 
the protein or peptide samples were pre-incubated at 37°C prior to CD and LS 
analysis and they were then analyzed either at such physiological temperature or 
at room temperature. However, the CD analysis of C44 by Deng's group was 
performed at 4°C (Deng et al, 2006). Besides, the deviation from the expected 
tetrameric state was probably due to aggregation at high concentrations in the LS 
experiment. 
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Table 4.2: Summary of physiochemical analysis of similar HR peptides in the present and 
previous studies. 
Molar 
, Oligomeric , 
Peptide Residues T^ (C) Ellipticity^ References 
state 
(deg cm moF ) 
His6-HR1' 8 9 9 - 9 5 8 6 2 . 9 4 T e t r a m e r ' " - 2 . 1 1 x Present study 
HR-Nl^ 8 8 2 - 9 7 3 77 Tetramer'' - 1 . 51 x 10^ Tripet et a/., 2004 
GST-removed HR2' 1 1 4 5 - 1192 ” M o n o m e r ' " - 3 . 8 3 x 10' Present study 
C44^ 1 1 5 0 - 1193 40 Tetramer'' - 2 . 5 0 x 10^ Deng et al, 2006 
HRl -b ' 9 1 6 - 9 5 0 “ M o n o m e r ' " - 3 . 0 9 X 10' Present study 
HR-N10^ 9 1 6 - 9 5 0 -- Monomer' ‘ - 3 . 6 0 x 1 T r i p e t et al.，2004 
HR2' 1151 - 1 1 8 5 ^ Trimer'" - 1 . 1 7 x lO" Present study 
HR-C4® 1151 - 1185 33 - 1 . 7 5 x 10^ Tripet et a/., 2004 
C36^ 1 1 5 0 - 1185 -12 - 1 . 1 4 X 10^ Deng et a/., 2006 
When no change in molar ellipticity was observed, the Tm was not determined. 
^Molar Ellipticity at 222 nm. 
'His6-HRl, GST-removed HR2, HRl-b and HR2 were dissolved in PBS and incubated at 37°C 
prior to analysis. 
®HR-N1, HR-N 10 and HR-C36 were dissolved in 0.1 M KCl, 0.05 M K2PO4, pH 7 and 
incubated at 22°C prior to analysis. 
9C44 and C36 were dissolved in PBS and incubated at 4 � C prior to analysis. 
Analyzed by LS at room temperature. 
"Analyzed by analytical centrifugation at 22�C. 
'^These items could not be resolved. 
Second, although the thermal denaturation profile of our HRl-b / HR2 
complex displayed a similar Tm for the HR-N 10 / HR-C4 complex of Tripet's 
group (compare 59.46°C with 56�C，respectively), the molar ellipticities of them 
were quite different (compare -3.04 x 10^ deg cm^ mol"^ of HRl-b / HR2 
with -1.79 X 106 deg cm^ mol"^ of HR-NIO / HR-C4, which was just slightly 
larger than that of HR-C4 alone (Table 4.2)). Indeed, the a-helicity of the 
six-helix coiled-coil bundle should be much greater than that of the HR2 trimer 
alone. The deviation was likely due to the differences in analysis condition. In our 
study, the HRl-b / HR2 complex was pre-incubated in PBS at 37°C prior to CD 
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analysis and also analyzed at such a physiological condition. However, the CD 
analysis of HR-NIO / HR-C4 complex of Tripet's group was performed in a 
benign buffer (0.1 M KCl, 0.05 M K2PO4, pH 7) at 22�C (Tripet et al, 2004). 
Since the viral membrane fusion process occurs inside the human bodies, we 
suggested that a comparable physiological condition, for example, a 37°C analysis 
temperature, should be used for the characterization of the SARS-CoV S protein 
fusion core to mimic the real situation. 
Third, it is noteworthy that the HRl-b / HR2 complex did not refold 
simultaneously to its original a-helical structure as the His6-HR1 / HR2 complex 
and HR-2-Helix did in the thermal reversible reaction. The time course 
measurement further implied that the a-helicity of the HRl-b / HR2 complex was 
increasing by time. This discovery has never been reported by the previous studies, 
as the a-helix folding usually occurs on a nanosecond or microsecond time scale. 
Moreover, we are also the first and only research group to present the chemical 
denaturation studies of SARS-CoV S protein fusion core, which may raise the 
focus on the electrostatic nature of the six-helix coiled-coil bundle, but not only 
concentrate on the contribution of its hydrophobic interaction. Nevertheless, these 
novel findings can broaden our knowledge on the fusion mechanism of 
SARS-CoV and provide insights for the design of peptide inhibitors that target the 
fusion core. 
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4.2 Identification of SARS-CoV Entry Inhibitors 
Although many steps unique to SARS-CoV replication could be targeted for 
development of antiviral drugs, the membrane fusion process is of our primary 
interest as the residues in the S protein fusion core are highly conserved among 
diverse SARS-CoV isolates (Figure 4.4). Therefore, high-affinity entry inhibitors 
targeting that highly conserved HR coiled-coil surface will have broad activity 
against diverse SARS-CoV isolates and are less likely to be bypassed by 
drug-escape mutants. 
4.2.1 HIV-luc/SARS pseudotyped virus entry inhibition assay 
The HIV-luc/SARS pseudotyped virus entry inhibition assay is a highly sensitive, 
reproducible and efficient system for the studies on viral entry mechanism, cell 
tropism, neutralization antibody analysis and receptor identification (Nie et al, 
2004). The HIV-luc/SARS pseudotyped viruses with the codon-optimized S 
proteins incorporated into HIV cores were proved to be a safe viral entry model, 
which only go through a single-cycle infection and acquire the host range of the 
parent viruses (Nie et al., 2004). The HIV-luc/SARS pseudotyped viruses can 
infect Vero-E6 cells, as the wild-type SARS-CoV, resulting in the cellular 
expression of luciferase that can be easily detected by luminometry. Thus, as a 
first step, we used this assay to screen the HR recombinant proteins and synthetic 
peptides, which had been characterized in the last chapters, and also a series of 
small molecule compounds for their SARS-CoV entry inhibition activities. The 
rationale of this study is that the HR peptides and small molecules may interfere 
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with the normal function of S protein, such as membrane fusion, hence, 
preventing the SARS-CoV from entering the host cells. 
4.2.2 Identification of peptide inhibitors 
Using a strategy similar to that utilized in the discovery of inhibitors of HIV-1 
gp41-driven membrane fusion, which ultimately produced the first US Food and 
Drug Administration (FDA) approved drug enfuvirtide (T-20), several research 
groups have been starting to develop SARS-CoV peptide inhibitors (Table 4.3). 
The peptide inhibitors, which are derived from HRl or HR2 regions of the 
SARS-CoV S protein, are thought to inhibit the membrane fusion process by 
binding to the corresponding HR2 or HRl during the pre-hairpin intermediate 
state and interfering the six-helix coiled-coil fusion core formation. Through 
different wild-type SARS-CoV cell-based assays, the HR2-deriveci peptides were 
shown to have higher inhibitory activities than the HRl-derived peptides. These 
results were consistent with observations from the related MHV area (Bosch et al.， 
2003). However, in our study, it is surprising that other than the GST-removed 
HR2 and HR2, HRl-a also showed inhibitory activities. 
Indeed, this contradictory result was also revealed by another research group 
(Yuan et al, 2004). They showed that the HRl-derived peptide HRl-1 (residues 
889 - 926) exhibited a potent inhibitory activity. They attributed the fusion core 
formation interference ability of HRl-1 to its 'atypical-helix' structure: it might 
inhibit self-associated oligomerization and bind to HR2. However, the CD 
analysis of our similar HRl-derived peptide, HRl-a (residues 899 - 926), was 
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inconsistent with their interpretation (Figure 3.37 (A)). With the random coil 
structure of HRl-a, it could still form a homotrimer (Figure 3.34 (A)), but it was 
not able to form complex with HR2. In addition, although our data showed that 
another HRl-derived peptide, HRl-b (residues 916 - 950)，had a random coil 
structure and it could not undergo self-associated oligomerization (Figure 3.35 (A)) 
and was able to form six-helix coiled-coil bundle with HR2, it did not show any 
inhibitory potency. Therefore, the inhibition mechanism of HRl-a or HRl-1, and 
even the reasons of low inhibitory activities of most of the HRl-derived peptides, 
are still unknown. On the other hand, Hise-HRl (residues 899 - 958) also did not 
exhibit any inhibitory activity. It maybe due to the high coiled-coil tendency of 
His6-HRland it formed a thermal stable homotetramer. Although His6-HR1 could 
undergo conformational changes to form the six-helix coiled-coil bundle with 
GST-removed HR2 (residues 1145 - 1192), the in vitro binding condition (though 
we had tried to mimic the real situation) maybe different from the cellular 
environment, and thus, it might not interact with the HR2 region of the HIV-luc / 
SARS pseudotyped vims. 
Predictably, both of our HR2-derived peptides, GST-removed HR2 and HR2 
(residues 1151 - 1185) had the inhibitory activities. Although we showed that 
HR2 with residues 1145 - 1192 was the optimal HRl-interacting region for the 
formation of the six-helix coiled-coil bundle, its inhibitory activity was weaker 
than that of HR2. However, a similar HR2-derived peptide, HR2-38 (residues 
1149 - 1186), was shown to have a very strong inhibitory potency with an EC50 
below 5 nM (Yuan et al, 2004). On the contrary, another similar HR2-derived 
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peptide, HR2-6 (residues 1150 - 1189) had no inhibitory activity (Bosch et al., 
2004), comparing with our HR2 peptide. It maybe due to the changes in the 
conformation of HR2-derived peptides after the addition or deletion of several 
amino acids, and consequently influence their inhibitory activities. Nevertheless, 
the inhibitory potency of these SARS-CoV HR2-derived peptides was 
considerably lower than the nanomolar activity measured for the corresponding 
inhibition of HIV-1 gp41 membrane fusion by T-20. Therefore, some 
modifications and optimizations should be performed to the normal HR-derived 
peptides to increase their inhibitory activities, analogous to those peptide 
inhibitors, 5-Helix and D-peptide, identified in the HIV-1 studies (Eckert et al., 
1999; Eckert and Kim, 2001a). 
Besides, the discrepancy between the EC50 values of different studies is 
probably attributed to the physicochemical properties of peptides used and 
different assay conditions, including longer incubation times and different 
read-out methods. 
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Table 4.3: Summary of SARS-CoV peptide inhibitors in the present and previous studies. 
System 
Peptide Residues E C 5 0 (uM) ,, References 
^ ( W T / P T ) 1 3 
8 9 2 - 9 3 1 50 WT Liu et ai, 2004 
CP-1 1 1 5 3 - 1189 19 WT Liu et a/., 2004 
HRl-1 8 8 9 - 9 2 6 3 . 6 8 / 0 . 1 4 W T / P T Yuan et a/., 2004 
HR2-18 1161 - 1187 5 . 2 2 / 1.19 W T / P T Yuan et al, 2004 
HR2-1 1 1 2 6 - 1189 43 WT Bosch et ai, 2004 
HR2-2 1 1 3 0 - 1189 24 WT Bosch et a/., 2004 
HR2-6 1 1 5 0 - 1189 >50 WT Bosch et al., 2004 
HR2-8 1 1 2 6 - 1193 17 WT Bosch et al., 2004 
HR2-9 1 1 2 6 - 1184 34 WT Bosch et a/., 2004 
HR2-38 1 1 4 9 - 1186 < 0.005 WT Zhu et a/., 2004 
His6-HR1 8 9 9 - 9 5 8 ^ PT Present study 
HRl -a 899 - 926 1.61 PT Present study 
HRl -b 9 1 6 - 9 5 0 > 2 5 PT Present study 
GST-removed HR2 1 1 4 5 - 1192 2.15 PT Present study 
HR2 1151 - 1185 0.34 PT Present study 
"WT = Wild-type SARS-CoV; PT = SARS pseudotyped virus. 
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4.2.3 Identification of small molecule inhibitors 
It has been shown that relatively high micromolar concentrations of the 
HR-derived peptides of SARS-CoV S protein were required for efficient 
inhibition of viral infection. Also, such peptide inhibitors maybe constrained due 
to several disadvantages: lack of oral bioavailability, possible metabolic 
degradation, and high cost of production. At the stage of further optimization of 
the peptide inhibitors, we propose another approach for the development of 
SARS-CoV entry inhibitors: the non-peptide SARS-CoV fusion inhibitors. Small 
and bioavailable molecules may act as effective inhibitors against SARS-CoV 
infection if they can prevent the six-helix bundle formation. In fact, this strategy 
has been employed in the development of anti-HIV-1 drugs demonstrated by Jiang 
and co-workers. They successfully identified several small molecules that bind to 
the hydrophobic deep groove on the surface of the central coiled-coil consisting of 
HIV-1 gp41 N peptides (Debnath et al, 1999; Jiang et al, 2000，Jiang et al, 
2002). At this juncture, we employed 39 small molecule compounds and started 
investigating their inhibitory activities against the SARS-CoV. 
Amongst the 39 small molecules (Table 2.1), 33 of them are natural 
compounds that can be found in the nature (HKC-1 to HKC- 37), 2 of them 
(reserpine and valinomycin) were shown to have antiviral activities against 
SARS-CoV with unknown mechanism (Wu et al., 2004)，2 of them (ADS-Jl and 
XTT) were identified to block the HIV-1 gp41 six-helix bundle formation 
(Debnath et al, 1999; Zhao et al, 2002) and 2 of them (luteolin and quercetin) 
(Yi et al, 2004) that were identified to have SARS-CoV entry inhibition activities 
CHAPTER 4. Discussion 173 
were used as the positive controls. 
HIV-luc/SARS pseudotyped virus entry inhibition assay - in vivo screening 
Using the HIV-luc/SARS pseudotyped virus entry inhibition in vivo screening 
method, we screened 39 small molecule compounds and identified 5 small 
molecules, HKC-5, HKC-21, HKC-24, HKC-25 and ADS-Jl (Figure 4.5), that 
displayed inhibitory activities for the entry process of SARS-CoV into host cells. 
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1] HO ^ ^ HO^^^^r 
^ ^ ^ / • ^ O C H j , 0 O OH 
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E C 5 0 = 3 . 8 9 i^M E C 5 0 = 6 4 . 8 0 |iM 
Figure 4.5: Chemical structures and EC 50 of the effective small molecule compounds. 
(A) HKC-5. (B) HKC-21. (C) HKC-24. (D) HKC-25. (E) ADS-J l . (F) Quercetin. 
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For the positive controls of this assay, luteolin was shown to have no effect. 
Indeed, this compound remained insoluble in even higher than 5% DMSO and 
precipitated out in the infection mixture. Our result and observation contradicted 
those of a previous study, which showed that luteolin could prevent infection of 
Vero-E6 cells by both pseudotype and wild-type SARS-CoV (Yi et aL, 2004). 
However, another positive control, quercetin, was shown to have a comparable 
inhibitory activity with an EC50 of 64.80 fiM to that of the Yi's group, who 
showed that it had an EC50 of 83.40 |aM (Yi et al_’ 2004). They suggested that 
quercetin, which has anti-tumour and anti-allergy properties, might be a potential 
drug in the clinical treatment of SARS. 
The 5 effective small molecule compounds were chosen since they not only 
had antiviral activities against HIV-luc/SARS pseudotyped virus, their EC50 
values were also lower than that of the positive control, quercetin (Figure 4.5). For 
4 of the 5 effective small molecules were the natural compounds: HKC-5, 
HKC-21, HKC-24 and HKC-25. Although their inhibitory activities were shown 
to be higher than that of quercetin, their EC50 values were still high — much higher 
than those of the peptide inhibitors. 
HKC-5, which is the berberine, is an alkaloid present in a number of 
clinically-important medicinal plants, including Hydrastis canadensis (goldenseal), 
Coptis chinensis (coptis or goldenthread), Berberis aquifolium (Oregon grape), 
Berberis vulgaris (barberry), and Berberis aristata (tree turmeric). Berberine has 
been shown to exhibit significant antimicrobial activity against a variety of 
bacteria (Sun et al, 1988), fungi (Nakamoto et al., 1990), protozoans 
CHAPTER 4. Discussion 175 
(Vennerstrom et al, 1990) and viruses (Gudima et al.’ 1994). HKC-21, which is 
Silymarin，is extracted from the seeds of Silybum marianum or milk thistle. It has 
been shown to be effective in treating virtually every type of liver disease 
including cirrhosis, chemical or alcohol-induced fatty liver, and hepatitis (Sailer et 
al., 2001). HKC-24 and HKC-25 are the D- and L- forms of tetrahydropalmatine 
(THP), which are highly abundant in a Chinese herb, Corydalis yanhusuo, and 
L-THP can also be isolated from Stephania plants. D- and L-THP have marked 
analgesic, sedative, tranquilizing, hypnotic, antihypertensive and hypo-locomotion 
activities, and L-THP has been reported to always exhibit a more potent effect 
than the D-isomer (Chueh et al, 1995; Hsieh et al, 1994; Lin et al., 1996). It can 
be explained why the EC50 value of D-THP (32.60 |iM) was almost twice of that 
of L-THP (18.74 |jM). The above natural small molecule compounds have a 
common polycyclic fused ring structrue, which may contribute to substantial 
hydrophobicity and target the hydrophobic pockets on the HRl surface to interfere 
the six-helix coiled-coil fusion core formation. Nevertheless, these natural small 
moleulce compounds, especially HKC-25, offer excellent opportunities for further 
optimization and potential clinic use as anti-SARS drugs. 
Amongst the 5 small molecule compounds, the inhibitory activity of ADS-Jl 
was the highest with an EC50 of 3.89 |jM, which was comparable with those of the 
peptide inhibitors. ADS-Jl, chemically named 4-hydroxy-5-[[4-[[4-
[[5-hydroxy-6-[(2-methoxy-5-sulfophenyl)azo]-7-sulfo-2-naphthalenyl] amino]-6-
(phenylamino)-l,3,54riazin-2-yl]amino]-5-methoxy-2-methylphenyl]azo]-2,7-
Naphthalenedisulfonic acid (CAS Registry Number: 70236-51-0), is a 
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polysulfonic acid compound. Its heterocyclic structure makes it become a 
potential protein inhibitor. Previous studies showed that ADS-Jl can bind to the 
hydrophobic deep groove on the surface of the central coiled-coil consisting of 
HIV-1 gp41 N peptides and inhibit the gp41-mediated membrane fusion (Debnath 
et al.’ 1999; Jiang et al, 2000，Jiang et al., 2002). Since the HRl and HR2 
sequences of SARS-CoV S protein are highly similar to those of HIV-1 gp41 
(Figure 4.4), and also they shared the same membrane fusion function to those of 
HIV-1 gp41，we revisited this non-peptide HIV-1 entry inhibitor, ADS-Jl, to show 
its potential inhibitory activity for the SARS-CoV. 
Recombinant protein- and synthetic peptide-based in vitro biophysical assay 
and molecular docking analysis of ADS-Jl 
As ADS-Jl can bind to the hydrophobic deep groove on the surface of the central 
coiled-coil consisting of HIV-1 gp41 N peptides and inhibit the gp41-mediated 
membrane fusion，it would be expected to interact with the hydrophobic deep 
groove on the surface of the central coiled-coil consisting of SARS-CoV S protein 
HRl peptides and inhibit the S protein-mediated membrane fusion. If an 
underlying mechanism of action is at work, by means of the single in vivo 
HIV-luc/SARS pseudotyped virus entry inhibition assay, it could remain 
overlooked by the effect of ADS-Jl on virus-cell binding. Therefore, we further 
developed the recombinant protein- and synthetic peptide-based biophysical 
assays to investigate the interference ability of ADS-Jl on the six-helix bundle 
formation in vitro. 
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We employed three distinct biophysical methods, which were used to 
characterize the SARS-CoV S protein fusion core in the present study, to 
determine the effect of ADS-Jl on the six-helix bundle formation. From the 
GST-pulldown aided in vivo screening, ADS-Jl was shown to block the binding 
between Hise-HRl and GST-HR2, while the negative control XTT, which had no 
inhibitory activity against the HIV-luc/SARS pseudotyped virus infection, also 
had no effect on the interaction between His6-HR1 and GST-HR2. However, from 
the SE-HPLC and Native-PAGE aided in vivo screening, both ADS-Jl and XTT 
had no effect on the HRl-b / HR2 complex formation. Indeed, these three 
experiments provided us some hints on the binding mode of ADS-Jl to the HRl 
coiled-coil. ADS-Jl can block the interaction between HRl from residues 899 -
958 and HR2 from residues 1145 - 1192, but not HRl from residue 916 - 950 and 
HR2 from residues 1151 - 1185, which implied that ADS-Jl may bind to residues 
899 - 916 of HRl . As discussed in Chapter 4.1.4, the N-terminal HRl residues 
899 - 916 actually form half of the relatively deep groove region for the binding 
of the HR2 helical regions (residues 1161 - 1175) and make extensive interaction 
with the residues 1161 - 1192, and presumably stabilize the fusion core structure 
in the final post-fusion state. Thus, ADS-Jl may target the relatively deep groove 
on the surface of the central coiled-coil consisting of SARS-CoV S protein HRl 
peptides and inhibit the S protein-mediated membrane fusion. 
We further analyzed the potential interaction of ADS-Jl with the S protein 
coiled-coil domain using a computer-aided molecular docking program. By 
monitoring the total docking energy of ADS-Jl / HRl-DP complex as an indicator 
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of the ligand placement and activity, it can provide the information on the 
interaction pattern of ADS-Jl at the deep pocket and surrounding area to gain 
deeper insight on the structural characteristics that could justify the activity of this 
compound (Kroeger Smith, et al, 1995). Closer visual inspection of the possible 
interaction pattern and the total docking energy of ADS-Jl / HRl-DP complex 
revealed that the hydrophobic (phenyl and naphthalene) and negatively charged 
sulfonic acid groups of ADS-Jl may play important roles in interacting with the 
hydrophobic (Phe909，Ile913, Ile916 and Leu920) and positively charged residues 
(Lys911) at the deep pocket. This further suggests that along with hydrophobic 
residues in the deep pocket, Gin 1177 of the HR2 peptide (Figure 3.45), which is 
in close proximity to Lys911 in the surrounding area of the pocket, may also be 
crucial to the stabilization of the six-helix coiled-coil bundle. Our results of 
ADS-Jl targeted on the hydrophobic deep pocket on the surface of the central 
coiled-coil of SARS-CoV S protein demonstrated consistency with those targeted 
on HIV-1 gp41 (Debnath et al., 1999), suggesting that ADS-Jl may act as an 
effective entry inhibitor of SARS-CoV. 
The in silico derivation of ADS-Jl and docking of its derivatives to HRl-DP 
From the above interpretation, we have shown that ADS-Jl may possess 
inhibitory activity against SARS-CoV. However, this compound may not be an 
ideal candidate for the drug development because of its large molecular weight 
with 1079.07 Da, which is much larger than traditional drug-like compounds. In 
the docking study, we discovered that a cluster of chemical groups were clearly 
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projected out of the deep pocket region and made no noticeable interaction with 
HRl (Figure 3.47 (B)). This provided us with a clue that the molecular weight of 
ADS-Jl could be further reduced. Therefore, we employed in silico derivatization 
to modify ADS-Jl. Ten derivatives, ADS-Jl a to ADS-Jlj , were designed by 
extracting the significant interacting groups from ADS-Jl and incorporated with 
different hydrophobic groups at appropriate chemically viable positions (Figure 
3.46). In an attempt to corroborate the possible anti-SARS-CoV activity of in 
silico derivatives, we initiated the molecular docking strategy again. 
ADS-Jl a was first designed on the basis of the docking study to eliminate the 
chemical groups of ADS-Jl that might not participate in the interaction with 
HRl-DP or surrounding region. In order to further investigate the hydrophobic 
effect of different chemical groups, we replaced the phenyl group that was 
attached to the triazine ring of ADS-Jl a with other four potential hydrophobic 
groups: either phenyl or naphthalene groups attached with some bulky groups. 
The resulting compounds were ADS-Jlb to ADS-Jle. Among these five 
compounds, ADS-Jl a to ADS-Jlc showed comparable and favorable docking 
energies as their parent compound ADS-Jl. Indeed, from the docking results 
(Figure 3.47)，only ADS-Jl a and ADS-Jlb showed similar interaction patterns to 
that of ADS-Jl. These two compounds contained highly hydrophobic groups that 
could fit into the deep pocket of HRl . Also, their SO3H groups were able to have 
ionic interaction with Lys911 in appropriate distances. However, the hydrophobic 
interaction between ADS-Jlc and HRl-DP was shown to be poorer. Close 
inspection of the docking pose of ADS-Jlc showed that the introduction of the 
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naphthalene group altered the conformation of the whole compound substantially, 
thereby, having poorer hydrophobic contact in the deep pocket, though the ionic 
interaction could still be retained. For ADS-Jld and ADS-Jle, although they 
contained extremely bulky hydrophobic groups, close inspection of its docking 
pose showed that the bulky groups totally altered the conformation of the 
compounds and then making a poor contact with the deep pocket. The 
naphthalene groups attached with two SO3H were also projected away from 
HRl-DP resulting in a longer distance between the negative charged groups and 
Lys911. This caused the relatively unstable interaction between ADS-Jld / 
ADS-Jle and HRl-DP. 
ADS-Jlf to ADS-Jlh were subsequently designed. Actually, ADS-Jlf was a 
possible intermediate in the ADS-Jl synthesis scheme (Naicker et al., 2004). Its 
interaction with HRl-DP was favorable. Its 4-amino-5-methoxy- 2-methylphenyl 
and dichlorotriazin groups were shown to be fitted into the deep pocket of HRl, 
but its SO3H group was unable to have ionic interaction with Lys911 in an 
appropriate distance. ADS-Jlg and ADS-Jlh were designed by replacing the 
dichlorotriazin ring of ADS-Jlf with a phenyl and a naphthalene group, 
respectively. The case of ADS-Jlh was similar to that of ADS-Jld / ADS-Jl e. The 
naphthalene group of ADS-Jlh altered the conformation of the compound and 
might lead to a poor contact with the deep pocket and Lys911. The result of 
ADS-Jlg was opposite to that of ADS-Jlh. The phenyl group of ADS-Jlg could 
perfectly fit into the deep pocket and the ionic interaction between its SO3H and 
Lys911 could still be retained. 
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ADS-Jli and ADS-Jlj were also possible intermediates in the ADS-Jl 
synthesis scheme. The interaction of ADS-Jl i with HRl-DP was favorable. Nearly 
the whole compound could fit into the deep pocket. However, the longest distance 
between its SO3H and Lys903 probably indicated no ionic interaction between 
them. But as the main contributor should be the hydrophobic force, the good 
hydrophobic contact makes ADS-Jli stable. In fact, ADS-Jlj acted as a negative 
control. It was expected to have a poor interaction with HRl-DP. The docking 
results agreed with our prediction. ADS-Jlj was used to check the most stable 
docking position of the sulfonic acids attached naphthalene group. The docking 
study showed that these negatively charged groups should be positioned outside 
the deep pocket, better close to the Lys911, for each docking candidate. 
Implications for the discovery of SARS-CoV entry small molecule inhibitors 
Learning from the remarkable inhibitory activity of ADS-Jl shown in the HIV-1 
case, the investigation of the interactions responsible for stabilizing the binding of 
ADS-Jl complexed with the deep pocket in the relatively deep groove region on 
HRl of SARS-CoV S protein provides valuable insight into the discovery of more 
effective entry inhibitors against SARS-CoV. Our molecular docking model 
shows that the close contact between the highly hydrophobic bulky groups of 
ADS-Jl and the hydrophobic residues in deep pocket may block the hydrophobic 
interaction between HR2 and the deep groove of HRl. Also ADS-Jl may prevent 
the peripheral ionic interaction between HRl and HR2 with the positively charged 
residue Lys911. Our result from the measurement of the docking energy between 
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ADS-Jl and HRl-DP further provides information to guide these investigations. 
Moreover, although the in silico derivatization study of ADS-Jl cannot 
provide substantial improvement of activity; the molecular weight of the 
compound (average MW = 630 Da) became much smaller compared with ADS-Jl 
(1079.07 Da) and is a remarkable improvement (Table 1). Also, this study 
suggests several potential derivatives, such as ADS-Jl a, ADS-Jlb and ADS-Jl g, 
which provide some clues for further "fine tuning" ADS-Jl. Therefore, further 
studies of the structure-activity relationship (SAR) of these compounds may 
provide useful information for designing more potent and less toxic small 
molecular SARS-CoV entry inhibitors. 
CHAPTER 4. Discussion 183 
4.3 Characterization of SARS-CoV 3(：1/��Substrate 
Specificity 
In this study, we introduced a rapid and high-throughput screening method to 
generate a comprehensive overview of the substrate specificity preferences of 
SARS-CoV via a combinatory approach that uses MALDI-TOF MS and 
the novel "cartridge replacement" solid-phase peptide synthesis strategy. Research 
on the substrate specificity preferences of SARS-CoV 3CL''™ is gaining increasing 
attention, owing to the biological significance of SARS-CoV BCL""^ ® in the viral 
life cycle and the feasibility to design specific SARS-CoV 3CLPr�inhibitors as 
potential anti-SARS drugs. It has been explicitly demonstrated that SARS-CoV 
3CLpro cleaves the coronavirus replicase polyproteins at no less than 11 conserved 
sites, preferentially involving the Leu-GlnJ^ sequence in P2 and PI positions at the 
cleavage site, respectively (Anand et al 2003; Hegyi et al. 2002; Ziebuhr et al 
2000). To further extend our knowledge on the substrate specificity of SARS-CoV 
3CLpro，we aimed to comprehensively study the biological importance of amino 
acid residues in six selected positions (namely P2, P3, P4, PI，，P2' and P3') 
flanking the conserved PI position at the SARS-CoV 3CL''™ cleavage site by a 
rapid and high-throughput approach (Table 2.2). 
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4.3.1 A comprehensive overview of the substrate specificity of 
SARS-CoV 3CLPro 
The P3, P4, PI，and P3，positions 
From the primary screening procedure, the results of the PS03, PS04, PS05 and 
PS07 peptide substrates can be interpreted precisely. 
For PS03 and PS05 peptide substrates, the corresponding peptide peaks (m/z 
value of 1737.01 for PS03 and m/z values of 1749.05，1781.04 and 1767.05 for 
PS05) retained on the mass spectra could be clearly resolved after the cleavage 
reaction (Figure 3.49 (C) and (E)); the SARS-CoV 3CV"° cannot cleave those 
peptides for which the non-overlapping m/z values were shown, and hence, those 
uncleaved peptides can be easily identified. These results demonstrated the 
substrate specificity of SARS-CoV SCL*"^ ® are less dependent on the P3 position at 
the cleavage site. The substitution of Pro in the P3 position in the peptide substrate 
is unfavorable for SARS-CoV 3(：1/'�cleavage (Figure 3.49 (C) and Table 3.2), in 
which this bulky Pro residue and may cause steric hindrance to binding of 
SARS-CoV 3CLPr° with its substrate. Furthermore, the PI，position which is 
frequently occupied by Ser residue, also contributes to the substrate specificity of 
SARS-CoV 3CLPro considerably. Our peptide cleavage results revealed that PI’ 
position is highly unfavorable to the substitution by Pro, Asp and Glu residues 
(Figure 3.49 (E) and Table 3.2). Our findings on the intolerance of Asp or Glu 
substitutions in P I ' position suggests that the acidic residues at the binding 
interface of the SARS-CoV SCL""^ ® active site are probably in close proximity and 
sterically complementary to P I ' position of the substrate, leading to electrostatic 
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repulsions between the negatively-charged acidic residues that hinder the substrate 
binding to SARS-CoV 3CL''™. The molecular docking simulation of PS05 peptide 
substrate� demonstrated that the P I ' position is proximal to the Glu47 and Asp48 
residues at the SARS-CoV 3(：1/'�active site (Figure 4.5), which further 
confirmed our interpretations. Besides, the unfavorable substitution by Pro in P I ' 
position could be accounted by the steric hindrance arising from its cyclic side 
chain (Figure 4.5)，which obstructs the substrate binding to SARS-CoV 
Previous studies also demonstrated that small aliphatic residues such as Ser, Ala 
and Gly are favored in P I ' position (Fan et al. 2005). 
From the results of PS04 and PS07 peptide substrates (Figure 3.49 (D) and 
(G))，all 20 peptide peaks were absent from the mass spectra after the SARS-CoV 
3CLPr�cleavage reaction: The SARS-CoV 3CLP'° can cleave all of the 20 peptides 
regardless of the types of amino acid substitutions at the P4 or P3' positions, i.e., 
the P4 and P3' positions have no effects on determining the substrate specificity 
preferences of SARS-CoV 3(：1/*"�(Figure 3.49 (D) and (G), and Table 3.2). 
The P2 and P2' positions 
For PS02 peptide substrates, there were only two peptide peaks that vanished after 
the cleavage reaction. Although these two peaks can be identified as 
corresponding to their exact m/z values, several remaining peptide peaks with 
close masses introduced ambiguity in the mass spectra. In addition, for PS06 
peptide substrates, there were only two peptide peaks found on the mass spectra 
'"The molecular docking works had been presented by Miss Regina Choy (Choy, W.Y., M.Phil 
thesis, 2005). 
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after the cleavage reaction. One of the peptide peaks (m/z value of 1795.09) may 
contain two other peptide entities with exact m/z values, i.e., the lie / Leu 
containing peptide. In fact, this result was also observed in one of the cleaved 
peaks of PS02 peptide substrates (m/z value of 1739.03). Therefore, a secondary 
screening procedure using the defined batch synthesis approach (Table 3.3) was 
employed to solve the above problem. 
In addition to the well-known conserved Gin residue in PI position at the 
SARS-CoV 3CLPro cleavage site, the P2 position, which is exclusively occupied 
by Leu residue, also serves as another important determinant of substrate 
specificity. Our peptide cleavage results indicated that only the peptide substrate 
with Phe replacement in P2 position was also favorable for SARS-CoV SCL*"^ ® 
cleavage (Figure 3.49 (B) and Table 3.2). Also, the results of the three peptide 
batches (PS02-1, PS02-2 and PS02-3) in secondary screening procedure further 
confirmed the results obtained from the primary screening procedure. PS02-3 
peptide batch showed that lie was intolerant in P2 position for SARS-CoV 
Our results demonstrated consistency with other findings (Fan et al. 2004; Fan et 
al. 2005), suggesting that the P2 position serves as an important hydrophobic 
pocket for SARS-CoV 3CLP''°-specific binding; thus, the peptide substrate with 
replacement of the original Leu with the hydrophobic Phe in P2 position was still 
susceptible to SARS-CoV 3CLP'° cleavage (Figure 4.6). Other studies also 
demonstrated that SARS-CoV favorably tolerates Phe and Val substitutions, 
and to a lesser extent, for Met and lie substitutions in the P2 position (Fan et al 
2004; Fan et al 2005), hence revealing the significance of the P2 hydrophobic 
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pocket in the determination of SARS-CoV BCL^ ™ substrate specificity. 
Moreover, our results demonstrated the substrate specificity of SARS-CoV 
3CLP"^  are less dependent on the P2' position at the cleavage site. The 
substitutions of Pro, lie or Leu in P2' position in the peptide substrates are 
unfavorable for SARS-CoV SClF'^ cleavage (Figure 3.49 (F) and Table 3.2), in 
which this bulky Pro residue and P-branching lie and Leu residues may cause 
steric hindrance to the binding of SARS-CoV with its substrates (Figure 
4.6). The results of PS06-I and PS06-L peptide batches further confirmed the 
results of the primary screening: neither lie nor Leu is tolerated in the P2' position 
for SARS-CoV 3CLPr�. 
Figure 4.6: Comparison between the molecular models of different selected peptide substrates 
docked to the active site of SARS-CoV 
CHAPTER 4. Discussion 188 
The Cys 145 (orange) and His41 (yellow) residues in the catalytic dyad of SARS-CoV 3CLP'° 
(purple) and the conserved Gin residue (gray) in PI position at the cleavage site of the peptide 
substrate (red) were shown. (A) PS02 peptide with Phe (green) in P2 position was in close 
proximity to the active site of SARS-CoV 3CL'"'°. Peptide substrates that were unfavorable for 
SARS-CoV 3CLPr° cleavage were deviated away from the active site of SARS-CoV SCL*""", 
which includes the PS03 peptide with Pro (blue) in the P3 position (B); PS05 peptide with Pro 
(blue) in the P1，position (C); PS05 peptide with Asp (blue) in the PI ' position that was in 
close proximity to the acidic residues (brown) at the active site (D); PS05 peptide with Glu 
(blue) in the PI，position that was in close proximity to the acidic residues (brown) at the 
active site (E); PS06 peptide with Pro (blue) in the P2' position (F); PS06 peptide with lie 
(blue) in the P2' position (G); PS06 peptide with Leu (blue) in the P2' position (H). 
4.3.2 The development of the rapid and high-throughput 
screening strategy for protease substrate specificity 
In contrast to providing quantitative measurements on the kinetic data of the 
interaction between SARS-CoV and the substrates, the scope of our studies 
mainly focuses on the description of a useful tool for rapid and comprehensive 
screening of substrate specificity for SARS-CoV 3€1/叩，which is also applicable 
to the studies of other proteases. By combining the MALDI-TOF MS and 
synthetic peptide-based approaches, peptide-cleavage studies on the defined equal 
molar mixture of a batch of 20 peptide substrates before and after the protease 
cleavage reaction could be performed simultaneously on a single MALDI-TOF 
MS analysis. The MALDI-TOF mass spectrometer is a delicate and sensitive 
instrument that enables clear and precise discrimination of different peptides, even 
with single amino acid difference. Therefore, each of the 20 peptide substrates 
with equal molar ratios in the same mixture can be monitored simultaneously on a 
single MALDI-TOF MS analysis before and after the protease cleavage reaction. 
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Our approach is advantageous over the traditional methods that are restricted to 
testing single peptide with defined condition one at a time and the setup of a total 
of 20 identical experimental conditions for every analysis. After generating the 
comprehensive cleavage profile on the 20 peptides simultaneously based on the 
primary screening procedure of the 'cartridge replacement' strategy, we can easily 
identify some of the biologically important residues taking part in the recognition 
process. Nevertheless, we employed the secondary screening procedure using the 
defined batch-synthesis approach to synthesize target peptides in different batches 
for exact identification purpose (ambiguous residues like lie / Leu and Gin / Lys 
that carry identical or close masses). Our approach provides an option in which 
the resolution of the MALDI-TOF mass spectrometer instrument is not sensitive 
enough to distinguish between species with 1-Da mass difference. Also, 
MALDI-TOF MS analysis is tolerant to impurities; therefore, the reaction mixture 
can be analyzed directly after a simple desalting procedure, which reduces the 
workload of subsequent downstream purifications of cleavage products prior to 
analysis. 
For the synthesis of peptide substrates, we deliberately applied the novel 
"cartridge replacement" strategy, which was based on the flexibility on modifying 
the solid-phase peptide synthesis process, in which each amino acid cartridge can 
be filled with different contents of amino acids in defined ratios, to generate the 
desired combinations of mixed peptide substrates according to experimental 
needs. By the incorporation of MALDI-TOF MS analysis and "cartridge 
replacement" peptide synthesis approach, we presented a useful tool that is widely 
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applicable to studies that involve the monitoring of protease cleavage activity, 
which includes the rapid screening of potential protease inhibitors of other 
coronaviruses and HIV. On the basis of our studies, future experiments will be 
carried out to address the effectiveness of various synthetic peptide-based 
inhibitors in blocking the protease activity, with the ultimate aim of anti-SARS 
drugs development. 
End of chapter. 
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Appendix 
I. Nucleotide Sequence of S protein of SARS-CoV 
‘atgtttattt tcttattatt tcttactctc actagtggta gtgaccttga ccggtgcacc 
6丨 acttttgatg atgttcaagc tcctaattac actcaacata cttcatctat gaggggggtt 
121 tactatcctg atgaaatttt tagatcagac actctttatt taactcagga tttatttctt 
18' ccattttatt ctaatgttac agggtttcat actattaatc atacgtttgg caaccctgtc 
24丨 a t a c c t t t t a aggatggta t t t a t t t t g c t gccacagaga aa t caaa tg t tg tccg tggt 
3。丨 tgggtttttg gttctaccat gaacaacaag tcacagtcgg tgattattat taacaattct 
如 actaatgttg ttatacgagc atgtaacttt gaattgtgtg acaacccttt ctttgctgtt 
421 tc taaaccca tgggtacaca gacacatact a t g a t a t t c g a t a a t g c a t t t a a t t g c a c t 
側 ttcgagtaca tatctgatgc cttttcgctt gatgtttcag aaaagtcagg taattttaaa 
54丨 cacttacgag agtttgtgtt taaaaataaa gatgggtttc tctatgttta taagggctat 
6。| caacctatag atgtagttcg tgatctacct tctggtttta acactttgaa acctattttt 
66丨 aagttgcctc ttggtattaa cattacaaat tttagagcca ttcttacagc cttttcacct 
切 gctcaagaca tttggggcac gtcagctgca gcctattttg ttggctattt aaagccaact 
丨 acatttatgc tcaagtatga tgaaaatggt acaatcacag atgctgttga ttgttctcaa 
丨 aatccacttg ctgaactcaa atgctctgtt aagagctttg agattgacaa aggaatttac 
则 cagacctcta atttcagggt tgttccctca ggagatgttg tgagattccc taatattaca 
兆丨 aacttgtgtc cttttggaga ggtttttaat gctactaaat tcccttctgt ctatgcatgg 
丨。2丨 gagagaaaaa aaatttctaa ttgtgttgct gattactctg tgctctacaa ctcaacattt 
_ t t t t c a a c c t t t a a g t g c t a t g g c g t t t c t gccactaagt t g a a t g a t c t t t g c t t c t c c 
丨丨4丨 a a t g t c t a t g c a g a t t c t t t tg tag tcaag ggagatgatg taagacaaat agcgccagga 
丨2�i caaactggtg t t a t t g c t g a t t a t a a t t a t aaa t tgccag a t g a t t t c a t g g g t t g t g t c 
1261 c t t g c t t g g a a tac taggaa c a t t g a t g c t a c t t c a a c t g g t a a t t a t a a t t a t a a a t a t 
丨32丨 a g g t a t c t t a gacatggcaa gct taggccc t t tgagagag a c a t a t c t a a t g t g c c t t t c 
丨38丨 t cccc tga tg gcaaacc t tg caccccacct g c t c t t a a t t g t t a t t g g c c a t t a a a t g a t 
144丨 t a t g g t t t t t acaccactac tggcat tggc t accaacc t t acagagt tg t a g t a c t t t c t 
15�丨 t t t g a a c t t t t aaa tgcacc ggccacggtt tgtggaccaa a a t t a t c c a c t g a c c t t a t t 
丨56丨 aagaaccagt g t g t c a a t t t t a a t t t t a a t ggactcactg g t a c t g g t g t g t t a a c t c c t 
162丨 t c t t c aaaga g a t t t c a a c c a t t t c a a c a a t t t ggccg tg a t g t t t c t g a t t t c a c t g a t 
_ t ccg t tcgag a t cc t aaaac a t c t g a a a t a t t a g a c a t t t c a c c t t g c t c t t t t g g g g g t 
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1741 gtaagtgtaa t tacacctgg aacaaatgct tcatctgaag t t g c t g t t c t atatcaagat 
腳 g t taactgca c t g a t g t t t c tacagcaatt catgcagatc aactcacacc agcttggcgc 
腳 a t a t a t t c t a ctggaaacaa tg ta t tccag actcaagcag gc tg t c t t a t aggagctgag 
侧 catgtcgaca c t t c t t a t g a gtgcgacatt cctat tggag c tggca t t tg tgc tagt tac 
侧 ca tacag t t t c t t t a t t a c g tagtactagc caaaaatcta t t g tggc t t a t ac t a tg t c t 
9041 t taggtgctg a tag t tcaa t t gc t t a c t c t aataacacca t tgc ta tacc t a c t a a c t t t 
oini 
tcaat tagca t tactacaga agtaatgcct g t t t c t a t g g ctaaaacctc cgtagat tgt 
加 1 aa ta tg taca tctgcggaga t t c t ac tgaa tg tgc taa t t tgc t t c tcca atatggtagc 
2221 t t t tgcacac aactaaatcg tgcactctca ggta t tgc tg ctgaacagga tcgcaacaca 
2281 
cgtgaagtgt tcgctcaagt caaacaaatg tacaaaaccc caac t t tgaa a t a t t t t g g t 
2341 g g t t t t a a t t t t t cacaaa t a t tacc tgac cctctaaagc caactaagag g t c t t t t a t t 
2401 
gaggacttgc t c t t t a a t a a ggtgacactc gctgatgctg gct tcatgaa gcaatatggc 
施 1 gaatgcctag g tga t a t t aa tgctagagat c t c a t t t g t g cgcagaagtt caatggactt 
2521 acagtgt tgc cacctctgct cactgatgat a tga t tgc tg cctacactgc tgc tc tag t t 
2581 
agtggtactg ccactgctgg a tggacat t t ggtgctggcg c tgc t c t t ca a a t a c c t t t t 
2 � gctatgcaaa tggcatatag gt tcaatggc a t tggagt ta cccaaaatgt t c tc ta tgag 
2701 
aaccaaaaac aaatcgccaa ccaa t t t aac aaggcgatta g tcaaat tca agaatcactt 
acaacaacat caactgcat t gggcaagctg caagacgttg ttaaccagaa tgctcaagca 
2821 
t taaacacac t tg t t aaaca ac t tagc tc t a a t t t t gg tg caat t tcaag tgtgctaaat 
測 g a t a t c c t t t cgcgacttga taaagtcgag gcggaggtac aaattgacag g t t a a t t a ca 
2941 ggcagacttc aaagccttca aacc ta tg ta acacaacaac taatcagggc tgctgaaatc 
3001 agggcttctg c t aa t c t t gc tgctactaaa atgtctgagt g t g t t c t t g g acaatcaaaa 
3061 agagttgact t t tg tggaaa gggctaccac c t t a t g t c c t tcccacaagc agccccgcat 
3121 gg tg t tg tc t tcc taca tg t cacgtatgtg ccatcccagg agaggaactt caccacagcg 
0101 
ccagcaat t t gtcatgaagg caaagcatac t t ccc tcg tg aagg tg t t t t t g t g t t t a a t 
3241 ggcac t tc t t g g t t t a t t a c acagaggaac t t c t t t t c t c cacaaataat tactacagac 
3301 
aa t aca t t t g tctcaggaaa t t g tga tg t c g t t a t tggca tca t taacaa cacag t t t a t 
• gatcctc tgc aacctgagct t gac tca t t c aaagaagagc tggacaagta c t tcaaaaat 
鄉 catacatcac cagatgt tga tct tggcgac a t t tcaggca t t aacgc t t c tgtcgtcaac 
3似 at tcaaaaag aaattgaccg cctcaatgag gtcgctaaaa a t t t a aa tga a t cac tca t t 
gaccttcaag aattgggaaa atatgagcaa t a t a t t a a a t ggccttggta t g t t t ggc t c 
3601 ggc t t ca t tg ctggactaat tgccatcgtc a tggt tacaa t c t t g c t t t g t tgcatgact 
3661 ag t tg t tgca g t tgcctcaa gggtgcatgc t c t t g t g g t t c t tgctgcaa g t t tga tgag 
3721 gatgactctg agccagttct caagggtgtc aaa t t aca t t acacataa 
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Appendix I: Nucleotide sequence of S protein of SARS-CoV. 
SARS-CoV CUHK-SulO complete genome sequence [GenBank accession no. AY282752] 
was shown as above. The letters in red color indicate the nucleotide sequence of HRl 
(residues 899 - 958) while the letters in blue color indicate the nucleotide sequence of HR2 
(residues 1 1 4 5 - 1192). 
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II. Protein sequence of S protein of SARS-CoV 
1 m f i f l l f l t l t sgsdldrct tfddvqapny tqhtssmrgv yypdeifrsd t l y l t q d l f l 
61 pfysnvtgfh t inhtfgnpv ipfkdgiyfa ateksnvvrg wvfgstmnnk sqsvii inns 
121 tnvviracnf elcdnpffav skpmgtqtht mifdnafnct fey i sdafs l dvseksgnfk 
h l refvfknk dgflyvykgy qpidvvrdlp sgfn t lkp i f k lp lg in i tn f r a i l t a f s p 
241 aqdiwgtsaa ayfvgylkpt tfmlkydeng titdavdcsq nplaelkcsv ksfeidkgiy 
3�i qtsnfrvvps gdvvrfpnit nlcpfgevfn atkfpsvyaw erkkisncva dysvlynstf 
361 fstfkcygvs a tk lnd lc fs nvyadsfvvk gddvrqiapg qtgviadyny klpddfmgcv 
421 lawntrnida tstgnynyky rylrhgklrp ferdisnvpf spdgkpctpp alncywplnd 
似 yg fy t t t g ig yqpyrvvvls fe l Inapatv cgpkls tdl i knqcvnfnfn g l t g tgv l t p 
541 sskrfqpfqq fgrdvsdftd svrdpktsei Idispcsfgg vsvitpgtna ssevavlyqd 
则 vnctdvstai hadqltpawr iystgnnvfq tqagcl igae hvdtsyecdi pigagicasy 
附 h t v s l l r s t s qksivaytms Igadssiays nnt ia ip tnf s is i t tevmp vsmaktsvdc 
721 nmyicgdste canl 1 Iqygs f c t q l n r a l s giaaeqdrnt revfaqvkqra yktptIkyfg 
781 gfnfsq i lpd p lkp tk r s f i ed l l fnkv t l adagfmkqyg eclgdinard 1 icaqkfngl 
� tv lppl l tdd miaaytaalv sgtatagwtf gagaalqipf amqmayrfng igvtqnvlye 
则 nqkqianqfn kaisqiqesl t t t s t a l g k l qdvvnqnaqa Int lvkqlss nfgaissvln 
则 d i Is r ldkve aevqidr l i t gr lqslqtyv tqq l i raae i rasanlaatkmsecvlgqsk 
• rvdfcgkgyh Imsfpqaaph gvvflhvtyv psqe rn f t t a paichegkay fpregvfvfn 
• g tswfi tqrn f f s p q i i t t d ntfvsgncdv vigi inntvy dplqpeldsf keeldkyfkn 
"41 htspdvdlgd isginasvvn iqkeidrlne vaknlnesli dlqelgkyeq yikwpwyvwl 
• g f i a g l i a i v mvtillccmt sccsclkgac scgscckfde ddsepvlkgv klhyt 
Appendix n： Protein sequence of S protein of SARS-CoV. 
Protein sequence of S protein of the SARS-CoV CUHK-SulO strain [GenBank accession no. 
AAP30713] was shown as above. The letters in red color indicate the amino acid sequence of 
HRl (residues 899 - 958) while the letters in blue color indicate the amino acid sequence of 
HR2 (residues 1145-1192) . 
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III. Protein sequence of of SARS-CoV 
‘ s g f r k m a f p s gkvegcmvqv t c g t t t l n g l wlddtvycpr hvictaedml npnyed l l i r 
6丨 ksnhsfIvqa gnvqlrvigh smqncl1rlk vdtsnpktpk ykfvr iqpgq t f sv lacyng 
12丨 spsgvyqcam rpnht ikgsf Ingscgsvgf n idydcvsfc ymhhmelptg vhagtdlegk 
18丨 fygpfvdrq t a q a a g t d t t i t lnvlawlya avingdrwfl n r f t t t l n d f nlvamkynye 
241 pi tqdhvdi1 g p l s a q t g i a vldmcaalke 1Iqngmngrt i I g s t i l e d e f t p fdvv rqc 
3 � ' s g v t f q 
Appendix III: Protein sequence ofSCLP'" of SARS-CoV. 
Protein sequence of 3CLPr° of the SARS-CoV BJOl strain [GenBank accession no. 
NP_828863] was shown as above. 
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IV. Vector maps 
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2. Vector map and MCS of pGEX-6P-l 
PGEX-6P-2 (27-4598-01) 
PreScission"^ Protease 
丨Leu Glu Val Leu Phe GliT^Gly Pro'Leu Gly Ser Pro Gly lie Pro Gly Ser Thr Arg Ala Ala Ala Ser 
CTG G M GTT CTG TTC GAG GGG CCC CT6GGA TCCCCA GGA ATT CCC GG.G T C ^ C T CGA.GCG GCC GC.A TCG 
‘BamH I ‘ EcoR I ' sma I Xhol' Not I ‘ 
pGEX-6P-3 (27-4599-01) 
PreScission^" Protease 
lieu Glu Val Leu Phe Gln^Gly Pro I Leu Gly Ser Pro Asn Ser Arg Val Asp Ser Ser Gly Arg 
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCCCCG AAT TCC CGG.GTC GA^C.TCG AGO GGC CGC. 
BamH I ' E c o R | l ' s m a l Sai l xhol ‘ 
___ m i l l I 
^ J ^ � / pSj10ABam7Stop7 \ \ \ 
/ / \ 
I pGEX 
-4900 bp 丫 
bssh 
Apa I L 
BstE II r ^ PBR322 
Mlu I � n • 
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V. Electrophoresis markers 
1. GeneRulerTM ikb DNA Ladder (Fermentas Cat. #SM1333) 
I & l L l 痛 胆 一 ― % 
30000 20.0 4.0 
/ 10000 20.0 4.0 
7000 20.0 4.0 
a s 5000 75.0 15.0 
< 4000 20.0 4.0 
JpJJJ ； 3000 20.0 4.0 
I 2000 20.0 4.0 
80.0 16.0 
1 ^ S - 1000 25.0 5.0 
§ 700 25.0 5.0 
g 500 7S.0 15.0 
⑴ I h H - 400 25.0 5.0 
r" 300 25.0 5.0 
-g 200 25.0 5.0 
75 25.0 5.0 
0.5pa/lane,8cm length gel, 
1XTAE, TVfcm, 45min 
2. GeneRukr™ lOObp DNA Ladder (Fermentas Cat. #SM0323) 
S b p iig/0.5卯 % 
/ 3000 28.0 5.6 
f ! 2000 28.0 5.6 
V 1900 28.0 5.6 
A 1200 28.0 5.6 
J , 1000 80.0 le.o 
• g Z 900 27.0 5.4 
s i S S Z BOO 27.0 5.4 
S S B — 27.0 5.4 
1. - 600 27.0 5.4 
g — 500 80.0 le.O 
I ^ S - Am 30.0 6.0 
5 ^ B - 300 30.0 6.0 
^ 200 30.0 6.0 
I ^ H - 103 30.0 6.0 
_ 
0.5gg/lare. 8cm length gel, 
1XTBE,5\'ybm,1h 
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3. High-range Rainbow Molecular Weight Markers (GE Healthcare Cat. 
#RPIN756) 
Myosin 4 m K 
Phusphorylasc b " S P B 97 K 
Bovine scrum jlKimin ^agjjpr 66 K 
Ovalbumin 45 K 
Carboniv； anhyJrasc 50 K 
Trypsin inhibitor 20.1 K 
I.ysoz>mc IHI^ 14. J K 
3. Low-range Rainbow Molecular Weight Markers (GE Healthcare Cat. 
#RPN756) 
Ovalbumin 45 K 
Carbonk anhydrasc w V) K 
Tryp&in inhibitor 20.1 K 
I ysozymc 侧 14.^  K 
Aprotinin m^m- 6..S K 
Insulin fb) chain V5 K 
Insulin la) chain 2.5 K 
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VI. SDS-PAGE gel preparation protocol 
Constitutes of 5 ml running acrylamide gel solution: 
15% 12% 10% 8% 6% 
Distilled Water 1.1ml 1.6 ml 1.9 ml 2.3 ml 2.6 ml 
30% Acrylamide/bis mix 2.5 ml 2 ml 1.7 ml 1.3 ml 1 ml 
Tr is (1 .5M,pH8.8) 1.3 ml 1.3 ml 1.3 ml 1.3 ml 1.3 ml 
10% SDS 50 III 50^1 50 i^l 50 i^l 50 [l\ 
10% Ammonium persulfate 50 |il 50 |il 50^1 50 |il 50 |il 
TEMED 2^1 2^1 2 |il 2\i\ 2 yd 
Constitutes of 5 ml 5% stacking acrylamide gel solution: 
Distilled Water 3.4 ml 
30% Acrylamide/bis mix 830 i^l 
Tris (1 M, pH 6.8) 630 \i\ 
10% SDS 50 i^l 
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